1 TITLE PAGE  

RA PHARMACEUTICALS , INC. 
RA101495-01.203:  A PHASE 2 MULTICENTER , OPEN-LABEL , UNCONTROLLED 
STUDY TO EVALUATE THE SAFETY , TOLERABILITY , EFFICACY , 
PHARMACOKINETICS , AND PHARMACODYNAMICS OF RA101495  IN SUBJECTS 
WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO HAVE AN INADEQUATE 
RESPONSE TO ECULIZUMAB  
Protocol Number: 5$
Indication Studied: 3DUR[\VPDO1RFWXUQDO+HPRJORELQXULD
Developmental Phase of Study: 
Company/Sponsor Signatory: 5D3KDUPDFHXWLFDOV,QF
Protocol Version: $PHQGPHQW
Release Date of Protocol: -DQXDU\

7KLVVWXG\ZLOOEHFRQGXFWHGE\5D 3KDUPDFHXWLFDOV,QFDQGDI ILOLDWHVLQFRPSOLDQFHZLWKWKH
SURWRFRO*RRG&OLQLFDO3UDFWLFHD QGDOORWKHUDSSOLFDEOHUHJX ODWRU\UHTXLUHPHQWVLQFOXGLQJWKH
DUFKLYLQJRIHVVHQWLDOGRFXPHQWV

CONFIDENTIAL 
7KLVGRFXPHQWFRQWDLQVFRQILGHQWLDOLQIRUPDWLRQ$Q\XVHGLVWU LEXWLRQRUGLVFORVXUHZLWKRXWWKH
SULRUZULWWHQFRQVHQWRI5D3KDUPDFHXWLFDOV,QFLVVWULFWO\S URKLELWHGH[FHSWWRWKHH[WHQW
UHTXLUHGXQGHUDSSOLFDEOHODZVRUUHJXODWLRQV3HUVRQVWRZKRP WKHLQIRUPDWLRQLVGLVFORVHGPXVW
EHLQIRUPHGWKDWWKHLQIRUPDWL RQLVFRQILGHQWLDODQGPD\QRWEH IXUWKHUGLVFORVHGE\WKHP



5$
3URWRFRO5$ $PHQGPHQW''-D QXDU\
&21),'(17,$/
CENTER INVESTIGATOR SIGNATURE PAGE 
3URWRFRO7LWOH$3KDVH0XOWL FHQWHU2SHQ/DEHO8QFRQWUROOHG 6WXG\WR(YDOXDWHWKH6DIHW\
7ROHUDELOLW\(IILFDF\3KDUPD FRNLQHWLFVDQG3KDUPDFRG\QDPLFV RI5$LQ6XEMHFWVZLWK
3DUR[\VPDO1RFWXUQDO+HPRJORELQXULDZKRKDYHDQ,QDGHTXDWH5HVS RQVHWR(FXOL]XPDE
3URWRFRO$PHQGPHQW3URWRFRO'DWH-DQXDU\
,KDYHUHFHLYHGDQGUHYLHZHGWKH,QYHVWLJDWRUÂ¶V%URFKXUHIRU5$ 
,KDYHUHDGWKLVSURWRFRODQGDJUHHWKDWWKHVWXG\LVHWKLFDO
,DJUHHWRFRQGXFWWKHVWXG\DVRXWOLQHGLQWKLVSURWRFRODQGL QDFFRUGDQFHZLWKDOODSSOLFDEOH
UHJXODWLRQVDQGJXLGHOLQHVLQFOXGLQJWKHFXUUHQW,QWHUQDWLRQDO &RQIHUHQFHRQ+DUPRQLVDWLRQ
*RRG&OLQLFDO3UDFWLFH*XLGHOLQH
,DJUHHWRPDLQWDLQWKHFRQIL GHQWLDOLW\RIDOOLQIRUPDWLRQUHFH LYHGRUGHYHORSHGLQFRQQHFWLRQ
ZLWKWKLVSURWRFRO
,DJUHHWKDWDOOHOHFWURQLFVLJQDWXUHVZLOOEHFRQVLGHUHGWKHH TXLYDOHQWRIDKDQGZULWWHQ
VLJQDWXUHDQGZLOOEHOHJDOO\ELQGLQJ


BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB BBBBBBBBBBBBBB BBB
6LJQDWXUHRI,QYHVWLJDWRU      'DWH
5$
3URWRFRO5$ $PHQGPHQW''-D QXDU\
&21),'(17,$/
2S Y N O P S I S  

Protocol title $3KDVH0XOWLFHQWHU2SHQ/DEHO8QFRQWUROOHG6WXG\WR(YDOXD WHWKH
6DIHW\7ROHUDELOLW \(IILFDF\ 3KDUPDFRNLQHWLFVDQG3KDUPDFRG\QDPLFVRI
5$LQ6XEMHFWVZLWK3DUR[\VPDO1RFWXUQDO+HPRJORELQXULDZ KR
KDYHDQ,QDGHTXDWH5HVSRQVHWR(FXOL]XPDE 
Protocol number 5$
Version $PHQGPHQW
''-DQXDU\
Phase of clinical 
development3KDVH
Investigational 
medicinal product5$DGPLQLVWHUHGE\GDLO\VXEFXWDQHRXVLQMHFWLRQ
Study Population $GXOWVZLWKSDUR[\VPDOQRFWXUQDOKHPRJORELQXULD31+
Investigative Sites $SSUR[LPDWHO\FHQWHUVDUHSODQQHGLQRQHRUPRUHRIWKHIROOR ZLQJ
ORFDWLRQV86$DQG$UJHQWLQD
Planned number of 
subjects 8SWRVXEMHFWVZLOOEHHQUROOHGLQWKHVWXG\ 
Study objectives x7RDVVHVVWKHVDIHW\DQGWROHUDELOLW\RI5$LQVXEMHFWVZ LWK31+
x7RDVVHVVSUHOLPLQDU\HIILFDF\RI5$LQVXEMHFWVZLWK31+ 
x7RDVVHVVWKHSKDUPDFRNLQHWLFV3.DQGSKDUPDFRG\QDPLFV3'R I
5$LQVXEMHFWVZLWK31+
Study design 6WXG\5$LVDPXOWLFHQWHURSHQODEHOXQFRQWUROOH GVWXG\WR
HYDOXDWHWKHVDIHW\WROHUDELOLW\HIILFDF\SKDUPDFRNLQHWLFVDQG
SKDUPDFRG\QDPLFVRI5$LQ VXEMHFWVZLWK31+ZKRKDYHDQ
LQDGHTXDWHUHVSRQVHWRHFXOL]XPDEWUHDWPHQWIRU31 +
7KHSODQQHGHQUROOPHQWLVDSSUR[LPDWHO\ VXEMHFWV (QUROOPHQWZLOOEH
VWDJJHUHGVXFKWKDWHDFK'D\9 LVLWRFFXUVDWOHDVW GD\VDIWHUWKH'D\
9LVLWIRUWKHSUHYLRXVO\HQUROOHGVXEMHFW
7KHVWXG\LQFOXGHVDQ ZHHNVFUHHQLQJSHULRGDQGDZHHN 7UHDWPHQW
3HULRG'XULQJWKH7UHDWPHQW3HULRGVXEMHFW VZLOOUHWXUQWRWKHFOLQLFZHHNO\
IRUWKHILUVWZHHNVIROORZHGE\YLVLWVHYHU\ZHHNVWRHYDOXDWHVDI HW\
WROHUDELOLW\ HIILFDF\3.DQG3'$GGLWLRQDODVVHVVPHQWVZLOOLQFOXGH
LPPXQRJHQLFLW\ 4XDOLW\RI/LIH42/TXHVWLRQQDLUHV ELRPDUNHUVDPSOHV
DQGRSWLRQDO SKDUPDFRJHQRPLFV 6DIHW\DVVHVVPHQWVLQFOXGHSK\VLFDOH[DP
YLWDOVLJQVHOHFWURFDUGLRJUDP(&*FOLQLFDOODERUDWRU\WHVWV DQGDGYHUVH
HYHQWV$(V
7KHULVNRINeisseria meningitidis LQIHFWLRQZLOOEHFORVHO\PRQLWRUHGGXULQJ
WKHVWXG\'XULQJWKHVFUHHQLQJSHULRGSULRUWRVWXG\HQWU\DOOVXEMHFWV PXVW
KDYHDGRFXPHQWHGQHJDWLYHUHVXOWIRU Neisseria meningitidis FRORQL]DWLRQ
YLDDWKURDWVZDE$OOVXEMHFWVPXVWKDYHGRFXPHQWDWLRQRISULR UNeisseria 
5$
3URWRFRO5$ $PHQGPHQW''-D QXDU\
&21),'(17,$/
meningitidis YDFFLQDWLRQDQGERRVWHULIDSSURSULDWHSULRUWRVWXG\HQWU\ 
7KH'D\9LVLWVKRXOGEHVFKHGXOHGWRFR LQFLGHZLWKWKHQH[WVFKHGXOHG
GRVHRIHFXOL]XPDELH rGD\VDIWHUIURPWKHODVWHFXOL]XPDEGRVH 
(FXOL]XPDEVKRXOG127EHDGPLQLVWHUHG DWWKH'D\9LVLW RUDWDQ\WLPH
WKHUHDIWHUGXULQJWKHVWXG\ 
'XULQJWKH 7UHDWPHQW3HULRGWRPLWLJDWHWKHULVNRILQIHFWLRQVXEMHFWV ZLOO
EHFRXQVHOHGDQGUHPLQGHGRIHDUO\ VLJQVDQGV\PSWRPVRI Neisseria 
meningitidis LQIHFWLRQ$SDWLHQWVDIHW\FDUGGHWDLOLQJWKHVLJQVDQG
V\PSWRPVRILQIHFWLRQ ZLWKLQVWUXFWLRQVWRVHHNLPPHGLDWHPHGLFDODWWHQWLRQ
ZLOOEHSURYLGH GWRHDFKVXEMHFW 7KHFDUGZLOODOVRGHVFULEHWKHVXEMHFWÂ¶V
SDUWLFLSDWLRQLQWKHVWXG\DQGWKHULVNVRILQIHFWLRQDVVRFLDWH GZLWKLQKLELWLRQ
RIWKHWHUPLQDOFRPSOHPHQWV\VWHP 7KHSDWLHQWVDIHW\FDUGPXVWEHFDUULHG
ZLWKWKHSDWLHQWDWDOOWLPHVZKLOHRQ WUHDWPHQW
$WWKHFRQFOXVLRQRIWKH 7UHDWPHQW3HULRG VXEMHFWVZKRFRPSOHWHWKHVWXG\
DQGDUHGHPRQVWUDWLQJEHQHILWZLOOKDYHWKHRSWLRQWRHQUROOLQ DQH[WHQVLRQ
VWXG\WRFRQWLQXHUHFHLYLQJWUHDWPHQWZLWK5$ $OWHUQDWLYHO\ WKH\
PD\RSWWRUHFHLYHVWDQGDUGRI FDUHWUHDWPHQWRIIVWXG\DIWHUFRQVXOWDWLRQ
ZLWKWKHLUWUHDWLQJSK\VLFLDQ,IWKH VXEMHFWZLWKGUDZVHDUO\IURPWKH
5$ VWXG\IRUDQ\UHDVRQKHVKHZLOOQRWEHHOLJLEOHIRUWKH
H[WHQVLRQVWXG\ 
$OOVXEMHFWVZLOOUHFHLYHDORDGLQJGRVHRIPJNJWREHDGPLQLV WHUHG
VXEFXWDQHRXVO\ 6&DWWKH'D\9LVLW)ROORZLQJLQ FOLQLFHGXFDWLRQDQG
WUDLQLQJDOO VXEMHFWVZLOOVHOILQMHFWGDLO\6&GRVHVRIPJNJRI
5$ IRUZHHNV([FHSWIRU'D\R QVWXG\FOLQLFGD\VWKHGRVH
VKRXOGEHDGPLQLVWHUHGDIWHUWKH3.DQG3'FROOHFWLRQKDVEHHQ FRPSOHWHG
$IWHUDWOHDVWZHHNVRIWUHDWPHQW ZLWK5$DWPJNJGDLO\ LID
VXEMHFWKDVQRWDFKLHYHGDQ DGHTXDWHUHVSRQVHGHILQHGDVDODFWDWH
GHK\GURJHQDVH >/'+@[XSSHUOLPLWRIQRUPDO>8/1@ WKHGRVHVKRXOG
EHHVFDODWHGWRPJNJGDLO\'RVHHVFDODWLRQPD\SURFHHGR QO\LIQR
VHYHUHLH*UDGHÂ•RUVHULRXVWUHDWPHQWHPHUJHQW$(VDUH UHSRUWHGDWWKH
PJNJGDLO\GRVH 
Duration of study 
participation7KHWRWDOGXUDWLRQRIVWXG\SDUWLFLSDWLRQIRUDOOVXEMHFWVZLOO LQFOXGHD
6FUHHQLQJ3HULRG RIXSWRZHHNVDQGDZHHN7UHDWPHQW3HULRG IRUD
WRWDORIXSWRZHHNV 
Study population 7REHHOLJLEOHIRUWKLVVWXG\VXEMHFWVPXVWPHHW ALLRIWKHIROORZLQJ
LQFOXVLRQFULWH ULD
0DOHRUIHPDOH t\HDUV
 &RPSOHWHGLQIRUPHGFRQVHQWSURFHGXUHVLQFOXGLQJVLJQLQJDQG GDWLQJ
WKHLQIRUPHGFRQVHQWIRUP,&)
'LDJQRVLVRI31+E\IORZF\WRPHWU\
,QDGHTXDWHUHVSRQVHWRHFXOL]XPDEGHILQHGDVKDYLQJUHFHLYHG
HFXOL]XPDEIRUDWOHDVWPRQWKVSOXVRQHRUPRUHRIWKHIROORZ LQJ
FULWHULD
o$GRFXPHQWHGODFWDWHGHK\GURJHQDVH/'+OHYHOÂ•[8/1
ZLWKLQGD\VSULRUWR6FUHHQLQJ
o3UHVHQFHRIDNQRZQ&PXWDWLRQFRQIHUULQJUHVLVWDQFHWR
5$
3URWRFRO5$ $PHQGPHQW''-D QXDU\
&21),'(17,$/
HFXOL]XPDE
)HPDOHVXEMHFWVRIFKLOGEHDULQJSRWHQWLDOPXVWKDYHDQHJDWLYH 
SUHJQDQF\WHVWDW6FUHHQLQJDQGZLWKLQKRXUVSULR UWRWKHILUVWGRVHRI
5$
6H[XDOO\DFWLYHIHPDOHVXEMHFWVRIFKLOGEHDULQJSRWHQWLDOLH ZRPHQ
ZKRDUHQRWSRVWPHQRSDXVDORUZKRKDYHQRWKDGDELODWHUDO
RRSKRUHFWRP\K\VWHUHFWRP\ RUWXEDOOLJDWLRQDQGDOOPDOHVXEMHFWV
ZKRKDYHQRWEHHQVXUJLFDOO\VWHULOL]HGE\YDVHFWRP\PXVWDJU HHWRXVH
HIIHFWLYHFRQWUDFHSWLRQGXULQJWKHVWXG\(IIHFWLYHFRQWUDFHSWL RQLV
GHILQHGDV
o+RUPRQDOFRQWUDFHSWLRQHJRUDOFRQWUDFHSWLYHWUDQVGHUPDO
FRQWUDFHSWLYHFRQWUDFHSWLYHLP SODQWRULQMHFWDEOHKRUPRQDO
FRQWUDFHSWLYHIRUDWOHDVW PRQWKVSULRUWRVWXG\GUXJ
DGPLQLVWUDWLRQWKURXJKRXWWKHV WXG\DQGIRUZHHNVDIWHUWKH ODVW
GRVHRIVWXG\GUXJ
o'RXEOHEDUULHUELUWKFRQWUROHJPDOHFRQGRP IHPDOHFRQGRP
GLDSKUDJPVSRQJHRUFHUYLFDOFDSWRJHWKHUZLWKVSHUPLFLGDO
IRDPJHOILOPVXSSRVLWRU\VWDUWLQJDWWKH6FUHHQLQJ9LVLW
WKURXJKRXWWKHVWXG\DQGIRUZHHNVDIWHUWKHODVWGRVHRIVW XG\
GUXJ
o,QWUDXWHULQHFRQWUDFHSWLRQGHYLFHVWDUWLQJDWWKH6FUHHQLQJ9LV LW
WKURXJKRXWWKHVWXG\DQGIRUZHHNVDIWHUWKHODVWGRVHRIVW XG\
GUXJ
o7RWDODEVWLQHQFH IURPVH[XDOLQWHUFRXUVHIRUDWOHDVWRQHFRPSOHWH
PHQVWUXDOF\FOHSULRUWRWKH6FUHHQLQJ9LVLW WKURXJKRXWWKHVWXG\
DQGIRUZHHNVDIWHUWKHODVWGRVHRIVWXG\GUXJ
o0DLQWHQDQFHRIDPRQRJDPRXVUHODWLRQVKLSZLWKDPDOHSDUWQHUZK R
KDVEHHQVXUJLFDOO\VWHULOL]HGE\YDVHFWRP\
6XEMHFWVZKRPHHW ANYRIWKHIROORZLQJH[FOXVLRQFULWHULDPXVWEH
H[FOXGHGIURPWKHVWXG\ 
3ODWHOHWFRXQWÂ—/RUDEVROXWHQHXWURSKLOFRXQW$1&
FHOOVÂ—/DW6FUHHQLQJ
&DOFXODWHGJORPHUXODUILOWUDWLRQUDWHRIP/PLQPEDVHGRQ
PRGLILFDWLRQRIGLHWLQUHQDOGLVHDVH0'5'HTXDWLRQDW6FUHHQ LQJ
(OHYDWLRQRIOLYHUIXQFWLRQWHVWVGHILQHGDVGLUHFWELOLUXELQ! [8/1RU
HOHYDWHGWUDQVDPLQDVHVDODQLQHDPLQRWUDQVIHUDVH>$/7@RU DVSDUWDWH
DPLQRWUDQVIHUDVH>$67@![8/1
(OHYDWLRQRIDP\ODVHRUOLSDVH![8/1
+LVWRU\RIPHQLQJRFRFFDOGLVHDVH
&XUUHQWV\VWHPLFLQIHFWLRQRUVXVSLFLRQRIDFWLYHEDFWHULDOLQI HFWLRQ
3UHJQDQWSODQQLQJWREHFRPHSUHJQDQWRUQXUVLQJIHPDOHVXEMHF WV
5HFHQWVXUJHU\UHTXLULQJJHQHUDODQHVWKHVLDZLWKLQWKHZHHNV SULRUWR
6FUHHQLQJRUH[SHFWHGWRKDYHVXUJHU\UHTXLULQJJHQHUDODQHVWK HVLD
GXULQJWKHZHHN7UHDWPHQW3HULRG
$FWLYHPDOLJQDQF\UHTXLULQJVXUJHU \FKHPRWKHUDS\RUUDGLDWLRQZLWKLQ
WKHSULRUPRQWKVVXEMHFWVZLWKDKLVWRU\RIPDOLJQDQF\ZKR KDYH
5$
3URWRFRO5$ $PHQGPHQW''-D QXDU\
&21),'(17,$/
XQGHUJRQHFXUDWLYHUHVHFWLRQRURWKHUZLVHQRWUHTXLULQJWUHDWPH QWIRUDW
OHDVWPRQWKVSULRUWR6FUHHQLQJZLWKQRGHWHFWDEOHUHFXUUHQF HDUH
DOORZHG
+LVWRU\RIDQ\VLJQLILFDQWPHGLFDORUSV\FKLDWULFGLVRUGHUWKDW LQWKH
RSLQLRQRIWKHLQYHVWLJDWRUZRXOGPDNHWKHVXEMHFWXQVXLWDEOHI RU
SDUWLFLSDWLRQLQWKHVWXG\
7UHDWPHQWZLWKDQ\LQYHVWLJDWLRQDOPHGLFLQDOSURGXFWRU LQYHVWLJDWLRQDO
GHYLFHZLWKLQWKHGD\VSULRUWR6FUHHQLQJRUSDUWLFLSDWLRQL QDQRWKHU
FRQFXUUHQWFOLQLFDOWULDOLQYROYLQJDWKHUDSHXWLFLQWHUYHQWLRQ
SDUWLFLSDWLRQLQREVHUYDWLRQDOVWXGLHVDQGRUUHJLVWU\VWXGLHV LV
SHUPLWWHG
8QDEOHRUXQZLOOLQJWRFRPSO\ZLWKWKHUHTXLUHPHQWVRIWKHVWXG \
Endpoints and 
AssessmentsSafety and Tolerability
6DIHW\DVVHVVPHQWVZLOOLQFOXGHHYDOXDWLRQRI$(VDQG6$(VLQFOXGLQJ
PDMRUDGYHUVHYDVFXODUHYHQW0$9 (FULWHULDFOLQLFDOODERUDWR U\WHVWV
(&*VYLWDOVLJQVDQGSK\VLFDOH[DPLQDWL RQV6DIHW\HYDOXDWLRQVZLOODOVR
LQFOXGHDGHWHUPLQDWLRQRIDQWL GUXJDQWLERGLHV$'$
Primary Efficacy :
x7KHSULPDU\HYDOXDWLRQSHULRGLVIURP:HHNWR:HHN7KHSULPDU \
HIILFDF\HQGSRLQWLVWKHFKDQJHIURPEDVHOLQHLQVHUXP/'+OHYH OV
GXULQJWKLVSHULRG GHILQHGDVWKHPHDQ/'+YDOXHVRI:HHNV
DQGPLQXVWKHEDVHOLQHYDOXHRI/'+
Secondary Efficacy :
x&KDQJHVIURPEDVHOLQHLQ/'+WRWDOELOLUXELQWRWDOKHPRJORELQ IUHH
KHPRJORELQKDSWRJORELQUHWLFXORF\WHVDQGKHPRJORELQXULDDW HDFKRI
WKHVFKHGXOHGSRVWEDVHOLQHDVVHVVPHQWWLPHSRLQWV
Pharmacokinetic :
x3ODVPDFRQFHQWUDWLRQVRI5$D QGLWVPDMRUPHWDEROLWHV
x0D[LPXPSODVPDFRQFHQWUDWLRQ& PD[
x7LPHFRUUHVSRQGLQJWR& PD[WPD[
x$UHDXQGHUWKHGUXJFRQFHQWUDWLRQWLPHFXUYHV$8& W
x3ODVPDFRQFHQWUDWLRQVRIHFXOL]XPDE
Pharmacodynamic :
x&KDQJHVIURPEDVHOLQH&+ 
x&KDQJHVIURPEDVHOLQHLQVKHHS5%&V5%&O\VLVIRUFODVVLFDO
FRPSOHPHQWSDWKZD\
x&KDQJHVIURPEDVHOLQHLQ:LHVODEHQ]\PH OLQNHGLPPXQRVRUEHQWDVVD\
(/,6$IRUDOWHUQDWLYHFRPSOHPHQWSDWKZD\
x&KDQJHVIURPEDVHOLQHLQ&OHYHOV
Exploratory :
x&KDQJHVIURPEDVHOLQHLQTXDOLW\RIOLIH42/TXHVWLRQQDLUHV HJ
EORTC QLQ-C30, FACIT-Fatigue, and EQ-5D) 
x7UHDWPHQWVDWLVIDFWLRQTXHVWLRQQDLUH
x0HFKDQLVWLFELRPDUNHUVHJF RPSOHPHQWIXQFWLRQFRPSOHPHQW
5$
3URWRFRO5$ $PHQGPHQW''-D QXDU\
&21),'(17,$/
SURWHLQVELRPDUNHUVRILQIODPP DWLRQELRPDUNHUVIRUWKURPERVLV 
ELRPDUNHUVRIOLYHUIXQFWLRQ
x3KDUPDFRJHQRPLFDQDO\VHVRSWLRQDO
Statistical 
considerationsStudy Populations 7KHIROORZLQJVWXG\SRSXODWLRQVDUHGHILQHG
xSafety Population $OOVXEMHFWVZKRUHFHLYHDWOHDVWGRVH RI5$
xEfficacy Evaluable Population $OOVXEMHFW VLQWKH6DIHW\3RSXODWLRQ
ZKRFRPSOHWHWKHZHHN7UHDWPHQW3HULRG
xPer Protocol Population $OOVXEMHFWVLQWKH6DIHW\3RSXODWLRQZKR
FRPSOHWHWKHZHHN7UHDWPHQW3HULRGDQGKDYHQRPDMRUSURWRFR O
GHYLDWLRQV
xPK Population $OOVXEMHFW VLQWKH6DIHW\3RSXODWLRQZKRKDYHDWOHDVW
SODVPDVDPSOHREWDLQHGIRU3.DVVHVVPHQW
xPD Population $OOVXEMHFW VLQWKH6DIHW\3RSXODWLRQZKRKDYHDWOHDVW
SODVPDVDPSOHREWDLQHGIRU3'DVVHVVPHQW
General Considerations 
$GLVSRVLWLRQRIDOO FRQVHQWHGVXEMHFWVZLOOEHSURYLGHGDQG ZLOOLQFOXGHD
EUHDNGRZQRI VXEMHFWVZKRFRQVHQWHGZHUHWUHDWHGGLVFRQWLQXHGWUHDWPHQW
ZHUHORVWWRIROORZ XSRUZLWKGUHZFRQVHQW
&RQWLQXRXV YDULDEOHVZLOOEHVXPPDUL]HGZLWKWKHPHDQ VWDQGDUGGHYLDWLRQ
6'PHGLDQDQGUDQJH&DWHJRULFDOYDULDEOHVZLOOEHVXPPDUL]HGXVL QJ
FRXQWVDQGSURSRUWLRQV 
Safety:$GYHUVHHYHQWVZLOOEHFRGHGXVLQJWKH0HGLFDO'LFWLRQDU\IRU
5HJXODWRU\$FWLY LWLHV0HG'5$YHUVLRQRUKLJKHU ,QFLGHQFHUDWHV
IRUWUHDWPHQW HPHUJHQW$(V7($(VE\PD[LPXPVHYHULW\DQG6$(VZLOO
EHVXPPDUL]HG7KHVHVXPPDULHVZLOOEHSURYLGHGUHJDUGOHVVRIF DXVDOLW\
DQGIRUHYHQWVWKDWDUHFRQVLGHUHGUHODWHGWRWUHDWPHQWZL WK5$
4XDQWLWDWLYHODERUDWRU\HQGSRLQWVZLOOEHVXPPDUL]HGE\ WLPHSRLQW
'HVFULSWLYHVWDWLVWLFV IRU(&*SDUDPHWHUVL HKHDUWUDWH>+5@ 35LQWHUYDO
55LQWHUYDO456LQWHUYDO47LQWHUYDO47F% LQWHUYDODQG47F) LQWHUYDODW
HDFKDVVHVVPHQWWLPH SRLQWZLOOEHSUHVHQWHG
'HVFULSWLYHVW DWLVWLFVIRUYLWDOVLJQVKHDUW UDWHERG\WHPSHUDWXUHDQGEORRG
SUHVVXUHZLOOEHSUHVHQWHG 
7KHFRPSOHWHVHW RISK\VLFDOH[DPLQDWLRQILQGLQJVZLOOEHSURYLGHGLQ
OLVWLQJV&OLQLFDOO\VLJQLILFDQWSK\VLFDOH[DPLQDWL RQDEQRUPDOLWLHVZLOOEH 
LQFOXGHGDQGVXPPDUL]HGDV$(VLIDSSURSULDWH
Efficacy:1RIRUPDOVWDWLVWLFDOFRPS DULVRQVZLOOEHSHUIRUPHG 6XPPDU\
VWDWLVWLFVIRUWKHSULPDU\DQGRWKHUHIILFDF\HQGSRLQWVZLOOEH SURYLGHG
LQFOXGLQJWKHPHDQPHGLDQVWDQGDUGGHY LDWLRQDQGVWDQGDUG
Pharmacokinetics: 'UXJH[SRVXUHZLOOEHHYDOXDWHGXVLQJ3.SDUDPHWHUV
GHULYHGIURPQRQ FRPSDUWPHQWDOPHWKRGV$OOFDOFXODWLRQVIRUWKHILQDO
DQDO\VLVZLOOEHEDVHGRQDFWXDOVDPSOLQJWLPHV,QGLYLGXDO3. SDUDPHWHUV
ZLOOEHSUHVHQWHG LQOLVWLQJVDQGVXPPDUL]HGXVLQJGHVFULSWLYHVWDWLVWLFV
Pharmacodynamics 1RIRUPDOVWDWLVWLFDOFRPSDULVRQVZLOOEHSHUIRUPHG
6XPPDU\VWDWLVWLFVZLOOEHSURYLGHGLQFOXGLQJWKHPHDQPHGLDQ VWDQGDUG
GHYLDWLRQDQGVWDQGDUGHUURU 
5$
3URWRFRO5$ $PHQGPHQW''-D QXDU\
&21),'(17,$/
Determination of Sample Size $VDPSOHVL]HRIVXEMHFWVZLOO\LHOGD
VWDQGDUGHUURURIDSSUR[LPDWHO\ 8/IRUDQ/'+PHDQFKDQJHIURP
EDVHOLQHHVWLPDWH7KLVDVVXPHVDVWDQGDUGGHYLDWLRQRI 8/IRUWKH
EDVHOLQHDQGSRVW EDVHOLQHHQGSRLQWVDQGDZLWKLQVXEMHFWFRUUHODWLRQ
HVWLPDWHRI 
Interim Analysis 'XULQJWKLVRSHQODEHO VWXG\WKH6SRQVRUZLOOUHYLHZ
VDIHW\DQGHIILFDF\ GDWDDVLWEHFRPHV DYDLODEOHGXULQJWKH7UHDWPHQW3HULRG
)ROORZLQJFRPSOHWLRQRIWKH ZHHN7UHDWPHQW3HULRG GDWDZLOOEHFOHDQHG
DQGORFNHG DWWKHLQGLYLGXDOVXEMHFWOHYHODQGZLOOEHDYDLODEOHIRUILQD O
DQDO\VLVE\WKH6SRQVRURQDUROOLQJEDVLV 
5$
3URWRFRO5$ $PHQGPHQW''-D QXDU\
&21),'(17,$/
3 TABLE OF CONTENTS 
1 TITLE PAGE .................................................... ...........................................................1  
2 SYNOPSIS ...................................................... ..............................................................4  
3 TABLE OF CONTENTS ............................................. .............................................10  
4 LIST OF ABBREVIATIONS AND DEFINITIONS ......................... .....................15  
5 TIME AND EVENTS TABLE ......................................... .........................................18  
6 INTRODUCTION................................................... ...................................................22  
 29(59,(:2) 3$52;<60$/ 12&7851$/ +(02*/2%,185,$   
 0(&+$1,602) $&7,212)5$   
 &/,1,&$/75,$/(;3(5,(1&(:,7+ 5$   
 '(9(/230(17 5$7,21$/(   
 '26(-867,),&$7,21)25678'<    
  5$7,21$/()2567$57,1*'26(0*.*  
  5$7,21$/()2586(2)/2$',1*'26(   
  5$7,21$/()25 '26((6&$/$7,2172 0*.*'$,/<$)7(5:((.  
7 STUDY OBJECTIVES AND ENDPOINTS ................................ ............................33  
 2%-(&7,9(6   
 (1'32,176   
  6$)(7<$1' 72/(5$%,/,7<    
  ()),&$&<   
  3+$50$&2.,1(7,&    
  3+$50$&2'<1$0,&    
  (;3/25$725<    
8 STUDY DESIGN .................................................. ......................................................35  
 29(59,(:2) 678'<'(6,*1   
  5$7,21$/()25 678'<'(6,*1   
 678'<3(5,2'6   
  6&5((1,1*3(5,2'   
  75($70(17    
 68%-(&75(*,675$7,21 352&('85(6    
  6&5((1,1*$1' (152//0(17    
  75($70(17 *5283$66,*10(17    
  %/,1',1*   
 ',6&217,18$7,21 &5,7(5,$   
  ',6&217,18$7,212) ,19(67,*$7,21$/ 0(',&,1$/352'8&7  
  :,7+'5$:$/)5207+( 678'<   
 ($5/<678'<7(50,1$7,21    
 (1'2)678'<   
5$
3URWRFRO5$ $PHQGPHQW''-D QXDU\
&21),'(17,$/
9 SELECTION OF STUDY POPULATION ................................. ............................43  
 ,1&/86,21&5,7(5,$   
 (;&/86,21&5,7(5,$   
 5(029$/$1' 5(3/$&(0(172) 68%-(&76,17+( 678'<  
  35(0$785( ',6&217,18$7,21    
  5(3/$&(0(172) 68%-(&76   
10 INVESTIGATIONAL MEDICINAL PRODUCTS AND 
TREATMENTS..................................................... .....................................................46  
  678'<75($70(17 $'0,1,675$7,21    
  ,'(17,7<2) ,19(67,*$7,21$/ 0(',&,1$/352'8&7$1' 75($70(17   
  75($70(17 *52836   
  '26((6&$/$7,21    
  '26,1*6&+('8/(   
  '26(35(6(17$7,21    
  0,66(''26(6   
  678'<75($70(17 0$1$*(0(17    
  35(3$5$7,21$1' ',63(16,1*   
  678'<'58*6833/<6725$*($1'+$1'/,1*  
  ',6326$/5(7851255(7(17,212) 8186(''58*  
  '58*$&&2817$%,/,7<    
  &203/,$1&(    
11 STUDY ASSESSMENTS ............................................. .............................................49  
  68%-(&7$1' %$6(/,1(',6($6(&+$5$&7(5,67,&6   
  '(02*5$3+,& '$7$   
  ',6($6($1' 35,2575($70(17 +,6725<   
  35,25$1'&21&20,7$17 0(',&$7,216    
  6$)(7<$66(660(176    
  0(',&$/$1' 685*,&$/+,6725<   
  3+<6,&$/(;$0,1$7,21    
  9,7$/6,*16   
  (/(&752&$5',2*5$0    
  NEISSERIA MENINGITIDIS 7(67,1*   
  $'9(56((9(175(&25',1*   
  /$%25$725< 6$)(7<$66(660(176    
  %/22'&+(0,675<$1' +(0$72/2*<    
  85,1$/<6,6   
  35(*1$1&< 7(67   
  31+&/21(   
  ,00812*(1,&,7<    
  ()),&$&<$66(660(176    
  3+$50$&2.,1(7,&$1' 3+$50$&2'<1$0,& $66(660(176   
  (/(&7521,& ',$5<&$5'   
  (;3/25$725< $66(660(176    
  48$/,7<2) /,)($66(660(176    
  (257&4/4&   
5$
3URWRFRO5$ $PHQGPHQW''-D QXDU\
&21),'(17,$/
  )$&,7) $7,*8(   
  (4'   
  75($70(17 6$7,6)$&7,21 48(67,211$,5(   
  %,20$5.(56    
  3+$50$&2*(120,& $66(660(176    
12 SAFETY REPORTING............................................... ..............................................56  
  '(),1,7,216    
  $'9(56((9(17   
  6(5,286$'9(56((9(17   
  $'9(56((9(1762)63(&,$/,17(5(67   
  7+520%27,& $'9(56((9(176   
  +(3$7,&$'9(56((9(176   
  3$1&5($7,& (1=<0((/(9$7,216    
  ,1-(&7,216,7(5($&7,216   
  ,1)(&7,21   
  '26(02',),&$7,21)25 27+(5$'9(56((9(176  
  (9$/8$7,21$1' &/$66,),&$7,216    
  6(9(5,7<   
  &$86$/,7<   
  5(&25',1*5(3257,1*$1'021,725,1*   
  5(&25',1*$1' 5(3257,1*   
  $'9(56((9(176   
  6(5,286$'9(56((9(176   
  '($7+   
  021,725,1*    
  3267678'<(9(176   
  63(&,$/&,5&8067$1&(6    
  35(*1$1&<    
  27+(5   
13 STATISTICAL AND ANALYTICAL PLANS .............................. .........................64  
  6$03/(6,=('(7(50,1$7,21    
  $1$/<6,63238/$7,216    
  6$)(7<3238/$7,21    
  ()),&$&<(9$/8$%/( 3238/$7,21    
  3(535272&2/3238/$7,21    
  3+$50$&2.,1(7,& 3238/$7,21    
  3+$50$&2'<1$0,& 3238/$7,21    
  67$7,67,&$/ 3/$1   
  *(1(5$/&216,'(5$7,216    
  68%-(&7',6326,7,21    
  '(02*5$3+<$1' %$6(/,1(',6($6(&+$5$&7(5,67,&6   
  6$)(7<$1$/<6,6   
  $'9(56((9(176   
  $'9(56((9(1762)63(&,$/,17(5(67   
  &/,1,&$//$%25$725< (9$/8$7,21    
5$
3URWRFRO5$ $PHQGPHQW''-D QXDU\
&21),'(17,$/
  (/(&752&$5',2*5$06    
  9,7$/6,*16   
  3+<6,&$/(;$0,1$7,21    
  ()),&$&<$1$/<6,6   
  &/,1,&$/3+$50$&2/2*< $1$/<6,6   
  3+$50$&2.,1(7,& $1$/<6,6   
  3+$50$&2'<1$0,& $1$/<6,6   
  ,17(5,0$1$/<6,6   
14 ETHICAL CONSIDERATIONS ........................................ ......................................68  
  ,167,787,21$/ 5(9,(:%2$5',1'(3(1'(17 (7+,&6&200,77((
&20081,&$7,216    
  352*5(665(32576   
  ),1$/,19(67,*$725 5(3257   
  ,1)250('&216(172) 678'<68%-(&76   
  35272&2/&203/,$1&(    
  3527(&7,212) &21),'(17,$/,7<    
  ',6&/2685(2) 678'<5(68/76   
15 REGULATORY AND ADMINISTRATIVE CONSIDERATIONS .................. ...71  
  48$/,7<$6685$1&(   
  021,725,1*    
  $8',7   
  &/,1,&$/5(6($5&+25*$1,=$7,216    
  '$7$0$1$*(0(17    
  &$6(5(3257)2506   
  6285&('2&80(176    
  35(0$785( 7(50,1$7,2125 6863(16,212)7+( 678'<  
  &/,1,&$/678'<5(3257   
  38%/,&$7,21 32/,&<   
16 REFERENCES .................................................... .......................................................74  

LIST OF TABLES  
7DEOH  7LPHDQG(YHQWV7DEOH   
7DEOH  ([SHULPHQWDODQG3UHGLFWHG3.9DOXHVIRU5$LQ+XPDQV   
7DEOH  'RVH3UHVHQWDWLRQVE\:HLJKW%UDFNHWV   
7DEOH  &OLQLFDO&KHPLVWU\+HPDWRORJ\DQG&RDJXODWLRQ$QDO\WHV   
7DEOH  *UDGLQJWKH6HYHULW\RI/RFDO ,QMHFWLRQ6LWH5HDFWLRQV   
7DEOH  7KURPERWLF(YHQW'HVFULSWLRQ0$9(&ULWHULD   
 
 
RA101495  
Protocol RA101495-01.203                                                                                  Amendment 1 DD 17 Jan uary 2017
CONFIDENTIAL 
14LIST OF FIGURES  
Figure 1  Mechanism of Action of RA101495 i n Complement System .......... ...........................23  
Figure 2  Inhibition of C5a (left) and C5b-9 (MAC; right) Formation by 
RA101495 ...................................................... ..............................................................2 3 
Figure 3  Mean (SD) Plasma RA101495 Concentr ations Over Time by Dose 
Group Following Single-Dose SC Administration in Healthy Volunteers (Study RA101495-1001) .............................. .............................................25  
Figure 4  Mean (SD) Plasma RA101495 Concentr ations Over Time by Dose 
Group Following Multiple-Dose SC Administration of 0.2 mg/kg fo r 7 
Days in Healthy Volunteers (Study RA101495-1001) .............. ..................................25  
Figure 5  Mean (SD) Red Blood Cell Lysis Over Time by Dose Group Followin g 
Single-Dose SC Administration in Healthy Volunteers (Study 
RA101495-1001) ................................................ .........................................................26  
Figure 6  Mean (SD) Red Blood Cell Lysis Ov er Time by Dose Group in the 
Multiple-Dose Cohort Once Daily for 7-Days in Healthy Volunteer s in 
(Study RA101495-1001) ......................................... .....................................................27  
Figure 7  Predicted PK and PD Effects Result ing From Weight-Bracketed Dos ing 
of RA101495 (0.1mg/kg daily) .................................. ..................................................30  
Figure 8  RA101495 Loading Dose (0.3mg/kg) and Predicted Control of 
Hemolysis After the First Dose................................. ...................................................31  
Figure 9  Simulation of PK (blue) and PD (red) of RA101495 with a Loading  
Dose of 0.3mg/kg on Day 1 Followed by 0.1mg/kg Daily Thereafter . .......................32  
Figure 10  RA101495-01.203 Study Design .................................. ...............................................35  
Figure 11  Kaplan-Meier survival of PNH pati ents stratified by LDH level ( LDH 
dichotomized at 1.5xULN compared with age- and gender- matched 
controls) ..................................................... ............................................................... ...38  
Figure 12  Patient-reported symptoms in the  International PNH registry, st ratified 
by LDH level (dichotomized at 1.5xULN). ....................... ..........................................39  
Figure 13  Inhibition of Hemolysis in vitro  Lysis of PNH RBCs Without and With 
the Presence of RA101348 (identical peptide sequence to RA10149 5) ......................40  
5$
3URWRFRO5$ $PHQGPHQW''-D QXDU\
&21),'(17,$/
4 LIST OF ABBREVIATIONS AND DEFINITIONS 
Abbreviation Definitions
$'$ DQWLGUXJDQWLERG\
$( DGYHUVHHYHQW
$/3 DONDOLQHSKRVSKDWDVH
$/7 DODQLQHDPLQRWUDQVIHUDVH
$1& DEVROXWHQHXWURSKLOFRXQW
D377$377 DFWLYDWHGSDUWLDOWKURPERSODVWLQWLPH
$67 DVSDUWDWHDPLQRWUDQVIHUDVH
$8& DUHDXQGHUWKHGUXJFRQFHQWUDWLRQWLPHFXUYH
%81 EORRGXUHDQLWURJHQ
& FRPSOHPHQWFRPSRQHQW
&PD[ PD[LPXPSODVPDFRQFHQWUDWLRQ
&3. FUHDWLQHSKRVSKRNLQDVH
&52 FOLQLFDOUHVHDUFKRUJDQL]DWLRQ
&53 &UHDFWLYHSURWHLQ
&7 FRPSXWHGWRPRJUDSK\
&7&$( &RPPRQ7HUPLQRORJ\&ULWHU LDIRU$GYHUVH(YHQWV
'' GRFXPHQWGDWH
'1$ GHR[\ULERQXFOHLFDFLG
(&* HOHFWURFDUGLRJUDP
H&5) HOHFWURQLFFDVHUHSRUWIRUP
HGLDU\ (OHFWURQLFGLDU\
(/,6$ HQ]\PHOLQNHGLPPXQRVRUEHQWDVVD\
(4' (XUR4RO'TXHVWLRQQDLUH
(257&4/4& (XURSHDQ2UJDQL]DWLRQIRU5HVHDUFKDQG7UHDWPHQWRI&DQFHU4XDO LW\RI/LIH
4XHVWLRQQDLUH 
)$&,7) )XQFWLRQDO$VVHVVPHQWRI&KURQLF,OOQHVV7KHUDS\)DWLJXH6FDOH
*&3 *RRG&OLQLFDO3UDFWLFH
**7 JDPPDJOXWDP\OWUDQVIHUDVH
*3, JO\FRV\OSKRVSKDWLG\OLQRVLWRO
*3,$3 JO\FRV\OSKRVSKDWLG\OLQRVLWRODQFKRUHGSURWHLQV
+5 KHDUWUDWH
5$
3URWRFRO5$ $PHQGPHQW''-D QXDU\
&21),'(17,$/
Abbreviation Definitions
,&) LQIRUPHGFRQVHQWIRUP
,&+ ,QWHUQDWLRQDO&RQIHUHQFHRQ+DUPRQL]DWLRQ
,(& ,QGHSHQGHQW(WKLFV&RPPLWWHH
,15 LQWHUQDWLRQDOQRUPDOL]HGUDWLR
,03 LQYHVWLJDWLRQDOPHGLFLQDOSURGXFW
,5% ,QVWLWXWLRQDO5HYLHZ%RDUG
,65 LQMHFWLRQVLWHUHDFWLRQ
,9 LQWUDYHQRXV
/'+ ODFWDWHGHK\GURJHQDVH
/)7 OLYHUIXQFWLRQWHVWV
0$& PHPEUDQHDWWDFNFRPSOH[
0$9( PDMRUDGYHUVHYDVFXODUHYHQW
0&+ PHDQFRUSXVFXODUKHPRJORELQ
0&+& PHDQFRUSXVFXODUKHPRJORELQFRQFHQWUDWLRQ
0&9 PHDQFRUSXVFXODUYROXPH
0' PXOWLSOHGRVH
0'5' PRGLILFDWLRQRIGLHWLQUHQDOGLVHDVH
0HG'5$ 0HGLFDO'LFWLRQDU\IRU5HJXODWRU\$FWLYLWLHV
05, PDJQHWLFUHVRQDQFHLPDJLQJ
1$ QRWDSSOLFDEOH
1&, 1DWLRQDO&DQFHU,QVWLWXWH
1+3 QRQKXPDQSULPDWHV
12(/ QRREVHUYHGDGYHUVHHIIHFWOHYHO
3' SKDUPDFRG\QDPLFV
3, 3ULQFLSDO,QYHVWLJDWRU
3,*$ SKRVSKDWLG\OLQRVLWROJO\FDQFRPSOHPHQWDWLRQFODVV$
3. SKDUPDFRNLQHWLFV
31+ SDUR[\VPDOQRFWXUQDOKHPRJORELQXULD
37 SURWKURPELQWLPH
377 SDUWLDOWKURPERSODVWLQWLPH
4' RQFHGDLO\
42/ TXDOLW\RIOLIH
5$
3URWRFRO5$ $PHQGPHQW''-D QXDU\
&21),'(17,$/
Abbreviation Definitions
5%& UHGEORRGFHOO
51$ ULERQXFOHLFDFLG
6$' VLQJOHDVFHQGLQJGRVH
6$( VHULRXVDGYHUVHHYHQW
6& VXEFXWDQHRXV
6' VWDQGDUGGHYLDWLRQ
6) LWHPVKRUWIRUPKHDOWKVXUYH\
623 VWDQGDUGRSHUDWLQJSURFHGXUH
V5%& VKHHS5HG%ORRG&HOO
66 VWHDG\VWDWH
7($( WUHDWPHQWHPHUJHQWDGYHUVHHYHQW
WPD[ WLPHWRFRUUHVSRQGLQJ& PD[
8/1 XSSHUOLPLWRIQRUPDO
85, XSSHUUHVSLUDWRU\LQIHFWLRQ
9$6 YLVXDODQDORJXHVFDOH
:%& ZKLWHEORRGFHOO

5$
3URWRFRO5$ $PHQGPHQW''-D QXDU\
&21),'(17,$/
5 TIME AND EVENTS TABLE 
$VVHVVPHQWVWREHSHUIRUPHGGXULQJWKHVWXG\DUHVKRZQLQ 7DEOH
5$
3URWRFRO5$  $PHQGPHQW ''-DQXDU\
&21),'(17,$/
Table 1 Time and Events Table    
Phase Screening 
Period Treatment Period 
Study Week oo -8 to 1 0 1 2 3 4 6 8 10 12  
Study Daya oo -56 to -1  1 Â± 2b 8 Â± 2  15 Â± 2  22 Â± 2  29 Â± 2  43 Â± 4  57 Â± 4  71 Â± 4  84 Â± 4 
(End of Study)  
Study Procedure pp           
ICF process and signed ICF X           
Review eligibility criteria X  X          
Medical history and demographics X          
Prior and concomitant medications X X X X X X X X X X 
Physical examination X X    X    X 
Height and weightc X X    X    X 
Vital signs X X    X    X 
Electrocardiogram X X    X    X 
Neisseria throat swabd X           
Documentation of Neisseria vaccinationd X           
Blood chemistrye X X X X X X X X X X 
Hematology X X X X X X X X X X 
Coagulationf X X X X X X X X X X 
Urinalysis X X X X X X X X X X 
PNH clone size X     X  X  X 
Pregnancy testg X X    X  X  X 
Adverse eventsh  X X X X X X X X X 
Assessment of injection site reactionsi  X X X X X X X X X 
5$
3URWRFRO5$  $PHQGPHQW ''-DQXDU\
&21),'(17,$/
Phase Screening 
Period Treatment Period 
Study Week oo -8 to 1 0 1 2 3 4 6 8 10 12  
Study Daya oo -56 to -1  1 Â± 2b 8 Â± 2  15 Â± 2  22 Â± 2  29 Â± 2  43 Â± 4  57 Â± 4  71 Â± 4  84 Â± 4 
(End of Study)  
Pharmacokinetics RA101495ij  X X X X X X X X X 
Pharmacokinetics eculizumabk X X  X  X X    
Pharmacodynamics RA101495j  X X X X X X X X X 
Anti-drug antibodyl  Xk    X  X  X 
Quality of life questionnaires            
EORTC-QLQ-C30  X    X  X  X 
FACIT-Fatigue   X    X  X  X 
EQ-5D  X    X  X  X 
Treatment satisfaction assessment          X 
Additional biomarker samplesj  X X X X X X X X X 
Pharmacogenomic analysis (optional)m  Xl         
Electronic diary training, dispensation, 
and collection  X        X 
RA101495 administrationn  X X X X X X X X X 
Study drug dispensing and returno  X  X  X X X X X 

$EEUHYLDWLRQV(257&4/4& (XURSHDQ2UJDQL]DWLRQIRU5HVHDUFK DQG7UHDWPHQWRI&DQFHU4XDOLW\RI/LIH4XHVWLRQQDLUH(4' ( XUR4RO'
TXHVWLRQQDLUH)$&,7) )XQFWLRQDO$VVHVVPHQWRI&KURQLF,OOQHVV 7KHUDS\)DWLJXH6FDOH,&) LQIRUPHGFRQVHQWIRUP/'+ ODFWDWH GHK\GURJHQDVH1$ QRW
DSSOLFDEOH3' SKDUPDFRG\QDPLF3. SKDUPDFRNLQHWLF
5$
3URWRFRO5$  $PHQGPHQW ''-DQXDU\
&21),'(17,$/
D 6WXG\9LVLWVKDYHD9LVLWZLQGRZRI Â“GD\VDIWHUWKHDFWXDOSODQQHG9LVLWGD\IRUWKHILUVWZHHNV DQGÂ“GD\VIURPZHHNWRZHHN
E 7KH'D\9LVLWVKRXOGEHVFKHGXOHGWRFRLQFLGHZLWKWKHQH[W VFKHGXOHGGRVHRIHFXOL]XPDELHÂ“DIWHUIURPWKHODVWH FXOL]XPDEGRVH
(FXOL]XPDEVKRXOG127EHDGPLQLVWHUHGDWWKH'D\9LVLWRUDW DQ\WLPHWKHUHDIWHUGXULQJWKHVWXG\
F +HLJKWZLOOEHPHDVXUHGRQO\DWWKH6FUHHQLQJ9LVLW
G $OOVXEMHFWVPXVWKDYHDQHJDWLYHWKURDWVZDEIRU Neisseria meningitidis FRORQL]DWLRQIRUHOLJLELOLW\$OOVXEMHFWVPXVWKDYHGRFXPHQWD WLRQRISULRU
Neisseria meningitidis YDFFLQDWLRQDQGERRVWHULIDSSURSULDWHSULRUWRVWXG\HQWU\ 
H ,QFOXGLQJ/'+IRUSULPDU\HIILFDF\HQGSRLQWI &RDJXODWLRQWHVWVVKRXOGEHSHUIRUPHGDFFRUGLQJWRVWDQGDUG SUDFWLFHRQDOOVXEMHFWVWDNLQJDQWLFRDJXODQWWKHUDS\
J )RUDOOIHPDOHVXEMHFWVRIFKLOGEHDULQJSRWHQWLDODQHJDWLYH VHUXPSUHJQDQF\WHVWPXVWEHGRFXPHQWHGDWWKH6FUHHQLQJ9LVLW DQGDQHJDWLYHXULQH
SUHJQDQF\WHVWPXVWEHGRFXPHQWHG DWWKH'D\9LVLWSULRUWRG RVLQJ$OORWKHUSUHJQDQF\WHVWVZLOOEHXULQH
K $OO$(VDQG6$(VVKRXOGEHPRQLWRUHGXQWLOUHVROXWLRQRUVWDE LOL]DWLRQ6$(VWKDWRFFXUZLWKLQGD\VDIWHUODVWGRVHRIVW XG\GUXJVKRXOGEHUHSRUWHG
XVLQJWKHSURFHGXUHVRXWOLQHGLQ VHFWLRQ 7KHVH6$(VVKRXOGEHUHFRUGHGL QWKH&5)IRUWKLVVWXG\IRUV XEMHFWVZKRGRQRWHQUROOLQWKH
H[WHQVLRQVWXG\DQGUHFRUGHGLQWKHH[WHQVLRQVWXG\&5)VIRUV XEMHFWVZKRHQUROOLQWKHH[WHQVLRQVWXG\
L 7KHLQMHFWLRQVLWHVKRXOGEHDV VHVVHGDWHDFKFOLQLFYLVLWWK URXJK'D\(QGRI6WXG\
M %ORRGVDPSOHVIRU3.DQG3'DQGDGGLWLRQDOELRPDUNHUVDPSOLQJ DWWKHIROORZLQJWLPHSRLQWVLQUHODWLRQVKLSWRWKHILUVWGRVH RI5$SUHGRVH
ZLWKLQKRXUEHIRUHILUVWGRVHDGPLQLVWUDWLRQDQGDWD QGKRXUVSRVWGRVHRQ'D\)RUVXEMHFWVZKRKDYHDGRVHLQF UHDVHWRPJNJ
VDPSOHVIRU3.DQG3'VKRXOGEHFROOHFWHGDWSUHGRVH'D\RI WKHQHZGRVHVHHIRRWQRWHM2QFOLQLFYLVLWGD\V3.DQG3'V KRXOGEHFROOHFWHGSULRU
WRDGPLQLVWUDWLRQRI5$
N %ORRGVDPSOHVIRU3.RIHFXOL]XPDEVKRXOGEHFROOHFWHGDWVFU HHQLQJ'D\'D\'D\DQG'D\ZHHNZHHNDQG ZHHN9LVLWV7KH
VDPSOHVKRXOGEHFROOHFWHGSULRUWRDGPLQLVWUDWLRQRI5$ 
O %ORRGVDPSOHIRU$'$RQ'D\PXVWEHREWDLQHGSULRUWRGRVLQ JRI5$
P %ORRGVDPSOHIRURSWLRQDOSKDUPDFRJHQRPLFWHVWLQJPXVWEHREW DLQHGRQ'D\
Q 2QFOLQLFYLVLWGD\VWKHVWXG\GUXJ5$VKRXOGEHDGPLQ LVWHUHGDIWHUEORRGVDPSOHVIR U3.DQG3'DUHFROOHFWHG
R 3UHILOOHGV\ULQJHVFRQWDLQLQJ5$ZLOOEHGLVSHQVHGHYHU \ZHHNV6XEMHFWVZLOODOVRUHFHLYHDVHFXUHFRQWDLQHUWRGLV SRVHRIXVHGV\ULQJHVDW
HDFKYLVLWDQGVKRXOGEULQJWKHXVHGFRQWDLQHUFRQWDLQLQJDOOX VHGV\ULQJHVWRHDFKVWXG\YLVLW$OOVWXG\GUXJV\ULQJHVDQG GLVSRVDOFRQWDLQHUVPXVWEH
UHWXUQHGWRWKHVLWHDWWKHODVWV WXG\YLVLW'RVLQJRQVWXG\Y LVLWGD\VZLOOEHKHOGXQWLOWKHFRPSOHWLRQRIWKH3.DQG3'VD PSOHEORRGFROOHFWLRQKDVEHHQ
FRPSOHWHG
5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
6 INTRODUCTION 
5D3KDUPDFHXWLFDOV,QFLVGH YHORSLQJ5$DVXEFXWDQHRXV O\Â±DGPLQLVWHUHGDPLQR
DFLGF\FOLFSHSWLGHWKDWLQKLELWVWKHFOHDYDJHRIFRPSOHPHQWFR PSRQHQW&IRUWKHWUHDWPHQW
RISDUR[\VPDOQRFWXUQDOKHPRJORELQXULD31+
3OHDVHUHIHUWRWKH,QYHVWLJDWLRQDO%URFKXUHIRUDGGLWLRQDOLQI RUPDWLRQRQWKHFKHPLVWU\
WR[LFRORJ\SKDUPDFRORJ\DQGVDIHW\RI5$EDVHGRQVWXG LHVFRQGXFWHGLQDQLPDOVDQG
WKH3KDVHKHDOWK\YROXQWHHUVWXG\
6.1 O VERVIEW OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA  
3DUR[\VPDOQRFWXUQDOKHPRJORELQXULDLVDUDUHDFTXLUHGFORQDO KHPDWRSRLHWLFVWHPFHOOGLVRUGHU
FDXVHGE\DGHILFLHQF\LQJO\FRV\OSKRVSKDWLG\OLQRVLWRO*3,OL QNHGSURWHLQVRQFHOOVXUIDFHVDQG
FKDUDFWHUL]HGE\LQWUDYDVFXODU KHPRO\VLVDQGYHQRXVWKURPERVLV 'XHWRLWVUDULW\DFFXUDWH
HVWLPDWHVRILWVSUHYDOHQFHDUHOLPLWHG7KHPRVWGHWDLOHGHSLG HPLRORJLFDOVWXG\ZDVSHUIRUPHG
LQWKH8QLWHG.LQJGRPZKLFKH VWLPDWHGWKHLQFLGHQFHDWFDV HVSHUSRSXODWLRQ\HDU
ZLWKDSUHYDOHQFHRIFDVHVSHUSRSXODWLRQ> +LOO@$VXEVHTXHQWVWXG\LQ
)LQODQGHVWLPDWHGSUHYDOHQFHWREHDSSUR[LPDWHO\SHU SRSXODWLRQ> .DLUHPR @
31+LVXVXDOO\GLDJQRVHGLQSDWLHQWVLQWKHLUHDUO\VZLWKD VOLJKWIHPDOHSUHGRPLQDQFH7KH
FRQGLWLRQDIIHFWVLQGLYLGXDOVRIDOOUDFHVDQGHWKQLFLWLHV> 6RFLH 1LVKLPXUD 5RVVH
6FKUH]HQPHLHU @
3DWLHQWVZLWK31+PD\LQLWLDOO\SUHVHQWZLWKKHPRJORELQXULDDE GRPLQDOSDLQVPRRWKPXVFOH
G\VWRQLDVDQGIDWLJXH7KHGLVHDVHLVFKDUDFWHUL]HGE\LQWUDYD VFXODUKHPRO\VLVDQGWKURPERWLF
FRPSOLFDWLRQVLQYROYLQJXQXVXDOVLWHVVXFKDVKHSDWLFPHVHQWHU LFFHUHEUDODQGWKHGHUPDOYHLQV
>3DUNHU @31+LVDFRQVHTXHQFHRIDQRQ PDOLJQDQWFORQDOH[SDQVLRQRIR QHRUPRUH
KHPDWRSRLHWLFVWHPFHOOVWKDWKDYHD FTXLUHGDVRPDWLFPXWDWLRQ RIWKH;OLQNHG
SKRVSKDWLG\OLQRVLWROJO\FDQFRPSO HPHQWDWLRQFODVV$3,*$JHQH ZKLFKLVUHTXLUHGIRUWKH
ELRV\QWKHVLVRIDOLSLGPRLHW\*3,UHVSRQVLEOHIRUDWWDFKLQJ DYDULHW\RISURWHLQVWRWKHFHOO
VXUIDFH$VDFRQVHTXHQFHRIPX WDQW3,*$DOO*3,DQFKRUHGSUR WHLQV*3,$3DUHGHILFLHQW
RQDIIHFWHGVWHPFHOOVDQGWKHLUSURJHQ\7ZR*3,$3V&'GH FD\DFFHOHUDWLQJIDFWRUDQG
&'PHPEUDQHLQKLELWRURIUHDFWLYHO\VLVQRUPDOO\H[SUHVVHG RQKHPDWRSRLHWLFFHOOVDUH
UHVSRQVLEOHIRUSURWHFWLQJEORRGFHOOVIURPWKHO\WLFDFWLYLW\ RIWKHWHUPLQDOFRPSOHPHQW
PHPEUDQHDWWDFNFRPSOH[0$&3 DWLHQWVZLWK31+DUHXQDEOHWR V\QWKHVL]HIXQFWLRQDO
YHUVLRQVRIWKHVHSURWHLQVRQKHPDWRSRLHWLFVWHPFHOOVUHVXOWL QJLQWKHDFFXPXODWLRQRI
DOWHUQDWLYHSDWKZD\FRPSOHPHQW SURWHLQVRQWKHVXUIDFHRIUHGE ORRGFHOOV5%&&FOHDYDJH
IRUPDWLRQRIWKH0$&DQGVXEVHTXHQWO\VLV7KLVLQWUDYDVFXODU KHPRO\VLVLVWKHFKDUDFWHULVWLF
FOLQLFDOPDQLIHVWDWLRQRIWKHGLVHDVH> 3DUNHU @
6.2 M ECHANISM OF ACTION OF RA101495 
5$LQKLELWVFRPSOHPHQWDFWLYDWLRQDWWKHOHYHORI&6HH )LJXUHDFOLQLFDOO\YDOLGDWHG
WDUJHWIRUWKHWUHDWPHQWRI 31+5$ELQGVZLWKKLJKDIILQ LW\WRFRPSOHPHQW&DQG
SUHYHQWVLWVFOHDYDJHE\&FRQYHUWDVHLQWRWKHFOHDYDJHSURGXF WV&DDQG&E,QKLELWLRQRI&
FOHDYDJHWKHUHIRUHSUHYHQWVWKH DVVHPEO\DQGF\WRO\WLFDFWLYLW\ RI0$&RQ*3,$3GHILFLHQW
HU\WKURF\WHV5$FDQDOVRELQGWR&EWREORFNELQGLQJRI &ZKLFKIXUWKHUSUHYHQWVWKH
5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
DVVHPEO\RIWKH&E0$&8VLQJ VXUIDFHSODVPRQUHVRQDQFHDQG DQDO\VLVRIDKLJKUHVROXWLRQ
FRFU\VWDOVWUXFWXUH5$KDV EHHQVKRZQWRELQGWRDVSHF LILFVLWHRQ&GLVWLQFWIURPWKH
HFXOL]XPDEELQGLQJVLWHDQGH[KLELWVDVWURQJDQGUDSLGDVVRFLD WLRQZLWK&FRXSOHGZLWKDVORZ
GLVVRFLDWLRQUDWH
Figure 1 Mechanism of Action of RA101495 in Complement System 

7KHGRVHGHSHQGHQWLQKLELWLRQE\5$RI&DIRUPDWLRQXSRQ DFWLYDWLRQRIWKH&ODVVLFDO
3DWKZD\LVGHSLFWHGLQWKHOHIWSDQHORI)LJXUH7KHULJKWSD QHORI)LJXUHVKRZVWKHLQKLELWLRQ
E\5$RI&EIRUPDWLRQDVPHDVXUHGE\&ERU0$&IRUPD WLRQXSRQDFWLYDWLRQRI
WKH&ODVVLFDODQG$OWHUQDWLYHFRP SOHPHQWSDWKZD\V,QWKHVHH[S HULPHQWVWKHUHODWLYHOHYHOVRI
ERWK&DDQG0$&ZHUHPHDVXUHGE\HQ]\PHOLQNHGLPPXQRVRUEHQWD VVD\V(/,6$VXVLQJ
DQWLERGLHVVSHFLILFIRU&DDQG&E
Figure 2 Inhibition of C5a (left) and C5b-9 (MAC; right) Format ion by RA101495 
 
1RWH,QKLELWRULV5$
$EEUHYLDWLRQV& FRPSOHPHQWFRPSRQHQW0$& PHPEUDQHDWWDFNF RPSOH[
Confiden al
AlternavePathway Classical Pathway
MBLPathway
APC5Convertase
(C3bC3bBb)
C5
C5a C5bC6
C5b6C7,C8,C9
MACCPC5Convertase
(C3bC4bC2a)
RA101495Lysis
Log [Inhibitor] ï­M% Inhibition, C5a Production
-8 -6 -4 -2 0 2 4050100
ConfiConfidenden
aa
l
ll

5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
6.3 C LINICAL TRIAL EXPERIENCE WITH RA101495 
&OLQLFDOWULDOH[SHULHQFHZLWK5$WRGDWHLQFOXGHVDVLQJ OH3KDVHVWXG\5$
LQKHDOWK\YROXQWHHUV7KHVWXG\5$ZDVDUDQG RPL]HGGRXEOHEOLQG
SODFHERFRQWUROOHGVLQJOHDVFH QGLQJGRVH6$'DQGPXOWLSOHGR VH0'VWXG\GHVLJQHGWR
HYDOXDWHWKHVDIHW\SKDUPDFRNLQHWLFV3.DQGSKDUPDFRG\QDPLF V3'RI5$
7KHILUVWSDUWRIWKHVWXG\6$'HYDOXDWHGDVLQJOHGRVHRI5$ YHUVXVSODFHERDWGRVH
OHYHOVDQGPJNJLQVHSDUDWHFRKRUWV7KH 6$'HQUROOHGVXEMHFWV
UHFHLYHG5$PJNJLQWZRVXEMHFWVDQG PJNJLQIRXUVXEMHFWVHDFK
DQGHLJKWVXEMHFWVUHFHLYHGSODFHERWZRSHUHDFKGRVHOHYHO
7KHVHFRQGSDUWRIWKHVWXG\0'HYDOXDWHGGDLO\GRVHVRI5$ YHUVXVSODFHERDWD
VLQJOHGRVHOHYHOPJNJ7KH0'HQUROOHGVL[VXEMHFWVIR XUUHFHLYHG5$DQGWZR
UHFHLYHGSODFHER
5$ZKHQDGPLQLVWHUHGDVDVLQJOHGRVHDQGZLWKGD\UHSH DWGRVLQJGLVSOD\HGFRQVLVWHQW
DQGSUHGLFWDEOH3.WKDWWLJKWO\FRUUHODWHGZLWKWKH3'HIIHFW LQKLELWLRQRIKHPRO\VLVDQG
VXSSUHVVLRQRIFRPSOHPHQWDFWLYLW\
7KHSODVPDFRQFHQWUDWLRQVRI5$IROORZLQJVLQJOHGRVH6& DGPLQLVWUDWLRQ6$'
VKRZHGGRVHGHSHQGHQWLQFUHDVHVD FURVVDOOGRVHOHYHOVH[DPLQHG DQGPJNJ
)LJXUH7KHPHDQ& PD[UDQJHGIURPWRQJP/DFURVVGRVHV7KHPHDQ$8& 
UDQJHGIURPWRQJ
KP/DFURVVGRVHV7KHPHDQK DOIOLIHW ZDVFRQVLVWHQW
DFURVVGRVHOHYHOVDQGUDQJHGIURPWRKRXUV
,QWKHPXOWLSOHGRVH0'SRUWLRQRIWKHVWXG\WKHGD\PHDQ &PD[DQG$8& WDXZHUH
QJP/DQGQJ
KP/UHVSHFWLYHO\ZKLFKZHUHFRQVLVWHQWZL WKUHVXOWVIURPWKHPJNJ
VLQJOHGRVHFRKRUWRYHUWKHVDPHSRVWGRVHSHULRG)ROORZLQJG DLO\VFDGPLQLVWUDWLRQIRUGD\V
WKH&PD[DQG$8& WDXLQFUHDVHGE\DSSUR[LPDWHO\DQGIROGUHVSHFWLYHO\ )LJXUH'D\
WLPHWRPD[LPXPSODVPDFRQFHQWUDWLRQPHGLDQ7 PD[ KRXUVWRWDOERG\FOHDUDQFHPHDQ
&/) P/KNJHOLPLQDWLRQUDWHFRQVWDQW. HO KDQGKDOIOLIHW  K
ZHUHDOOVLPLODUWRVLQJOHGRV HDGPLQLVWUDWLRQLQGLFDWLQJWKDW WKHDEVRUSWLRQDQGHOLPLQDWLRQRI
5$GRHVQRWFKDQJHVLJQLILFDQWO\ZLWKUHSHDWGDLO\6&DGP LQLVWUDWLRQ7KHDSSDUHQW
YROXPHRI5$GLVWULEXWLRQ9 ])VKRZHGVRPHLQFUHDVHZLWKDGPLQLVWUDWLRQRIPXOWLSOH
GRVHVRI5$PJNJ6$'PHDQ9 ]) P/NJPJNJ0'PHDQGD\9 ])
 P/NJ+RZHYHUWKHGD\9 ])IRU5$ZDVVWLOOOHVVWKDQWRWDOERG\ZDWHU
VXJJHVWLQJWKDW5$GRHVQRWGLVWULEXWHLQWRWKHH[WUDYDVF XODUVSDFHXSRQUHSHDW6&
DGPLQLVWUDWLRQ

5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
Figure 3 Mean (SD) Plasma RA101495 Concentrations Over Time by Dose Group Following 
Single-Dose SC Administration in Healthy Volunteers (Study RA10 1495-1001) 




Figure 4 Mean (SD) Plasma RA101495 Concentrations Over Time by Dose Group Following 
Multiple-Dose SC Administration of 0.2 mg/kg for 7 Days in Heal thy Volunteers 
(Study RA101495-1001) 




0.05 mg/kg 0.1 mg/kg 0.2 mg/kg 0.4 mg/kg

5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
5$GHPRQVWUDWHGVWURQJSKDUPDFRG\QDPLFHIIHFWVRQWHUPLQD OFRPSOHPHQW5$
DGPLQLVWHUHGDVDVLQJOHGRVH DFKLHYHGUDSLGGRVHGHSHQGHQWLQK LELWLRQRI ex-vivoKHPRO\VLVDV
PHDVXUHGE\DVKHHSUHGEORRGFHOOV5%&O\VLVDVVD\)LJXUH 7KHPD[LPXP3'HIIHFWZDV
DSSDUHQWDSSUR[LPDWHO\KRXUVDIWHUDVLQJOHGRVH7KHPD[LPDO SHUFHQWLQKLELWLRQRIKHPRO\VLV
FRPSDUHGWREDVHOLQHUHDFKHG tIRUWKHDQGPJNJV LQJOHGRVHFRKRUWVDQG 
IRUWKHORZHVWGRVHPJNJFRKRUW0HDQKHPRO\VLVOHYHOV UHPDLQHGEHORZEDVHOLQHIRUXS
WRGD\VLQWKHPJNJFRKRUWXSWRGD\VLQWKHPJ NJFRKRUWDQGIRUXSWRGD\VLQ
WKHDQGPJNJFRKRUWV
5$DGPLQLVWHUHGIRUGD\VDFKLHYHGLQKLELWLRQRIKHPRO\VL VWKDWZDVUDSLGDQGVXVWDLQHG
DWÂ•DFURVVWKHGRVLQJSHULRGLQDOOVXEMHFWV )LJXUH7KHPHDQSHUFHQWLQKLELWLRQRI
KHPRO\VLVFRPSDUHGWREDVHOLQH UHDFKHG!EHJLQQLQJDWWKHIL UVWWLPHSRLQWKRXUVDIWHU
GRVLQJRQ'D\DQGFRQWLQXHGWKURXJKRXWGD\VRIGRVLQJDOO LQGLYLGXDOVXEMHFWVVKRZHG
tLQKLELWLRQRIKHPRO\VLVDWDOOWLPHSRLQWV$WKRXUVDIW HUWKHODVWGRVHLQKLELWLRQRI
KHPRO\VLVZDVREVHUYHGWREH tLQDOOVXEMHFWV(LJKWGD\VDIWHUWKHODVWGRVHRI5$ 
WKHPHDQLQKLELWLRQRIKHPRO\VLVUHPDLQHG t7ZRVXEMHFWVKDGLQKLELWLRQRIKHPRO\VLV
!WKURXJKGD\VDIWHUWKHODVWGD\RIGRVLQJ+HPRO\VLVUHW XUQHGWRSUHGRVHOHYHOVLQDOO
VXEMHFWVZLWKLQWZRZHHNVIROORZLQJWKHODVWGRVH
Figure 5 Mean (SD) Red Blood Cell Lysis Over Time by Dose Group  Following Single-Dose 
SC Administration in Healthy Volunteers (Study RA101495-1001) 



0.05 mg/kg 0.1 mg/kg 0.2 mg/kg 0.4 mg/kg
5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
Figure 6 Mean (SD) Red Blood Cell Lysis Over Time by Dose Group in the Multiple-Dose 
Cohort Once Daily for 7-Days in Healthy Volunteers in (Study RA101495-1001) 
 
  
 
 
1RWH)LJXUHRQWKHULJKWLVDGXSOLFDWHRIWKHILJXUHRQWKHO HIWZLWKDQH[SDQGHG\D[LV
6DIHW\$FURVVDOOWKH6$'FRKRUWVRIWKHRIWKHVXEMHFWV WUHDWHGZLWK5$KDG
DGYHUVHHYHQWV$(VZKLFKRFFXUUHGPRUHIUHTXHQWO\LQWKHKLJ KHVWGRVHFRKRUWPJNJ
$OOVXEMHFWVLQWKH0'PJNJKDGDWOHDVW$($OO$(VU HVROYHG,QDOOFRKRUWVRIWKH
6$'DQG0'WKHUHZHUHQR$(VWKDWOHGWRVWXG\GUXJGLVFRQWLQX DWLRQ1RVHULRXV$(V6$(
RUGHDWKVRFFXUUHGGXULQJWKHVWXG\
,QWKH6$'WKHPRVWFRPPRQ$(VUHJDUGOHVVRIFDXVDOLW\LQVXEMH FWVZKRUHFHLYHGVLQJOHGRVHV
RI5$ZHUHLQMHFWLRQVLWHHU\WKHPDVXEMHFWVFRKRUW XSSHUUHVSLUDWRU\WUDFWLQIHFWLRQ
85,VXEMHFWFRKRUWVXEMHFWVFRKRUWDQGKHDGDFKH VXEMHFWVFRKRUW2WKHU$(V
WKDWRFFXUUHGLQVXEMHFWHDFKZHU HEURQFKLWLVFRKRUWFDW KHWHUVLWHSKOHELWLVFRKRUW
IDWLJXHFRKRUWDQGEDFNSDLQFRKRUW$(VLQVXEMHFWVZ KRUHFHLYHGSODFHERZHUHGLDUUKHD
P\DOJLDKHDGDFKHDQGUDVKDOOLQVXEMHFWHDFK
$OO$(VRILQMHFWLRQVLWHHU\WKHPDHYHQWVZHUHUHSRUWHGLQVXEM HFWVZKRUHFHLYHGWKHKLJKHVW
VLQJOHGRVHRI5$PJNJ $OOZHUHUHSRUWHGDV*UDGH LQVHYHULW\ZLWKQRSDLQ
WHQGHUQHVVVZHOOLQJRULQGXUDWLRQ1RWUHDWPHQWZDVUHTXLUHG DQGDOOHYHQWVUHVROYHG
VSRQWDQHRXVO\DQGUDSLGO\IROORZLQJGRVLQJ$OOWKHVH$(VZHUH FRQVLGHUHGUHODWHGWRVWXG\GUXJ
E\WKHLQYHVWLJDWRU
,QWKH0'FRKRUWWKHPRVWFRPPRQ$(LQVXEMHFWVZKRUHFHLYHGP XOWLSOHGRVHVRI5$
UHJDUGOHVVRIFDXVDOLW\ZDVLQMHFWLRQVLWHHU\WKHPDVXEMHFWV DQGKHDGDFKHVXEMHFWV2WKHU
$(VZHUHG\VSHSVLD85,EDFNSDL QGL]]LQHVVFRQWDFWGHUPDWLW LVPLOLDULDDQGUDVKDOOLQ
VXEMHFWHDFK2QHVXEMHFWKDGLQMHFWLRQVLWHSDLQGXHWRDERRV WHUYDFFLQDWLRQ$(VLQVXEMHFWV
ZKRUHFHLYHGSODFHERZHUH85,VXEMHFWVDQGLQMHFWLRQVLWHU HDFWLRQLQMHFWLRQVLWHSDLQEDFN
SDLQDQGKHDGDFKHDOOLQVXEMHFWHDFK
Pl acebo RA101495Direct Hemolysis  Direct Hemolysis  
5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
7KUHHVXEMHFWVZKRUHFHLYHG5 $KDG*UDGHLQMHFWLRQVLWH HU\WKHPD2QHRIWKHVH
VXEMHFWVUHSRUWHGVHSDUDWH$(V RILQMHFWLRQVLWHHU\WKHPDRQ 'D\'D\'D\DQG'D\
7KHRWKHUVXEMHFWVKDGH YHQWHDFKRQ'D\DQGRQ'D\ $OO$(VRILQMHFWLRQVLWH
HU\WKHPDZHUHUHSRUWHGDWDVHYHULW\RI*UDGHZLWKQRSDLQW HQGHUQHVVVZHOOLQJRULQGXUDWLRQ
1RWUHDWPHQWZDVUHTXLUHGDQGD OOHYHQWVUHVROYHGVSRQWDQHRXVO\ SULRUWRWKHQH[WGRVH$OOZHUH
FRQVLGHUHGUHODWHGWRVWXG\GUXJE\WKHLQYHVWLJDWRU2QHVXEMH FWRQSODFHERKDGD*UDGH
LQMHFWLRQVLWHUHDFWLRQVWLQJLQJDQGQXPEQHVVDQG*UDGHLQM HFWLRQVLWHSDLQVWLQJLQJ%RWK
HYHQWVZHUHDVVHVVHGDVPLOGRI*UDGHVHYHULW\DQGUHVROYHG VSRQWDQHRXVO\
,QDOOFRKRUWVODERUDWRU\DQGHOHF WURFDUGLRJUDP(&*FKDQJHV IURPEDVHOLQHZHUHFRQVLGHUHG
QRWFOLQLFDOO\VLJQLILFDQWDQGQRQHZHUHUHSRUWHGDVDGYHUVHH YHQWV
6.4 D EVELOPMENT RATIONALE  
5$LVEHLQJGHYHORSHGWRWUHDWSDWLHQWVZLWK31+%DVHGR Q3.DQG3'GDWDJHQHUDWHGWR
GDWH5$KDVWKHSRWHQWLDOWRSURYLGHVHYHUDODGYDQWDJHV RYHUWKHRQO\FXUUHQWO\DSSURYHG
WKHUDS\IRU31+HFXOL]XPDE
'DLO\DGPLQLVWUDWLRQRI5$LVH[SHFWHGWRUHVXOWLQQHDU FRPSOHWHDQGVXVWDLQHG
VXSSUHVVLRQRI&IRULPSURYHGFRQWURORIKHPRO\VLV&RQWLQXRXV LQKLELWLRQRIKHPRO\VLVLV
LPSRUWDQWLQWKHSUHYHQWLRQRIEUHDN WKURXJKKHPRO\VLV(FXOL]XP DEDWWKHDSSURYHGGRVHRI
PJELZHHNO\KDVEHHQDVVRFLDWHGZLWKEUHDNWKURXJKKHPRO\VLVLQ VRPHSDWLHQWVUHTXLULQJGRVH
LQFUHDVHVEH\RQGWKHDSSURYHGGRVH GHVFULEHGLQWKHFXUUHQWSUR GXFWODEHO> +LOO@
%UHDNWKURXJKKHPRO\VLVZLWKHFXOL]XPDEWUHDWPHQWW\SLFDOO\RFFX UVWRZDUGVWKHHQGWKH
ELZHHNO\LQIXVLRQF\FOHDQGKDVEH HQVKRZQWREHDVVRFLDWHGZLW KVXEWKHUDSHXWLFHFXOL]XPDE
OHYHOVDWWKRVHWLPHSRLQWV> 1DND\DPD %URGVN\ @'DLO\GRVLQJZLWK5$LV
GHVLJQHGWRHQVXUHWKDW&LVFRQWLQXRXVO\LQKLELWHGDQGLVWKH UHIRUHH[SHFWHGWRHOLPLQDWHHQG
RIF\FOHEUHDNWKURXJKHSLVRGHV
$VDVHOIDGPLQLVWHUHG6&SURGXFW5$KDVWKHSRWHQWLDOW RLPSURYHWUHDWPHQWVDWLVIDFWLRQ
DQGLPSURYHGRVLQJFRQYHQLHQFHIRUSDWLHQWVZLWK31+DQGPD\H QDEOHDUHGXFWLRQLQWKHFRVW
RISURYLGLQJFDUH7KHFXUUHQWVWDQGDUGRIFDUHUHTXLUHVKHDOWK SURIHVVLRQDOVWRDGPLQLVWHU
HFXOL]XPDEYLDDELZHHNO\LQWUDYHQRXV,9LQIXVLRQ3XEOLVKHG VWXGLHVRISDWLHQWSUHIHUHQFHVIRU
6&YHUVXV,9WKHUDS\VKRZDFOHDUSUHIHUHQFHIRU6&DGPLQLVWUDW LRQDQG6&DGPLQLVWUDWLRQKDV
EHHQVKRZQWRLQFUHDVHFRPSOLDQFHSDWLHQWVDWLVIDFWLRQDQG42/ DVZHOODVUHGXFHWUHDWPHQW
FRVWVGUXJUHTXLUHPHQWVDQGWKHFRPSOLFDWLRQVRILQWUDYHQRXV DFFHVV>6WRQHU %HVDUDE
@3KDVHVWXGLHVRI5$ZLOOLQFOXGHTXDQWLWDWLYHLQVWUXPHQ WVIRUHYDOXDWLQJ42/
6.5 D OSE JUSTIFICATION FOR STUDY  
6.5.1 R ATIONALE FOR STARTING DOSE (0.1  MG/KG)  
7KHPJNJGD\GRVHZDVVHOHFWHGWRVDWLVI\WKHIROORZLQJFU LWHULD
y3UHGLFWHGVWHDG\VWDWHGUXJOHYHOVIRUWKHQRPLQDODVZHOODVW KHPD[LPXPGRVHEDVHGRQ
ZHLJKWEUDFNHWLQJDUHEHORZWKHQRREVHUYHGDGYHUVHHIIHFWOHY HO12$(/YDOXHVIRU
&PD[DQG$8& REVHUYHGLQWR[LFRORJ\VWXGLHV 7DEOH
5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
y3UHGLFWHGVWHDG\VWDWH& PD[DQG$8& DUHQRWH[SHFWHGWRH[FHH GWKHYDOXHVREVHUYHG
GXULQJWKH3KDVH5$0'VWXG\LQKHDOWK\YROXQWHHUV 7DEOH
y,QKLELWLRQRIKHPRO\VLVLVH[S HFWHGWREHPDLQWDLQHGDWÂ•DW DOOWLPHVIROORZLQJD
ORDGLQJGRVHRIPJNJVHH 6HFWLRQ 7KLVSUHGLFWLRQLVVXSSRUWHGE\RYHUOD\LQJ
WKHH[SHFWHG5$SODVPDFRQFHQWUDWLRQVDWVWHDG\VWDWHZL WKWKH3.3'
UHODWLRQVKLSREWDLQHGIURP3KDVHVWXGLHVLQKHDOWK\YROXQWHHU V)LJXUH$GHTXDWHDQG
VXVWDLQHGFRQWURORIKHPRO\VLVLVDNH\FRPSRQHQWRIERWKHIILF DF\DQGVDIHW\LQ31+,Q
WKLVGLVHDVHHYHQDPRGHVWWUDQVLHQWGHFUHDVHLQFRPSOHPHQWEO RFNDGHFDQOHDGWR
LPPHGLDWHÂ³EUHDNWKURXJKÂ´LQWUDYD VFXODUKHPRO\VLVDQGUHFUXGHVFH QFHRIVHYHUH31+
V\PSWRPV7KLVFRQVLGHUDWLRQLVSDUWLFXODUO\LPSRUWDQWZLWKUHV SHFWWRWKHSRWHQWLDOIRU
PLVVHGGRVHV

Table 2 Experimental and Predicted PK Values for RA101495 in Hu mans 
Pharmacokinetic 
ParameterStatisticRA101495 
(2 mg/kg) 
NOAEL 
NHPRA101495 
(0.2 mg/kg) 
QDx7; Day 
7 Human 
(SD)RA101495 (0.1 mg/kg) 
Steady State P rediction in
Human
1RPLQDO
0LQLPDO
PJNJ
4'0D[LPXP
GRVH

PJNJ
4'
Cmax(Î¼g/mL) 0HDQ   
AUC 0-24(hÂ·Î¼g/mL) 0HDQ  

,QGLFDWHVWKHSRWHQWLDOPD[LPXPGRVHUHFHLYHGE\SDWLHQWVGXH WRZHLJKWEUDFNHWHGGRVLQJ


5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
Figure 7 Predicted PK and PD Effects Resulting From Weight-Brac keted Dosing of 
RA101495 (0.1mg/kg daily) 

1RWH3UHGLFWHGSODVPDFRQFHQWUDWLRQUDQJHEOXHOLQHVUHVXOW LQJIURPZHLJKWEUDFNHWHGGRVLQJRI5$DW
PJNJGDLO\DQGH[SHFWHG3'HIIHFWKHPRO\VLV

6.5.2 R ATIONALE FOR USE OF LOADING DOSE 
,QRUGHUWRDFKLHYHDQGPDLQWDLQKHPRO\VLVFRQWUROHIILFLHQWO\ WKH6SRQVRUSURSRVHVWKHXVHRID
VLQJOHORDGLQJGRVHRIPJNJWRDGHTXDWHO\VXSSUHVVKHPRO\V LVDIWHUWKHILUVWGRVH6LQJOH
GRVHVRIXSWRPJNJ6&ZHUHVWXGLHGDQGZHUHZHOOWROHUDWHG LQWKHSKDVH6$'VWXG\LQ
KXPDQYROXQWHHUV7KHUDWLRQDOHIRUWKHXVHRIDPJNJORDGL QJGRVHLVVXSSRUWHGE\
RYHUOD\LQJWKHH[SHFWHG5$SODVPDWURXJKFRQFHQWUDWLRQVD IWHUWKHILUVWGRVHZLWKWKH
3.3'UHODWLRQVKLSREWDLQHGIURP3KDVHVWXGLHVLQKHDOWK\YRO XQWHHUV)LJXUH%DVHGRQWKH
3.3'PRGHOGHVFULEHGLQWKHVXSSO HPHQWDU\UHSRUWWKHORDGLQJ GRVHGRHVQRWLPSDFWH[SHFWHG
H[SRVXUHVDWVWHDG\VWDWH )LJXUH

5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
Figure 8 RA101495 Loading Dose (0.3mg/kg) and Predicted Control of Hemolysis After the 
First Dose 

1RWH$ORDGLQJGRVHRIPJNJ LVSUHGLFWHGWRDFKLHYHWKHWD UJHW3'HIIHFW!KHPRO\VLVLQKLELWLRQDWWURXJK
OHYHOVWRIDFLOLWDWHLPPHGLDWHFRQWURORIKHPRO\VLVDIWHUWKH ILUVWGRVH
6.5.3 R ATIONALE FOR DOSE ESCALATION TO 0.3MG/KG DAILY AFTER WEEK 2 
$VLOOXVWUDWHGLQ )LJXUH5$GUXJOHYHOVFRUUHVSRQGLQJWRRIWKHH[SHFWHGVWH DG\
VWDWHYDOXHVDUHHVWLPDWHGWREHD FKLHYHGE\GD\7KHFRUUHV SRQGLQJLQKLELWLRQRIKHPRO\VLVLV
HVWLPDWHGWREHJUHDWHUWKDQDWERWKSHDNDQGWURXJKGUXJO HYHOV$IWHUDWOHDVWZHHNVRI
WUHDWPHQWZLWK5$DWPJNJLIDVXEMHFWKDVQRWDFKL HYHGDQDGHTXDWHUHVSRQVH
GHILQHGDVDQ/'+[8/1WKHGRVHVKRXOGEHHVFDODWHGWR PJNJGDLO\'RVH
HVFDODWLRQPD\SURFHHGRQO\LIQRVHYHUHLH*UDGHÂ•RUVH ULRXVWUHDWPHQWHPHUJHQW$(VDUH
UHSRUWHGDWWKHPJNJGDLO\GRVH

5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
Figure 9 Simulation of PK (blue) and PD (red) of RA101495 with a Loading Dose of 0.3mg/kg 
on Day 1 Followed by 0.1mg/kg Daily Thereafter.  

1RWH/RDGLQJ'RVHRIPJNJ6&GRHVQRWLPSDFWVWHDG\VWDWH 3.RI5$0 500 1000 150002468
ss trough
050100
90
Time (hours)Plasma concentration ( ï­g/mL)0.3 loading + 0.1 mpk QDplasma level
%inh% Inhibition of hemolysis
5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
7 STUDY OBJECTIVES AND ENDPOINTS 
7.1 O BJECTIVES  
x7RDVVHVVWKHVDIHW\DQGWROHUDELOLW\RI5$LQVXEMHFWVZ LWK31+
x7RDVVHVVSUHOLPLQDU\HIILFDF\RI5$LQVXEMHFWVZLWK31+ 
x7RDVVHVV3.DQG3'RI5$LQVXEMHFWVZLWK31+
7.2 E NDPOINTS  
7.2.1 S AFETY AND TOLERABILITY  
6DIHW\DVVHVVPHQWVZLOOLQFOXGHHYDOXDWLRQRI$(VDQG6$(VLQF OXGLQJPDMRUDGYHUVHYDVFXODU
HYHQW0$9(FULWHULDFOLQLFDOODERUDWRU\WHVWV(&*VYLWDOV LJQVDQGSK\VLFDOH[DPLQDWLRQV
6DIHW\HYDOXDWLRQVZLOODOVRLQF OXGHDGHWHUPLQDWLRQRIDQWLGU XJDQWLERGLHV$'$/DERUDWRU\
DVVHVVPHQWVZLOOLQFOXGH31+FORQHVL]H
7.2.2 E FFICACY  
Primary efficacy 
x7KHSULPDU\HYDOXDWLRQSHULRGL VIURP:HHNWR:HHN7KHSU LPDU\HIILFDF\HQGSRLQWLV
WKHFKDQJHIURPEDVHOLQHLQVHUXP/'+OHYHOVGXULQJWKLVSHULRG GHILQHGDVWKHPHDQ/'+
YDOXHVRI:HHNVDQGPLQXV WKHEDVHOLQHYDOXHRI/' +
Secondary efficacy:  
x&KDQJHVIURPEDVHOLQHLQ/'+WRWDOELOLUXELQWRWDOKHPRJORELQ IUHHKHPRJORELQ
KDSWRJORELQUHWLFXORF\WHVDQGKHPRJORELQXULDDWHDFKRIWKH VFKHGXOHGSRVWEDVHOLQH
DVVHVVPHQWWLPHSRLQWV
7.2.3 P HARMACOKINETIC  
x3ODVPDFRQFHQWUDWLRQVRI5$DQGLWVPDMRUPHWDEROLWHV
x0D[LPXPSODVPDFRQFHQWUDWLRQ& PD[
x7LPHFRUUHVSRQGLQJWR& PD[WPD[
x$UHDXQGHUWKHGUXJFRQFHQWUDWLRQWLPHFXUYHV$8& W
x3ODVPDFRQFHQWUDWLRQVRIHFXOL]XPDE
7.2.4 P HARMACODYNAMIC  
x&KDQJHVIURPEDVHOLQH&+ 
x&KDQJHVIURPEDVHOLQHLQV5%&O\VLVIRUWKHFODVVLFDOFRPSOHPHQ WSDWKZD\
x&KDQJHVIURPEDVHOLQHLQ:LHVODE(/,6$IRUDOWHUQDWLYHFRPSOHPH QWSDWKZD\
x&KDQJHVIURPEDVHOLQHLQ&OHYHOV
5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
7.2.5 E XPLORATORY  
x&KDQJHVIURPEDVHOLQHLQ42/TXHVWLRQQDLUHVHJ(257&4/4& )$&,7)DWLJXHDQG
(4'
x7UHDWPHQWVDWLVIDFWLRQTXHVWLRQQDLUH
x0HFKDQLVWLFELRPDUNHUVHJFRP SOHPHQWIXQFWLRQFRPSOHPHQWSU RWHLQVELRPDUNHUVRI
LQIODPPDWLRQELRPDUNHUVIRUWKURP ERVLVELRPDUNHUVRIOLYHUIX QFWLRQ
x3KDUPDFRJHQRPLFDQDO\VHVRSWLRQDO6HH 6HFWLRQ 
5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
8 STUDY DESIGN 
8.1 O VERVIEW OF STUDY DESIGN  
6WXG\5$LVDPXOWLFHQWHURSHQODEHOXQFRQWUROOH GVWXG\WRHYDOXDWHVDIHW\
HIILFDF\SKDUPDFRNLQHWLFVDQGSKDUPDFRG\QDPLFVRI5$LQ VXEMHFWVZLWK31+$
VFKHPDWLFRIWKH5$VWXG\GHVLJQLVSURYLGHG)LJXU H
Figure 10 RA101495-01.203 Study Design 



7KHVWXG\ZLOOLQFOXGHVXEMHFWV ZKRKDYH31+DQGKDYHDQLQDGHT XDWHUHVSRQVHWRHFXOL]XPDE
GHILQHGDVKDYLQJUHFHLYHGHFXOL]XPDEIRUDWOHDVWPRQWKVSOX VRQHRUPRUHRIWKHIROORZLQJ
FULWHULD
 $GRFXPHQWHGODFWDWHGHK\GURJHQDVH/'+OHYHOÂ•[WKHXSS HUOLPLWRIQRUPDO
8/1ZLWKLQGD\VSULRUWR6FUHHQLQJ
 3UHVHQFHRIDNQRZQ&PXWDWLRQFRQIHUULQJUHVLVWDQFHWRHFXOL ]XPDE
7KHSODQQHGHQUROOPHQWLVDSSUR[ LPDWHO\VXEMHFWV(QUROOPHQ WZLOOEHVWDJJHUHGVXFKWKDW
HDFK'D\9LVLWRFFXUVDWOHDVWGD\VDIWHUWKH'D\9LVLW IRUWKHSUHYLRXVO\HQUROOHGVXEMHFW
7KHVWXG\LQFOXGHVDQZHHNVFUHHQLQJSHULRGDQGDZHHN7UH DWPHQW3HULRG'XULQJWKH
7UHDWPHQW3HULRGVXEMHFWVZLOO UHWXUQWRWKHFOLQLFZHHNO\GXU LQJWKHILUVWZHHNVIROORZHGE\
YLVLWVHYHU\ZHHNVWRHYDOXDWHRIVDIHW\WROHUDELOLW\HIILF DF\3.DQG3'$GGLWLRQDO
DVVHVVPHQWVZLOOLQFOXGHLPPXQRJHQLFLW\42/TXHVWLRQQDLUHVEL RPDUNHUVDPSOHVDQGRSWLRQDO
SKDUPDFRJHQRPLFV
6DIHW\DVVHVVPHQWVZLOOLQFOXGH HYDOXDWLRQRI$(VDQG6$(VLQF OXGLQJ0$9(FULWHULDFOLQLFDO
ODERUDWRU\WHVWV(&*VYLWDOVLJQVDQGSK\VLFDOH[DPLQDWLRQV 6DIHW\HYDOXDWLRQVZLOODOVR
LQFOXGHDGHWHUPLQDWLRQRIDQW LGUXJDQWLERGLHV$'$
$OOVXEMHFWVPXVWKDYHDQHJDWLYHUHVXOWIRU Neisseria meningitidis FRORQL]DWLRQYLDDWKURDWVZDE
SULRUWRVWXG\HQWU\$OOVXEMHFWVPXVWKDYHGRFXPHQWDWLRQRIS ULRUNeisseria meningitidis 
YDFFLQDWLRQDQGERRVWHULIDSSURSUL DWHSULRUWRVWXG\HQWU\ 

5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
7KH'D\9LVLWVKRXOGEHVFKHGXOHGWRFRLQFLGHZLWKWKHQH[WV FKHGXOHGGRVHRIHFXOL]XPDELH
rGD\VDIWHUIURPWKHODVWHFXOL]XPDEGRVH(FXOL]XPDEVKRXOG 127EHDGPLQLVWHUHGDWWKH
'D\9LVLWRUDWDQ\WLPHWKHUHDIWHUGXULQJWKHVWXG\ 
'XULQJWKH7UHDWPHQW3HULRGW RPLWLJDWHWKHULVNRILQIHFWLRQ VXEMHFWVZLOOEHFRXQVHOHGDQG
UHPLQGHGRIHDUO\VLJQVDQGV\PSWRPVRI Neisseria meningitidis LQIHFWLRQ$SDWLHQWVDIHW\FDUG
GHWDLOLQJWKHVLJQVDQGV\PSWRPVRILQIHFWLRQZLWKLQVWUXFWLRQV WRVHHNLPPHGLDWHPHGLFDO
DWWHQWLRQZLOOEHSURYLGHGWRHDFKVXEMHFW7KHFDUGZLOODOVR GHVFULEHWKHVXEMHFWÂ¶VSDUWLFLSDWLRQ
LQWKHVWXG\DQGWKHULVNVRILQI HFWLRQDVVRFLDWHGZLWKLQKLELW LRQRIWKHWHUPLQDOFRPSOHPHQW
V\VWHP7KHSDWLHQWVDIHW\FDUGP XVWEHFDUULHGZLWKWKHSDWLHQ WDWDOOWLPHVZKLOHRQWUHDWPHQW
$WWKHFRQFOXVLRQRIWKH7UHDWPHQW3HULRGVXEMHFWVZKRFRPSOHWH WKHVWXG\DQGDUH
GHPRQVWUDWLQJEHQHILWZLOOKD YHWKHRSWLRQWRHQUROOLQDQRSHQ ODEHOH[WHQVLRQVWXG\WRFRQWLQXH
UHFHLYLQJWUHDWPHQWZLWK5$RUWKH\PD\UHFHLYHVWDQGDUG RIFDUHWUHDWPHQWRIIVWXG\
DIWHUFRQVXOWDWLRQZLWKWKHLUWUH DWLQJSK\VLFLDQ,IWKHVXEMHF WZLWKGUDZVHDUO\IURPWKHVWXG\IRU
DQ\UHDVRQKHVKHZLOOQRWEHHOLJLEOHIRUWKHH[WHQVLRQVWXG\ 
$OOVXEMHFWVZLOOUHFHLYHDORDGLQJGRVHRIPJNJWREHDGP LQLVWHUHG6&DWWKH'D\9LVLW
)ROORZLQJLQFOLQLFHGXFDWLRQD QGWUDLQLQJDOOVXEMHFWVZLOOV HOIDGPLQLVWHUGDLO\6&GRVHVRI
PJNJRIVWXG\GUXJHYHU\KRXUVDWDSSUR[LPDWHO\WKHVDPH WLPHHDFKGD\IRUWKH
VXEVHTXHQWZHHNV2QVWXG\FOLQLFGD\VWKHGRVHVKRXOGEHD GPLQLVWHUHGDIWH UWKH3.DQG3'
FROOHFWLRQKDVEHHQFRPSOHWHG
$IWHUDWOHDVWZHHNVRIWUHDWPHQWZLWK5$DWPJNJ GDLO\LIDVXEMHFWKDVQRW
DFKLHYHGDQDGHTXDWHUHVSRQVHGHIL QHGDVDQ/'+[8/1WKH GRVHVKRXOGEHHVFDODWHGWR
PJNJGDLO\'RVHHVFDODWLRQPD\SURFHHGRQO\LIQRVHYHUH LH*UDGHÂ•RUVHULRXV
WUHDWPHQWHPHUJHQW$(VDUHUHSRUWHGDWWKHPJNJGDLO\GRVH 
8.1.1 R ATIONALE FOR STUDY DESIGN   
No Comparator 
7KHFXUUHQWVWXG\LQ31+VXEMHFW VLVGHVLJQHGDVDQRSHQODEHO VWXG\DQGGRHVQRWLQFOXGHD
SODFHERJURXS*LYHQWKHVHYHULW\RIWKHGLVHDVHDQGWKHDYDLO DELOLW\RIDQDSSURYHGWUHDWPHQWLW
LVFRQVLGHUHGLQDSSURSULDWHWRDGPLQLVWHUDSODFHERWRVXEMHFWV ZLWK31+
Dose Selection and Presentation 
7KHVWDUWLQJGRVHVHOHFWHGIRUWKHVWXG\LVPJNJIROORZLQ JDORDGLQJGRVHRIPJNJ
7KLVGRVHOHYHORI5$LVDQWLFLSDWHGWRDFKLHYHDQGPDLQW DLQtVXVWDLQHGLQKLELWLRQRI
KHPRO\VLVEDVHGRQWKH3KDVHKHDOWK\YROXQWHHUVWXG\DQGSKDU PDFRNLQHWLFVDQG
SKDUPDFRNLQHWLFPRGHOLQJVHH 6HFWLRQ 'RVH-XVWLILFDWLRQ$VHFRQGKLJKHUGRVHOHYHO
PJNJZLOOEHDYDLODEOHIRUWKRVHVXEMHFWVZKRGRQRWDGH TXDWHO\UHVSRQGWRWKHVWDUWLQJ
GRVHLHZLWK/'+ t[8/1
'RVHSUHVHQWDWLRQDQGDGPLQLVWUDWLRQRI5$ZLOOEHGHWHUP LQHGE\DWDUJHWZHLJKWEDVHG
DSSURDFKDFFRPSOLVKHGXVLQJIL[HGGRVHE\ZHLJKWEUDFNHWVVXSS RUWLQJDZHLJKWUDQJHRIWR
NJ7KLVPHWKRGRIGRVLQJZLOOLQVXUHWKDWQRVXEMHFWUHFHL YHVDVXEWKHUDSHXWLFGRVH
5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
$YRLGDQFHRIVXEWKHUDSHXWLFGRVHVLVFULWLFDOO\LPSRUWDQWLQ3 1+WRPLQLPL]HWKHULVNRI
EUHDNWKURXJKKHPRO\VLV
Primary Efficacy Endpoint 
7KHHIILFDF\HQGSRLQWIRUWKHVWXG\LVWKHFKDQJHLQ/'+IURPE DVHOLQHWRWKHSULPDU\HYDOXDWLRQ
SHULRGPHDQRIYDOXHVDWWKH:HHN:HHN:HHNDQG:HHN YLVLWV/'+KDVEHHQ
VHOHFWHGDVWKHSULPDU\HQGSRLQWE HFDXVH/'+LVDQHQ]\PHWKDW FDWDO\]HVWKHFRQYHUVLRQRI
ODFWDWHWRS\UXYLFDFLGDQGYLFHYHUVDKLJKO\DEXQGDQWLQHU\W KURF\WHVDQGLVDZHOOHVWDEOLVKHG
PDUNHURILQWUDYDVFXODUKHPRO\V LVLQ31+6LQFHWKHDSSURYDORI HFXOL]XPDE/'+KDVHPHUJHG
DVDFOLQLFDOO\DFFHSWHGPDUNHUI RUPRQLWRULQJWKHUHVSRQVHWR WKHUDS\DQGIRULGHQWLI\LQJ
VXEMHFWVH[SHULHQFLQJEUHDNWKURXJKKHPRO\VLV> 6ROLULVÂŠ  6ROLULVÂŠ@,QVXEMHFWV
DSSURDFKLQJWKHHQGRIWKHGD\HFXOL]XPDEGRVLQJLQWHUYDOW KHUHLVDFORVHFRUUHODWLRQ
EHWZHHQWKHUHWXUQRIFRPSOHPHQW DFWLYLW\FOLQLFDOPDQLIHVWDWL RQVRIEUHDNWKURXJKLQWUDYDVFXODU
KHPRO\VLVDQGHOHYDWLRQVLQ/'+> +LOO@
Rationale for the study population and the definition of inadeq uate response  
7KHVWXG\LQFOXVLRQFULWHULDGHILQHDVXESRSXODWLRQRISDWLHQWV ZLWK31+ZKRDUHQRWDGHTXDWHO\
EHQHILWWLQJIURPVWDQGDUGRIFDUHWKHUDS\ZLWKHFXOL]XPDEDQGU HSUHVHQWVDVWXG\SRSXODWLRQLQ
ZKLFKPD\EHQHILWVIRUWUHDWPHQWZLWK5$IRU31+$OOSDW LHQWVZRXOGEHUHTXLUHGWR
KDYHDQLQDGHTXDWHUHVSRQVHWRH FXOL]XPDEDVGHILQHGE\RQHRI IRXUFKDUDFWHULVWLFVGHVFULEHG
EHORZ
 3DWLHQWVZLWKDGRFXPHQWODFWDWHGHK\GURJHQDVH/'+OHYHOÂ• [8/1/'+ZLOOEH
LQFOXGHG/'+OHYHOVDUHXVHGIRUPRQLWRULQJWKHUHVSRQVHWRHF XOL]XPDEWKHUDS\DQGIRU
LGHQWLI\LQJSDWLHQWVH[SHULHQFLQJEUHDNWKURXJKKHPRO\VLV>%URGVN\ @,QSDWLHQWV
DSSURDFKLQJWKHHQGRIWKHGD\HFXOL]XPDEGRVLQJLQWHUYDOW KHUHLVDFORVHFRUUHODWLRQ
EHWZHHQWKHUHWXUQRIFRPSOHPHQW DFWLYLW\FOLQLFDOPDQLIHVWDWL RQVRIEUHDNWKURXJK
LQWUDYDVFXODUKHPRO\VLVDQGHOHYDWLRQVLQ/'+>+LOO@
6HYHUDOOLQHVRIHYLGHQFHVXSSRUW WKHFOLQLFDOUHOHYDQFHRIDQ /'+FXWRIIRI[8/1WRGHILQH
LQDGHTXDWHUHVSRQVHWRHFXOL]XPDE
o/'+Â•[8/1LVWKHVDPHFXWRIIWKDWZDVXVHGWRGHWHUPLQHHOL JLELOLW\IRUHQUROOPHQW
LQWRWKHSLYRWDOWULDOVWKDWVXSSRUWHGWKHDSSURYDORIHFXOL]XP DE>6ROLULVÂŠ%URGVN\
@

o/'+Â•[8/1LVDVVRFLDWHGZLWKLQFUHDVHGULVNRIWKURPERHPEROL FFRPSOLFDWLRQVLQ
SDWLHQWVZLWK31+XQLYDULDWH DGMXVWHGRGGVUDWLR&, >/HH@

o/'+Â•[8/1LVDVVRFLDWHGZLWKLQFUHDVHGULVNRIDOOFDXVHPRU WDOLW\LQSDWLHQWVZLWK
31+XQLYDULDWHDGMXVWHGRGGVUDWLR&, %\FRQWUDVW/'+OHYHOV
[8/1SUHGLFWDVXUYLYDOIXQFWLRQWKDWLVLQGLVWLQJXLVKDEOHI URPDJHDQGJHQGHU
PDWFKHGKHDOWK\FRQWUROV )LJXUH>-DQJ @
5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
Figure 11 Kaplan-Meier survival of PNH patients stratified by L DH level (LDH dichotomized 
at 1.5xULN compared with age- and gender- matched controls) 

6RXUFH-DQJ 

o/'+Â•[8/1LVDVVRFLDWHGZLWKD KLJKHULQFLGHQFHRISDWLHQW UHSRUWHGV\PSWRPV
LQFOXGLQJG\VSQHDKHPRJORELQXUL DDEGRPLQDOSDLQVFOHUDOLFWH UXVFKHVWSDLQDQG
G\VSKDJLDLQWKHLQWHUQDWLRQDO31+UHJLVWU\ )LJXUH>6FKUH]HQPHLHU @


5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
Figure 12 Patient-reported symptoms in the International PNH re gistry, stratified by LDH 
level (dichotomized at 1.5xULN). 


 3DWLHQWVZKRKDYHDNQRZQ&PXWDWLRQFRQIHUULQJUHVLVWDQFHW RHFXOL]XPDEDUHLQFOXGHG
WKLVVWXG\(FXOL]XPDEVSHFLILFDOO\ELQGVWRWKHWHUPLQDOFRPSO HPHQWSURWHLQ&LQKLELWLQJ
LWVFOHDYDJHLQWR&DDQG&EE\&FRQYHUWDVHVDQGWKHUHE\SUH YHQWLQJWKHUHOHDVHRIWKH
LQIODPPDWRU\PHGLDWRU&DDQGWKHIRUPDWLRQRIWKHF\WRO\WLFSR UH&EÂ±5HFHQWO\WZR
KHWHUR]\JRXVPXWDWLRQVLQWKH&JHQHORFDOL]HGWRWKH&ELQGL QJVLWHKDYHEHHQLGHQWLILHG
ZKLFKFRQIHUQHDUFRPSOHWHUHVLVWDQFHWRHFXOL]XPDE>1LVKLPXUD @2QHPXWDWLRQ
*Äº$ZDVLGHQWLILHGLQ-DSDQHVHSDWLHQWVZLWKDSRRUUH VSRQVHWRHFXOL]XPDEDQG
WKHRWKHUZDVLGHQWLILHGLQDQ$UJHQWLQLDQSDWLHQWRI$VLDQDQF HVWU\&Äº7%RWK
PXWDWLRQVUHVXOWLQQRQV\QRQ\PRXVDPLQRDFLGVXEVWLWXWLRQVLQW KHVDPHFULWLFDODUJLQLQH
UHVLGXHDWSRVLWLRQRIWKH&SURWHLQ$UJ+LVIRU*Äº $$UJ&\VIRU
&Äº77KHVHPXWDWLRQVPDUNHGO\UHGXFHWKHELQGLQJDIILQLW\ RIHFXOL]XPDEIRU&
6LQFH5$ELQGV&DWDVLWHUHPRWHIURPWKH$UJUHVLGX H
5$KDVWKHSRWHQWLDOWKDWWRUHWDLQHIILFDF\LQWKLVVXES RSXODWLRQRIUHIUDFWRU\SDWLHQWV
,QDQ ex-vivoVWXG\XVLQJ&GHULYHGIURPRQHVXF KSDWLHQWDUHODWHGFRPSRX QGZLWKVLPLODU
SRWHQF\5$FRPSOHWHO\LQKLELWHGKHPRO\VLVLQDQ in-vitro O\VLVDVVD\ )LJXUH
6HUXPIURPWKHSDWLHQWZDVDFLGLI LHGDQGPL[HGZLWK5%&VLQWKH SUHVHQFHRUDEVHQFH
RI5$'DWHRQILOH5D3KDUPDFHXWLFDOV,QFSHUIRUPHG LQWKHODERUDWRU\RI3URI
-XQ,FKL1LVKLPXUD2VDND8QLYHUVLW\

5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
Figure 13 Inhibition of Hemolysis in vitro Lysis of PNH RBCs Without and With the Presence 
of RA101348 (identical peptide sequence to RA101495) 

1RWH&,QKLELWRU 5$DSHSWLGHLQKLELWRURI&RPSOHPHQ W&ZLWKWKHVDPHVHTXHQFHDV5$

8.2 S TUDY PERIODS  
7KHWRWDOGXUDWLRQRIVWXG\SDUWLFLSDWLRQIRUDOOVXEMHFWVZLOO EHZLOOEHXSWRZHHNVLQFOXGLQJ
D6FUHHQLQJ3HULRGRIXSWRZHH NVDQGDZHHN7UHDWPHQW3HU LRG
8.2.1 S CREENING PERIOD  
7KH6FUHHQLQJ9LVLWZLOORFFXUDWOHDVWGD\VEXWQRPRUHWKD QGD\VEHIRUHWKHILUVWGRVHRI
5$RQ'D\
8.2.2 T REATMENT  
$OOVXEMHFWVZLOOUHFHLYHWUHDWPHQWZLWK5$IURP'D\WR 'D\GXULQJWKH7UHDWPHQW
3HULRG6XEMHFWVFRPSOHWLQJWKHZHHN9LVLWDQGDUHGHPRQVWUD WLQJEHQHILWLQFRQVXOWDWLRQ
ZLWKWKHWUHDWLQJSK\VLFLDQZLOOKDYHWKHRSWLRQWRHQUROOLQ DORQJWHUPRSHQODEHOH[WHQVLRQ
VWXG\WRFRQWLQXHUHFHLYLQJWUHDWPHQWZLWK5$,IDVXEMH FWFKRRVHVQRWWRSDUWLFLSDWHLQ
WKHH[WHQVLRQVWXG\WKHVXEMHFWZLOOUHFHLYHVWDQGDUGRIFDUH WUHDWPHQWRIIÂ±VWXG\DV
UHFRPPHQGHGE\WKHWUHDWLQJSK\VLFLDQ
8.3 S UBJECT REGISTRATION PROCEDURES  
8.3.1 S CREENING AND ENROLLMENT  
:ULWWHQLQIRUPHGFRQVHQWPXVWEHREWDLQHGEHIRUH$1<VWXG\UHOD WHGSURFHGXUHVDUHSHUIRUPHG
$WWKH6FUHHQLQJ9LVLWVXEMHFWVZLOOEHDVVLJQHGDXQLTXHVXEM HFWQXPEHU7KHIROORZLQJ
DVVHVVPHQWVZLOOEHSHUIRUPHGGXULQJVFUHHQLQJ


5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
x'HPRJUDSKLFDQGEDVHOLQHFKDUDFWHULVWLFV
x0HGLFDOKLVWRU\LQFOXGLQJDGHWDLOHGKLVWRU\RI31+GLDJQRVLV LQIRUPDWLRQV\PSWRPV
FRPSOLFDWLRQVDQGWUHDWPHQWRYH UWKHPRQWKVSULRUWR6FUHHQL QJ
x5HYLHZDQGGRFXPHQWDWLRQRISULRU ZLWKLQWKHSUHYLRXVGD\V DQGFRQFRPLWDQW
PHGLFDWLRQV
x3K\VLFDOH[DPLQDWLRQLQFOXGLQJKHLJKWDQGZHLJKW
x9LWDOVLJQVKHDUWUDWHERG\WHPSHUDWXUHEORRGSUHVVXUHLQW KHVLWWLQJSRVLWLRQDIWHUUHVWLQJ
IRUDWOHDVWPLQXWHV
xOHDG(&*LQDVXSLQHSRVLWLRQO\LQJGRZQIRUDWOHDVWPL QXWHVSULRUWRDQGGXULQJWKH
UHFRUGLQJ
x%ORRGVDPSOHVIRUFOLQLFDOFKHPLVWU\LQFOXGLQJ/'+KHPDWRORJ \DQGFRDJXODWLRQ
x8ULQHVDPSOHIRUXULQDO\VLV
x6HUXPSUHJQDQF\IRUIHPDOHVRIFKLOGEHDULQJSRWHQWLDORQO\
x7KURDWVZDEIRU Neisseria meningitidis 
7KHLQFOXVLRQDQGH[FOXVLRQFULWHULDZLOOEHUHYLHZHGWRGHWHUP LQHVXEMHFWHOLJLELOLW\IRUVWXG\
SDUWLFLSDWLRQDWWKH6FUHHQLQJ9LVLWDQGSULRUWRGUXJGRVLQJR Q'D\
8.3.2 T REATMENT GROUP ASSIGNMENT  
$OOHOLJLEOHVXEMHFWVZLOOUHFHLYH5$
8.3.3 B LINDING  
7KLVLVDQRSHQODEHOVWXG\
8.4 D ISCONTINUATION CRITERIA  
8.4.1 D ISCONTINUATION OF INVESTIGATIONAL MEDICINAL PRODUCT  
,IDVXEMHFWSUHPDWXUHO\GLVFRQWLQXHVWKHLQYHVWLJDWLRQDOPHGLF LQDOSURGXFW,035$DW
DQ\WLPHSULRUWRFRPSOHWLRQRIWKH'D\9LVLWGXULQJWKH7UH DWPHQW3HULRGWKHVXEMHFWVKRXOG
UHWXUQWRFOLQLFIRUDQ(QGRI6WXG\9LVLW7KHIROORZLQJSURFH GXUHVZLOOEHFRPSOHWHGDWWKLV
YLVLW
x5HYLHZDQGGRFXPHQWDWLRQRIF RQFRPLWDQWPHGLFDWLRQV
x3K\VLFDOH[DPLQDWLRQLQFOXGLQJZHLJKW
x9LWDOVLJQVKHDUWUDWHERG\WHPSHUDWXUHEORRGSUHVVXUHLQW KHVLWWLQJSRVLWLRQDIWHUUHVWLQJ
IRUDWOHDVWPLQXWHV
xOHDG(&*LQDVXSLQHSRVLWLRQO\LQJGRZQIRUDWOHDVWPL QXWHVSULRUWRDQGGXULQJWKH
UHFRUGLQJ
5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
x%ORRGVDPSOHVIRUFOLQLFDOFKHPLVWU\KHPDWRORJ\FRDJXODWLRQ DQG31+FORQHVL]H
x8ULQHVDPSOHIRUXULQDO\VLV
x6HUXPSUHJQDQF\IRUIHPDOHVRIFKLOGEHDULQJSRWHQWLDORQO\
x5HWXUQRIHOHFWURQLFGLDU\HGLDU\WRVLWH
x&RPSOHWLRQRI42/TXHVWLRQQDLUHV
x&RPSOHWLRQRIWUHDWPHQWVDWLVIDFWLRQTXHVWLRQQDLUH
x5HFRUG$(V
x%ORRGVDPSOHVIRU
Âƒ3.DQDO\VLV
Âƒ3'DQDO\VLV
Âƒ$'$GHWHUPLQDWLRQ
Âƒ$GGLWLRQDOELRPDUNHUV
x5HWXUQRIDOOXVHGDQGXQXVHGVWXG\GUXJV\ULQJHVDQGLQMHFWLRQ GHYLFHWRVLWH
8.4.2 W ITHDRAWAL FROM THE STUDY  
6XEMHFWVZKRDUHZLWKGUDZQIURPWKHVWXG\PXVWSURPSWO\GLVFRQW LQXHWUHDWPHQWZLWK
5$DQGPDNHHYHU\HIIRUWWRUHWXUQWRWKHFOLQLFWRFRPS OHWHDQ(QGRI6WXG\9LVLWDV
GHVFULEHGLQ 6HFWLRQ $OOXQXVHGVWXG\GUXJV\ULQJHVPXVWEHUHWXUQHGWRWKHFOLQLF DV
GHVFULEHGLQ 6HFWLRQ 
8.5 E ARLY STUDY TERMINATION  
7KH6SRQVRUPD\WHUPLQDWHWKLVVWXG\HDUO\HLWKHULQLWVHQWLU HW\RULQSDUWRUDWRQHRUPRUH
VWXG\VLWHVIRUUHDVRQDEOHFDXVHSURYLGHGWKDWZULWWHQQRWLFH LVVXEPLWWHGLQDGYDQFHRIWKH
LQWHQGHGWHUPLQDWLRQ7KHLQYHVWLJ DWRUPD\DOVRWHUPLQDWHWKHV WXG\DWWKHVLWHIRUUHDVRQDEOH
FDXVHDIWHUSURYLGLQJZULWWHQQRWLFHWRWKH6SRQVRULQDGYDQFH RIWKHLQWHQGHGWHUPLQDWLRQ
$GYDQFHQRWLFHLVQRWUHTXLUHGE\HLWKHUSDUW\LIWKHVWXG\LV VWRSSHGGXHWRVDIHW\FRQFHUQV,I
WKH6SRQVRUWHUPLQDWHVWKHVWXG\IRUVDIHW\UHDVRQVWKH6SRQVR UZLOOLPPHGLDWHO\QRWLI\WKH
LQYHVWLJDWRUDQGVXEVHTXHQWO\SURYLGHZULWWHQLQVWUXFWLRQVIRU VWXG\WHUPLQDWLRQ
8.6 E ND OF STUDY  
7KHHQGRIVWXG\LVGHILQHGDVWKHGDWHRIWKHODVWVXEMHFWÂ¶VO DVWYLVLW6XEMHFWVZKRFRPSOHWHWKH
7UHDWPHQW3HULRGDQGDUHGHUL YLQJEHQHILWIURP5$ZLOO KDYHWKHRSWLRQWRHQWHUDORQJ
WHUPH[WHQVLRQVWXG\
5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
9 SELECTION OF STUDY POPULATION 
9.1 I NCLUSION CRITERIA  
7REHHOLJLEOHIRUWKLVVWXG\VXEMHFWVPXVWPHHW ALLRIWKHIROORZLQJLQFOXVLRQFULWHULD
0DOHRUIHPDOH t\HDUV
&RPSOHWHGLQIRUPHGFRQVHQWSURFH GXUHVLQFOXGLQJVLJQLQJDQGGD WLQJWKHLQIRUPHGFRQVHQW
IRUP,&)
'LDJQRVLVRI31+E\IORZF\WRPHWU\
,QDGHTXDWHUHVSRQVHWRHFXOL]XPDEGHILQHGDVKDYLQJUHFHLYHGHF XOL]XPDEIRUDWOHDVW
PRQWKVSOXVRQHRUPRUHRIWKHIROORZLQJFULWHULD
o$GRFXPHQWHGODFWDWHGHK\GURJHQDVH/'+OHYHOÂ•[WKH8/1Z LWKLQGD\VSULRU
WR6FUHHQLQJ
o3UHVHQFHRIDNQRZQ&PXWDWLRQFRQIHUULQJUHVLVWDQFHWRHFXOL] XPDE
)HPDOHVXEMHFWVRIFKLOGEHDULQJSRWHQWLDOPXVWKDYHDQHJDWLYH SUHJQDQF\WHVWDW6FUHHQLQJ
DQGZLWKLQKRXUVSULRUWRWKHILUVWGRVHRI5$
6H[XDOO\DFWLYHIHPDOHVXEMHFWVRIFKLOGEHDULQJSRWHQWLDOL HZRPHQZKRDUHQRWSRVW
PHQRSDXVDORUZKRKDYHQRWKDGDELODWHUDORRSKRUHFWRP\K\VWHU HFWRP\RUWXEDOOLJDWLRQ
DQGDOOPDOHVXEMHFWVZKRKDYHQRW EHHQVXUJLFDOO\VWHULOL]HG E\YDVHFWRP\PXVWDJUHHWR
XVHHIIHFWLYHFRQWUDFHSWLRQGXULQJWKHVWXG\(IIHFWLYHFRQWUDF HSWLRQLVGHILQHGDV
o+RUPRQDOFRQWUDFHSWLRQHJRUDO FRQWUDFHSWLYHWUDQVGHUPDOFR QWUDFHSWLYHFRQWUDFHSWLYH
LPSODQWRULQMHFWDEOHKRUPRQDOFRQWUDFHSWLYHIRUDWOHDVWP RQWKVSULRUWRVWXG\GUXJ
DGPLQLVWUDWLRQWKURXJKRXWWKHVWXG\DQGIRUZHHNVDIWHUWKH ODVWGRVHRIVWXG\GUXJ
o'RXEOHEDUULHUELUWKFRQWURO HJPDOHFRQGRPIHPDOHFRQGRP GLDSKUDJPVSRQJHRU
FHUYLFDOFDSWRJHWKHUZLWKVSHUPLFLGDOIRDPJHOILOPVXSSRVLWRU \VWDUWLQJDWWKH
6FUHHQLQJ9LVLWWKURXJKRXWWKHVWXG\DQGIRUZHHNVDIWHUWK HODVWGRVHRIVWXG\GUXJ
o,QWUDXWHULQHFRQWUDFHSWLRQGHYLFHVWDUWLQJDWWKH6FUHHQLQJ9LV LWWKURXJKRXWWKHVWXG\
DQGIRUZHHNVDIWHUWKHODVWGRVHRIVWXG\GUXJ
o7RWDODEVWLQHQFHIURPVH[XDOLQ WHUFRXUVHIRUDWOHDVWRQHFRPSO HWHPHQVWUXDOF\FOHSULRU
WRWKH6FUHHQLQJ9LVLWWKURXJKRXWWKHVWXG\DQGIRUZHHNVD IWHUWKHODVWGRVHRIVWXG\
GUXJ
o0DLQWHQDQFHRIDPRQRJDPRXVUHODWLRQVKLSZLWKDPDOHSDUWQHUZK RKDVEHHQVXUJLFDOO\
VWHULOL]HGE\YDVHFWRP\
9.2 E XCLUSION CRITERIA  
6XEMHFWVZKRPHHW ANYRIWKHIROORZLQJH[FOXVLRQFULWHU LDPXVWEHH[FOXGHGIURPWKHV WXG\
5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
3ODWHOHWFRXQWÂ—/RUDEVROXWHQHXWURSKLOFRXQW$1& FHOOVÂ—/DW6FUHHQLQJ
&DOFXODWHGJORPHUXODUILOWUDWLRQUDWHRIP/PLQPEDVHGRQPRGLILFDWLRQRIGLHWLQ
UHQDOGLVHDVH0'5'HTXDWLRQDW6FUHHQLQJ
(OHYDWLRQRIOLYHUIXQFWLRQWHVWV GHILQHGDVGLUHFWELOLUXELQ![8/1RUHOHYDWHGWUDQVDQLPDVHV
$/7RU$67![8/1 
(OHYDWLRQRIDP\ODVHRUOLSDVH![8/1
+LVWRU\RIPHQLQJRFRFFDOGLVHDVH
&XUUHQWV\VWHPLFLQIHFWLRQRUVXVSLFLRQRIDFWLYHEDFWHULDOLQI HFWLRQ
3UHJQDQWSODQQLQJWREHFRPHSUHJQDQWRUQXUVLQJIHPDOHVXEMHF WV
5HFHQWVXUJHU\UHTXLULQJJHQHUDODQHVWKHVLDZLWKLQWKHZHHNV SULRUWR6FUHHQLQJRU
H[SHFWHGWRKDYHVXUJHU\UHTXLULQJJHQHUDODQHVWKHVLDGXULQJWK HZHHN7UHDWPHQW3HULRG
$FWLYHPDOLJQDQF\UHTXLULQJVXUJHU\FKHPRWKHUDS\RUUDGLDWLRQ ZLWKLQWKHSULRUPRQWKV
VXEMHFWVZLWKDKLVWRU\RIPDOLJQDQF\ZKRKDYHXQGHUJRQHFXUDW LYHUHVHFWLRQRURWKHUZLVH
QRWUHTXLULQJWUHDWPHQWIRUDWOHDVWPRQWKVSULRUWR6FUHHQL QJZLWKQRGHWHFWDEOH
UHFXUUHQFHDUHDOORZHG
+LVWRU\RIDQ\VLJQLILFDQWPHGLFDORUSV\FKLDWULFGLVRUGHUWKDW LQWKHRSLQLRQRIWKH
LQYHVWLJDWRUZRXOGPDNHWKHVXEMHFWXQVXLWDEOHIRUSDUWLFLSDWLR QLQWKHVWXG\
7UHDWPHQWZLWKDQ\LQYHVWLJDWL RQDOPHGLFLQDOSURGXFWRULQYHVWL JDWLRQDOGHYLFHZLWKLQWKH
GD\VSULRUWR6FUHHQLQJRUSDU WLFLSDWLRQLQDQRWKHUFRQFXUUHQW FOLQLFDOWULDOLQYROYLQJD
WKHUDSHXWLFLQWHUYHQWLRQSDUWLFLSDWLRQLQREVHUYDWLRQDOVWXGLH VDQGRUUHJLVWU\VWXGLHVLV
SHUPLWWHG
8QDEOHRUXQZLOOLQJWRFRPSO\ZLWKWKHUHTXLUHPHQWVRIWKHVWXG \
9.3 R EMOVAL AND REPLACEMENT OF SUBJECTS IN THE STUDY  
9.3.1 P REMATURE DISCONTINUATION  
(YHU\UHDVRQDEOHHIIRUWVKRXOGEHPDGHWRHQFRXUDJHUHWHQWLRQR IVXEMHFWVLQWKHVWXG\
PD[LPL]HFRPSOLDQFHZLWKVWXG\GUXJDQGIDFLOLWDWHDWWHQGDQFH DWDOOVFKHGXOHGVWXG\YLVLWV
$OOVXEMHFWVKDYHWKHULJKWWRUHIXVHIXUWKHUSDUWLFLSDWLRQLQ WKHVWXG\DWDQ\WLPHDQGIRUDQ\
UHDVRQ$VXEMHFWÂ¶VSDUWLFLSDWLRQPXVWWKHUHIRUHEHWHUPLQDWH GLPPHGLDWHO\XSRQKLVKHU
UHTXHVW
7KHLQYHVWLJDWRUZLOOPDNHHYHU\ DWWHPSWWRDVFHUWDLQWKHUHDVR QVIRUGLVFRQWLQXDWLRQDQGWR
GRFXPHQWWKLVLQGHWDLOLQWKHVRXUFHGRFXPHQWDWLRQDQGWKHDSS URSULDWHVHFWLRQVRIWKHHOHFWURQLF
FDVHUHSRUWIRUPH&5)6XEMHFWVPD\EHZLWKGUDZQIURPWKHVWX G\GXHWRDQ\RIWKHIROORZLQJ
UHDVRQV
5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
x6XEMHFWZLWKGUDZVFRQVHQW
x6XEMHFWLVQRQFRPSOLDQWGHILQHGDVUHIXVDORULQDELOLW\WRDG KHUHWRWKHVWXG\SURFHGXUHV
x8QDFFHSWDEOHRULQWROHUDEOHWUHDWPHQWUHODWHG$(V
x8VHRIDQ\RWKHULQYHVWLJDWLRQDOWUHDWPHQW
x$Q\LOOQHVVRUFLUFXPVWDQFHHJLQFDUFHUDWLRQWKDWZRXOGVXE VWDQWLDOO\LPSDFWWKHVWXG\
SURFHGXUHVRURXWFRPHPHDVXUHV
x$WWKHUHTXHVWRIWKH6SRQVRUUHJXODWRU\DJHQFLHVRULQGHSHQG HQWHWKLFVFRPPLWWHH
,(&LQVWLWXWLRQDOUHYLHZERDUG,5%
x/RVVWRIROORZXS
9.3.2 R EPLACEMENT OF SUBJECTS  
(QUROOHGVXEMHFWVZKRSUHPDWXUHO\GLVFRQWLQXHVWXG\WUHDWPHQWI RUDQ\UHDVRQSULRUWRWKH'D\
9LVLWPD\EHUHSODFHGDWWKHGLVFUHWLRQRIWKH6SRQVRULQ RUGHUWRREWDLQDQDGHTXDWHQXPEHU
RIHYDOXDEOHVXEMHFWVVHH 6HFWLRQ 
5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
10 INVESTIGATIONAL MEDICINAL PRODUCTS AND TREATMENTS 
10.1 S TUDY TREATMENT ADMINISTRATION  
10.1.1 I DENTITY OF INVESTIGATIONAL MEDICINAL PRODUCT AND TREATMENT  
7KHLQYHVWLJDWLRQDOPHGLFLQDO SURGXFW,035$ZLOOEHVX SSOLHGDVDVWHULOH
SUHVHUYDWLYHIUHHDTXHRXVVROXWLRQSUHILOOHGLQWRP/JODVV V\ULQJHVZLWKDJDXJHÃ²LQFK
VWDNHGQHHGOHSODFHGZLWKLQDVHOIDGPLQLVWUDWLRQGHYLFH
6XEMHFWVZLOOEHLQVWUXFWHGWRVHO IDGPLQLVWHU6&GRVHVGDLO\ 7KHGRVHGRVHYROXPHIRUHDFK
LQMHFWLRQZLOOGHSHQGRQWKHGRVH UHTXLUHPHQWDQGVXEMHFWÂ¶VERG \ZHLJKWVHH6HFWLRQDQG
6HFWLRQ
10.1.2 T REATMENT GROUPS  
$OOHOLJLEOHVXEMHFWVZLOOUHFHLYHDVLQJOHORDGLQJGRVHRI PJNJ5$6&IROORZHGE\
VWXG\GUXJDWPJNJ6&RQFHGDLO\
10.1.2.1 D OSE ESCALATION  
$IWHUZHHNVRIWUHDWPHQWZLWK5$DWPJNJLIDVXE MHFWKDVQRWDFKLHYHGDQ
DGHTXDWHUHVSRQVHGHILQHGDVDQ/'+[8/1WKHGRVHVKRXOG EHHVFDODWHGWRPJNJ
GDLO\'RVHHVFDODWLRQPD\SURFHHGRQO\LIQRVHYHUHLH*UD GHÂ•RUVHULRXVWUHDWPHQW
HPHUJHQWDGYHUVHHYHQWVDUHUHSRUWHGDWWKHPJNJGRVH
)RUVXEMHFWVZKRKDYHDGRVHLQFUHDVHWRPJNJVDPSOHVIRU 3.DQG3'VKRXOGEHFROOHFWHG
DWSUHGRVHRIWKHILUVWGD\RIW KHQHZGRVHWKHQDWVFKHGXOHG YLVLWVSHUWKH7LPHDQG(YHQWV
7DEOH7DEOH
10.1.3 D OSING SCHEDULE  
7KH'D\9LVLWVKRXOGEHVFKHGXOHGWRFRLQFLGHZLWKWKHQH[WV FKHGXOHGGRVHRIHFXOL]XPDELH
rGD\VDIWHUIURPWKHODVWHFXOL]XPDEGRVH(FXOL]XPDEVKRXOG 127EHDGPLQLVWHUHGRQ
WKH'D\9LVLWRUDWDQ\WLPHWKHUHDIWHUGXULQJWKHVWXG\
$OOVXEMHFWVZLOOUHFHLYHDORDGLQJGRVHRIPJNJGRVHRI5$ RQ'D\ZKLFKZLOOEH
DGPLQLVWHUHGGXULQJWKHVWXG\YLVLWE\WKHVLWHVWDII'XULQJW KHUHPDLQGHURIWKH7UHDWPHQW
3HULRGVXEMHFWVZLOOVHOIDGPLQLVWHUWKHGDLO\GRVHPJNJ RUPJNJHYHU\KRXUVDW
DSSUR[LPDWHO\WKHVDPHWLPHHDFKGD\2QGD\VRIWKHVFKHGXOHG VWXG\YLVLWDWWKHLQYHVWLJDWRU
VLWHWKHGRVHPXVWEHDGPLQLVWH UHGDIWHUWKHEORRGZRUNLVFRP SOHWHGDWWKHLQYHVWLJDWRUVLWH
10.1.4 D OSE PRESENTATION  
'RVHVRI5$ZLOOEHGHWHUPLQH GE\DWDUJHWGRVHDQGZHLJK WDFFRPSOLVKHGXVLQJDIL[HG
GRVHE\ZHLJKWEUDFNHWV7KHVHEUDFNHWVDUHJURXSHGE\ERG\ZHLJ KWFDWHJRU\VXFKWKDWHDFK
VXEMHFWZLOOUHFHLYHWKHQROHVVWKDQWKHWDUJHWPLQLPXPGRVHW RDYRLGVXEWKHUDSHXWLFGRVLQJ
)RUWKHPJNJGRVHVXEMHFWVZLOOUHFHLYHDWDPLQLPXPD IL[HGGRVHRIPJNJUDQJH
5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
WRPJNJ)RUWKHPJNJGRVHOHYHOVXEMHFWVZLO OUHFHLYHDPLQLPXPGRVHRI
PJNJUDQJHPJNJWRPJNJ7DEOHVXPPDUL]HVGRVH SUHVHQWDWLRQVIRU5$
PJNJDQGPJNJGRVHV6XEMHFWVZKRSUHVHQWZLWKDKLJK HUERG\ZHLJKW!NJZLOO
EHDFFRPPRGDWHGRQDFDVHE\FDVHEDVLVLQFRQVXOWDWLRQZLWK WKHPHGLFDOPRQLWRU
Table 3 Dose Presentations by Weight Brackets 
Target 
Dose 
(mg/kg)  Dose Presentation 
Weight Range 
(kg) Dose Range 
(mg/kg) Fill Volume Dose  
Number mL mg 
0.1 1 0.150 6 Â•43 to <61 0.10 to 0.14 
0.1 2 0.220 8.8 Â•61 to <88 0.10 to 0.14 
0.1 3 0.310 12.4 Â•88 to <109  0.11 to 0.14 
0.3 4 0.416 16.6 Â•43 to <56 0.30 to 0.39 
0.3 5 0.574 23 Â•56 to <77 0.30 to 0.41 
0.3 6 0.810 32.4 Â•77 to <109  0.30 to 0.42 

10.1.4.1 M ISSED DOSES  
,IDVXEMHFWPLVVHVRQHGRVHLHGD\RI5$WKHVXEM HFWVKRXOGGRFXPHQWWKHPLVVHG
GRVHLQKLVKHUVXEMHFWHGLDU\ DQGWDNHWKHQH[WSODQQHGGRVH DVVFKHGXOHG7KHVXEMHFWVKRXOG
FRQWDFWWKHLQYHVWLJDWRUDVVRRQDVSRVVLEOH,IDVXEMHFWPLVV HVRUPRUHGRVHVWKHVXEMHFWPXVW
QRWLI\WKHLQYHVWLJDWRULPPHGLDWHO\
10.2 S TUDY TREATMENT MANAGEMENT  
10.2.1 P REPARATION AND DISPENSING  
3UHILOOHGV\ULQJHVZLOOEHGLVSHQVHGWRHDFKVXEMHFWHYHU\Z HHNVEHJLQQLQJRQ'D\RIWKH
7UHDWPHQW3HULRG
6XEMHFWVZLOOEHSURYLGHGWUDLQLQJDQGGHWDLOHGLQVWUXFWLRQVUH JDUGLQJDGPLQLVWUDWLRQRI
5$XVLQJWKHSUHILOOHGV\ULQJHVDQGWKHLQMHFWLRQGHYLFH ZLOOEHVXSSOLHGLQDVHSDUDWH
PDQXDO
10.2.2 S TUDY DRUG SUPPLY , STORAGE , AND HANDLING  
5$ZLOOEHSURYLGHGDVDVWHULO HSUHVHUYDWLYHIUHHDTXH RXVVROXWLRQIRULQMHFWLRQ
FRQWDLQLQJPJP/RIDFWLYHLQJUHGLHQW5$LQDIRUPXO DWLRQRIP0VRGLXP
SKRVSKDWHDQGP0VRGLXPFKORUL GHDWDS+RISUHILOOHGL QWRDP/JODVVV\ULQJHZLWKD
Ã²LQFKJDXJHVWDNHGQHHGOH6L[GRVDJHVWUHQJWKVZLOOEHVX SSOLHGDVVKRZQLQ7DEOH
5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
7KH,03VKRXOGEHVWRUHGDWÂƒ&WRÂƒ&DWWKHVWXG\VLWH2QFH GLVSHQVHGWRVXEMHFWVWKH,03
PD\EHVWRUHGDWFRQWUROOHGURR PWHPSHUDWXUHÂƒ&WRÂƒ&>Âƒ )WRÂƒ)@IRUXSWRGD\V
SURWHFWHGIURPVRXUFHVRIKHDWOLJKWDQGGDPDJH6WRUDJHRI,0 3RXWVLGHRIURRPWHPSHUDWXUHV
VKRXOGEHDYRLGHG
6XEMHFWVZLOOEHLQVWUXFWHGWRVHO ILQMHFW6&GRVHVGDLO\HYHU\ KRXUVDWDSSUR[LPDWHO\WKH
VDPHWLPHHDFKGD\7KHVXEMHFWZLOOEHSURYLGHGZLWKDQLQMHFW LRQGHYLFHIRUXVHGXULQJWKH
VWXG\6XEMHFWPD\LQMHFWLQWKHDEGRPHQSUHIHUUHGVLWHWKL JKRUXSSHUDUP
$OOVXEMHFWVZLOOUHFHLYHDVWXG\GUXJNLWWKDWZLOOLQFOXGH5$ SUHILOOHGV\ULQJHVDV\ULQJH
GLVSRVDOFRQWDLQHUDOFRKROZL SHVDQGDGKHVLYHGUHVVLQJV
10.2.3 D ISPOSAL , RETURN , OR RETENTION OF UNUSED DRUG 
$WDOOYLVLWVVXEMHFWVZLOODOVRUHFHLYHDVHFXUHFRQWDLQHUWR GLVSRVHRIXVHGV\ULQJHVZKLOHDW
KRPH$WHDFKYLVLWWKHVXEMHFWVKRXOGEULQJWKHXVHGFRQWDLQHU FRQWDLQLQJDOOXVHGV\ULQJHVWREH
UHWXUQHGWRWKHVLWH7KHXQXVHGVWXG\GUXJXQXVHGV\ULQJHVV KRXOGEHUHWDLQHGE\WKHVXEMHFW
DQGEHXVHGILUVWLQWKHLPPHGLDWHWZRZHHNV
$OOVWXG\GUXJV\ULQJHVDQGGLVSRVDOFRQWDLQHUVPXVWEHUHWXU QHGWRWKHVLWHDWWKHODVWVWXG\
YLVLW
10.2.4 D RUG ACCOUNTABILITY  
$QHGLDU\ZKHUHWKHVXEMHFWGRFXPHQWVVWXG\GUXJDGPLQLVWUDWLR QZLOOEHXVHGWRUHFRQFLOH
DFFRXQWDELOLW\GXULQJWKHVWXG\7KHQXPEHURIVWXG\GUXJV\ULQ JHVGLVSHQVHGXVHGDQGUHWXUQHG
ZLOOEHGRFXPHQWHG
10.3 C OMPLIANCE  
6XEMHFWVZLOOEHUHTXLUHGWRUHF RUGWKHGDWHWLPHDQGORFDWLR QRILQMHFWLRQVHDFKGD\LQDQH
GLDU\7KHHGLDU\HQWULHVZLOO EHHYDOXDWHGWRGHWHUPLQHFRPSO LDQFHZLWKVWXG\GUXJ
DGPLQLVWUDWLRQ,IDVXEMHFWGRHVQRWFRQILUPGDLO\GRVLQJXVLQ JWKHHGLDU\WKHLQYHVWLJDWRUZLOO
UHFHLYHDQDXWRPDWHGQRWLILFDWLRQWRFRQWDFWWKHVXEMHFW
5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
11 STUDY ASSESSMENTS 
3OHDVHUHIHUWR 7DEOHIRUWKHWLPLQJRIVWXG\DVVHVVPHQWV
11.1 S UBJECT AND BASELINE DISEASE CHARACTERISTICS  
11.1.1 D EMOGRAPHIC DATA 
7KHIROORZLQJGHPRJUDSKLFGDWDZLOOEHFROOHFWHGGDWHRIELUWK JHQGHUHWKQLFLW\DQGUDFH
11.1.2 D ISEASE AND PRIOR TREATMENT HISTORY  
$GHWDLOHGKLVWRU\RI31+IRUDPLQLPXPRIPRQWKVSULRUWR6F UHHQLQJZLOOEHREWDLQHG
LQFOXGLQJEXWQRWOLPLWHGWRWKHIROORZLQJGDWDGDWHRIGLDJ QRVLV31+FORQHVL]HDWGLDJQRVLV
LIDYDLODEOHKLVWRU\RIWKURPERWLFHYHQWVKLVWRU\RIWUDQVI XVLRQVDQGKLVWRU\RI31+VSHFLILF
SULRUWKHUDS\HJLPPXQRVXSSUH VVLYHVDQWLFRDJXODQWVDVVRFLD WHGERQHPDUURZGLVRUGHUV
7KHGDWHHFXOL]XPDEWUHDWPHQWZ DVLQLWLDWHGDQGGRVHUHFHLYHGZ LOOEHGRFXPHQWHG$GRVLQJ
KLVWRU\IRUHDFKVXEMHFWLQFOXGL QJGDWHVDQGDOOGRVDJHFKDQJH VIRUDPLQLPXPRIPRQWKVSULRU
WR6FUHHQLQJZLOODOVREHUHFRUGHG
11.1.3 P RIOR AND CONCOMITANT MEDICATIONS  
$OOSUHVFULSWLRQVDQGRYHUWKHF RXQWHUPHGLFDWLRQVWDNHQGXULQJ WKHGD\VSULRUWRWKH
6FUHHQLQJ9LVLWZLOOEHGRFXPHQWHG
&RQFRPLWDQWPHGLFDWLRQVLQFOXGHDQ\SUHVFULSWLRQRURYHUWKHFR XQWHUPHGLFDWLRQWKDWLV
RQJRLQJRQ'D\RUWKDWLVLQLWLDWHGIROORZLQJWKHILUVWGRVH RIVWXG\GUXJRQ'D\
)LQGLQJVZLOOEHUHFRUGHGRQWKHVXEMHFWÂ¶VVRXUFHGRFXPHQWVDQG HQWHUHGRQWKHDSSURSULDWH
H&5)$Q\FKDQJHVWRFRQFRPLWDQWPHGLFDWLRQVGXULQJWKH7UHDWPH QW3HULRGZLOOEHUHFRUGHGLQ
WKHH&5)
11.2 S AFETY ASSESSMENTS  
11.2.1 M EDICAL AND SURGICAL HISTORY  
5HOHYDQWPHGLFDOKLVWRU\ZLOOEHGRFXPHQWHGWRDVVHVVVXEMHFWH OLJLELOLW\
'HWDLOHGPHGLFDOKLVWRU\UHJDUGLQJWKHRFFXUUHQFHRIVSHFLILFH YHQWVRUFRQGLWLRQVHJ
XQGHUO\LQJERQHPDUURZSDWKRORJ\PDMRUYDVFXODUHYHQWVSXOPRQ DU\K\SHUWHQVLRQLPSDLUHG
UHQDORUKHSDWLFIXQFWLRQLQIHFWLRQVPDOLJQDQFLHVIRUDPLQL PXPRIPRQWKVSULRUWR
6FUHHQLQJZLOODOVREHFROOHFWHG
11.2.2 P HYSICAL EXAMINATION  
3K\VLFDOH[DPLQDWLRQVZLOOLQFOXGHWKHIROORZLQJDVVHVVPHQWV
x*HQHUDOLQVSHFWLRQ
5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
x:HLJKWNJDQGKHLJKWKHLJKWLQFPWREHFROOHFWHGDW6FUHHQL QJ9LVLWRQO\
x([DPLQDWLRQRIWKHLQMHFWLRQVLWHDQGGUDLQLQJQRGHV
x+HDGHDUVH\HVQRVHWKURDWH[DPLQDWLRQ
x0XFRVDOH[DPLQDWLRQIRULFWHUXV
x&DUGLDFH[DPLQDWLRQ
x$XVFXOWDWLRQRIOXQJV
x$EGRPLQDOH[DPLQDWLRQOLYHUVSOHHQDQGORZHUDEGRPHQ
x$VVHVVPHQWIRUQHXURORJLFDOGHILFLWV
x0XVFXORVNHOHWDODVVHVVPHQW
$Q\DEQRUPDOLWLHVIRXQGZLOO EHUHFRUGHGLQWKHH&5)
11.2.3 V ITAL SIGNS  
9LWDOVLJQVKHDUWUDWHERG\WHPSHUDWXUHDQGEORRGSUHVVXUH ZLOOEHPHDVXUHGLQWKHVLWWLQJ
SRVLWLRQDIWHUUHVWLQJIRUDWO HDVWPLQXWHV,IEORRGVDPSOHV DUHVFKHGXOHGDWWKHVDPHWLPHYLWDO
VLJQVVKRXOGEHPHDVXUHGEHIRUHWKHEORRGGUDZ%ORRGSUHVVXUH PD\EHPHDVXUHGPDQXDOO\RU
E\DXWRPDWHGGHYLFHSUHIHUDEO\ LQWKHQRQGRPLQDQWDUP7KHVD PHPHDVXUHPHQWWHFKQLTXH
VKRXOGEHXVHGWKURXJKRXWWKHVWXG\IRUDOOVXEMHFWV7HPSHUDWX UHZLOOEHPHDVXUHGZLWKDQ
HOHFWURQLFGHYLFH
11.2.4 E LECTROCARDIOGRAM  
6XEMHFWVVKRXOGEHLQDVXSLQHSRVLWLRQO\LQJGRZQIRUDWOHD VWPLQXWHVSULRUWRDQGGXULQJWKH
OHDG(&*UHFRUGLQJ(&*VZ LOOEHDVVHVVHGDVQRUPDORUDEQRU PDOE\WKHLQYHVWLJDWRUDQ\
DEQRUPDOILQGLQJVZLOOEHGHVFUL EHGLQWKHH&5)DQGWKHLQYHVWL JDWRUZLOODVVHVVFOLQLFDO
VLJQLILFDQFH7KH(&*UHFRUGLQJVWULSZLOOEHVLJQHGDQGGDWHG E\WKHLQYHVWLJDWRUDQGVWRUHGLQ
WKHPHGLFDOUHFRUGV
(&*VVKRXOGEHSHUIRUPHGSULRUW REORRGGUDZVZKHQERWKDVVHVVP HQWVDUHFRPSOHWHGVHH
7DEOH
11.2.5 NEISSERIA MENINGITIDIS  TESTING  
$OOVXEMHFWVPXVWKDYHDQHJDWLYHUHVXOWIRU Neisseria meningitides FRORQL]DWLRQYLDDWKURDWVZDE
SULRUWRVWXG\HQWU\7KHWKURDWVZDEVIRU Neisseria meningitidis ZLOOEHREWDLQHGDW6FUHHQLQJ
DQGVHQWWRDFHUWLILHGODERUDWRU\IRUDQDO\VLVWRFRQILUPDEVH QFHRIFRORQL]DWLRQ
$OOVXEMHFWVPXVWKDYHGRFXPHQWDWLRQRISULRU Neisseria meningitidis YDFFLQDWLRQDQGERRVWHULI
DSSURSULDWHSULRUWRVWXG\HQWU\
11.2.6 A DVERSE EVENT RECORDING  
*XLGDQFHRQWKHLGHQWLILFDWLRQPRQLWRULQJDQGUHSRUWLQJRI$( VLVSURYLGHGLQ 6HFWLRQ 
5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
11.2.7 L ABORATORY SAFETY ASSESSMENTS  
11.2.7.1 B LOOD CHEMISTRY AND HEMATOLOGY  
&OLQLFDOFKHPLVWU\DQGKHPDWRORJ\DQDO\WHVWREHFROOHFWHGDUH LGHQWLILHGLQ 7DEOHDQGVKRXOG
EHSHUIRUPHGDVVSHFLILH GLQWKH7LPHDQG(YHQWV 7DEOH$OOFRDJXODWLRQWHVWVVKRXOGEH
SHUIRUPHGDVSHUVWDQGDUGSUDFWLFHRQDQ\VXEMHFWWDNLQJDQWLFR DJXODQWWKHUDS\LQDGGLWLRQWR
VSHFLILHGDVVHVVPHQWVLQWKL VVFKHGXOHRIHYHQWV
Table 4 Clinical Chemistry, Hematology, and Coagulation Analyte s 
Clinical Chemistry Hematology
DODQLQHDPLQRWUDQVIHUDVH$/7 IUHHKHPRJORELQ
DOEXPLQ KDSWRJORELQ
DONDOLQHSKRVSKDWDVH$/3 KHPDWRFULW
DP\ODVH KHPRJORELQ
DVSDUWDWHDPLQRWUDQVIHUDVH$67 PHDQFRUSXVFXODUKHPRJORELQ0&+
ELFDUERQDWH PHDQFRUSXVFXODUKHPRJORELQFRQFHQWUDWLRQ
ELOHDFLGV 0&+&
ELOLUXELQWRWDOGLUHFWDQGLQGLUHFW PHDQFRUSXVFXODUYROXPH0&9
EORRGXUHDQLWURJHQ%81 SODWHOHWFRXQW
FDOFLXP 5%&FRXQW
FKORULGH UHWLFXORF\WHFRXQW
FUHDWLQLQH ZKLWHEORRGFHOO:%&FRXQWDQGGLIIHUHQWLDO
JDPPDJOXWDP\OWUDQVIHUDVH**7 Coagulation 
JOXFRVH LQWHUQDWLRQDOQRUPDOL]HGUDWLR,15SURWKURPELQ
WLPH37ODFWDWHGHK\GURJHQDVH/'+
OLSDVH ILEULQRJHQ
SRWDVVLXP SDUWLDOWKURPERSODVWLQWLPH377RUDFWLYDWHG
SDUWLDOWKURPERSODVWLQWLPH D377RU$377 VRGLXP
WRWDOSURWHLQ Other
XULFDFLG &UHDFWLYHSURWHLQ&53
 FUHDWLQHSKRVSKRNLQDVH&3.

5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
11.2.7.2 U RINALYSIS  
$XULQDO\VLVZLOOEHSHUIRUPHGWRPHDVXUHS+VSHFLILFJUDYLW\ SURWHLQTXDOLWDWLYHJOXFRVH
TXDOLWDWLYHNHWRQHVTXDOLWDWLYHELOLUXELQTXDOLWDWLYH XURELOLQRJHQRFFXOWEORRG
KHPRJORELQDQGFHOOV$PLFURV FRSLFH[DPLQDWLRQZLOOEHSHUIRU PHGLIQHFHVVDU\
+HPRJORELQXULDZLOOEHDVVHVVHGXVLQ JDXULQHFRORULPHWULFVFRU LQJV\VWHP
11.2.7.3 P REGNANCY TEST 
$VHUXPSUHJQDQF\WHVWIRUKXPDQFKRULRQLFJRQDGRWURSLQZLOOEH SHUIRUPHGRQIHPDOHVXEMHFWV
RIFKLOGEHDULQJSRWHQWLDODW6FUHHQLQJ
$XULQHGLSVWLFNSUHJQDQF\WHVWKXPDQFKRULRQLFJRQDGRWURSLQ ZLOOEHSHUIRUPHGRQIHPDOH
VXEMHFWVRIFKLOGEHDULQJSRWHQWLDODW'D\SUHGRVHDQG'D\ 'D\DQG'D\(QGRI
6WXG\
11.2.8 PNH  CLONE  
%ORRGVDPSOHIRUPHDVXUHPHQWRI31+ FORQHVL]HZLOOEHFROOHFWH GDW6FUHHQLQJDQG'D\
'D\DQG'D\RU(QGRI6WXG\9LVLW31+FORQHVL]HZLOO EHGHWHUPLQHGE\SHULSKHUDO
EORRGIORZF\WRPHWU\DQDO\VLV5%&VDQGJUDQXORF\WHV
11.2.9 I MMUNOGENICITY  
$PXOWLWLHUHG$'$WHVWLQJDSS URDFKKDVEHHQLPSOHPHQWHGDFFRUG LQJWR)'$*XLGDQFHIRU
,QGXVWU\$VVD\'HYHORSPHQWDQG9DOLGDWLRQ)RU,PPXQRJHQLFLW\7 HVWLQJ2I7KHUDSHXWLF
3URWHLQ3URGXFWV$SULO
%ORRGVDPSOHVIRU$'$VZLOOEHFROOHFWHGSULRUWRGRVLQJRQ'D\ DQGRQ'D\'D\DQG
'D\RUDWWKH(QGRI6WXG\9LVLWLQDOOHQUROOHGVXEMHFWV 7KHVHVDPSOHVZLOOEHEDQNHGDQG
XVHGWRLQYHVWLJDWHDQGFKDUDFWH UL]HDQ\$'$UHVSRQVHRYHUWLPH LQWKHJHQHUDOVWXG\
SRSXODWLRQ
6DPSOHVZLOOEHVHQWWRDFHQWUDOODERUDWRU\WRGHWHUPLQHWKHS UHVHQFHRUDEVHQFHRIDQWLERGLHV
DJDLQVW5$XVLQJDQLQLWLDOVFUHHQLQJDVVD\EDVHGRQDQ( /,6$IRUPDW6DPSOHVWHVWLQJ
SRVLWLYHDUHWKHQVXEMHFWHGWRDFRQILUPDWRU\DVVD\&RQILUPHG SRVLWLYHVDUHWKHQIXUWKHU
FKDUDFWHUL]HGE\WLWHULQJ1HXWUDOL]LQJDQWLERGLHVZLOOWKHQE HFRQILUPHGXVLQJDELRDVVD\RI
LQKLELWLRQRIVKHHSUHGEORRGFHOOKHPRO\VLV
,QWKHHYHQWRIXQH[SODLQHGDOWHU DWLRQVLQGUXJFRQFHQWUDWLRQV RI5$RUORVVRIHIILFDF\LQ
SUHYLRXVO\ZHOOFRQWUROOHGSDWLHQ WVGHWHUPLQDWLRQRI$'$LQFO XGLQJDVVD\IRUQHXWUDOL]LQJ
$'$ZLOOEHPDGH6KRXOGDSDWLHQ WGHYHORSQHXWUDOL]LQJ$'$ WKHLPSDFWRQ5$
SKDUPDFRNLQHWLFVZLOOEHFRQVLGHU HGLQFRQVXOWDWLRQZLWKWKHPH GLFDOPRQLWRUDORQJZLWKDOO
RWKHUFDVHGHWDLOVWRGHWHUPLQHLIWKHVXEMHFWVKRXOGFRQWLQXH VWXG\WUHDWPHQW)XUWKHUEORRG
VDPSOHVPD\DOVREHWDNHQRYHU WLPHWRPRQLWRUWLWHUDQGRUUH VROXWLRQ
$QDO\VLVRILPPXQRJHQLFLW\ZLOOLQFOXGHDVXEVHWDQDO\VHVRI VXEMHFWVZLWKFRQILUPHG$'$
DQGVXEMHFWVZLWKQHXWUDOL]LQJ$ '$LQZKLFKGDWDIURPWKHVH VXEMHFWVDUHFRPSDUHGWRDWKH
5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
HQWLUHVDIHW\SRSXODWLRQDQGEVXEMHFWVZLWKRXWFRQILUPHG$'$ $QDO\VHVRI3.3'VDIHW\DQG
HIILFDF\DVGHILQHGLQWKHVWDWLVWLFDODQDO\VLVSODQZLOOEH LQFOXGHGLQWKHVXEMHFWDQDO\VHV
'HWDLOHGLQVWUXFWLRQVUHJDUGLQJV DPSOHFROOHFWLRQSURFHVVLQJ DQGVKLSSLQJZLOOEHSURYLGHGLQD
VHSDUDWHODERUDWRU\PDQXDO
11.3 E FFICACY ASSESSMENTS  
(IILFDF\DVVHVVPHQWVLQFOXGHWKH PHDVXUHPHQWRIVHUXP/'+OHYHO VDVDPHDVXUHRI
LQWUDYDVFXODUKHPRO\VLV$GGLWLRQDODVVHVVPHQWVZLOOLQFOXGHOD ERUDWRU\DVVHVVPHQWVRIWRWDO
ELOLUXELQWRWDOKHPRJORELQIUHHKHPRJORELQKDSWRJORELQUHWL FXORF\WHVDQGKHPRJORELQXULD
11.4 P HARMACOKINETIC AND PHARMACODYNAMIC ASSESSMENTS  
%ORRGVDPSOHVIRUWKHPHDVXUHPHQWRISODVPDFRQFHQWUDWLRQVRI5 $DQGPHWDEROLWHVZLOO
EHFROOHFWHGRQDOOVXEMHFWV$ OOVXEMHFWVZLOODOVRKDYHDEOR RGVDPSOHIRUPHDVXUHPHQWRI
HFXOL]XPDESODVPDFRQFHQWUDWLRQV
%ORRGVDPSOHVIRUSKDUPDFRG\QDPLF DVVHVVPHQWVZLOOEHFROOHFWHG DQDOOVXEMHFWVDQGLQFOXGH
PHDVXUHPHQWRI
x&+
xV5%&O\VLVIRUFODVVLFDOFRPSOHPHQWSDWKZD\
x:LHVODE(/,6$IRUDOWHUQD WLYHFRPSOHPHQWSDWKZD\
x&OHYHOV
%ORRGVDPSOHVIRU3.DQG3 'ZLOOEHFROOHFWHGDWWKHIROORZLQJ WLPHSRLQWVLQUHODWLRQVKLSWRWKH
ILUVWGRVHRI5$SUHGRVHZLWKLQKRXUEHIRUHILUVWGR VHDGPLQLVWUDWLRQDQGDWDQG
KRXUVSRVWGRVHRQ'D\)RUVXEMHFWVZKRKDYHDGRVHLQFUHD VHWRPJNJVDPSOHVIRU3.
DQG3'VKRXOGEHFROOHFWHGDW SUHGRVH'D\RIWKHQHZGRVH
%ORRGVDPSOHVIRU3.RIHFXOL]XPDEVKRXOGEHFROOHFWHGDWVFUHH QLQJ'D\'D\'D\
DQG'D\7KHVDPSOHVKRXOGEHFRO OHFWHGSULRUWRDGPLQLVWUDW LRQRI5$
$OOVDPSOHVZLOOEHVHQWWRDFHQWUDOODERUDWRU\IRUDQDO\VLV 'HWDLOHGLQVWUXFWLRQVUHJDUGLQJ3.
DQG3'VDPSOHFROOHFWLRQSUR FHVVLQJDQGVKLSSLQJZLOOEHSURY LGHGLQDVHSDUDWHODERUDWRU\
PDQXDO
11.5 E LECTRONIC DIARY CARD 
6XEMHFWVZLOOEHUHTXLUHGWRUH FRUGWKHIROORZLQJLQIRUPDWLRQH DFKGD\LQDVXEMHFWHGLDU\GXULQJ
VWXG\SDUWLFLSDWLRQ
x&RQILUPDWLRQRIDGPLQLVWUDWLRQRIGDLO\HYHU\KRXUVGRVHR I5$WKDWLQFOXGHV
GDWHWLPHDQGORFDWLRQRILQMHFWLRQRI5$
5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
6XEMHFWHGLDULHVZLOOEHFROOHFWHGGLVSHQVHGDWWKHWLPHSRLQW VVKRZQLQWKH7LPHDQG(YHQWV
7DEOH7DEOH6XEMHFWVZLOOEHJLYHQGHWDLOHGLQVWUXFWLRQVRQKRZWRFRPSO HWHHQWULHVLQ
VXEMHFWGLDULHVWKURXJKRXWVWXG\SDUWLFLSDWLRQ
11.6 E XPLORATORY ASSESSMENTS  
11.6.1 Q UALITY OF LIFE ASSESSMENTS  
4XDOLW\RIOLIHDVVHVVPHQWVZLOOEHSHUIRUPHGDFFRUGLQJWRWKH 7LPHDQG(YHQWV7DEOH7DEOH
7KHIROORZLQJ42/TXHVWLRQQDLUHVZLOOEHXVHGGXULQJWKLVVWXG\ 
x(XURSHDQ2UJDQL]DWLRQIRUWKH5HVHDUFKDQG7UHDWPHQWRI&DQFHU 4XDOLW\RI/LIH
4XHVWLRQQDLUH&(257&4/4&
x)XQFWLRQDO$VVHVVPHQWRI&KURQLF,OOQHVV7KHUDS\)DWLJXH)$&,7 )DWLJXH6FDOH
x(XUR4RO'(4'
11.6.1.1 EORTC-QLQ-C30 
7KH(257&4/4&FRQVLVWVRITXHVWLRQVZKLFKDUHLQFRUSRUD WHGLQWRIXQFWLRQDO
GRPDLQVSK\VLFDOUROHFRJQLWLYHHPRWLRQDODQGVRFLDOGRPDL QVDJOREDOKHDOWKVWDWXVJOREDO
42/VFDOHV\PSWRPVFDOHVID WLJXHSDLQDQGQDXVHDDQGYRPL WLQJVFDOHVVLQJOHLWHPVWKDW
DVVHVVDGGLWLRQDOV\PSWRPVHJG\VSQHDDSSHWLWHORVVVOHHS GLVWXUEDQFHFRQVWLSDWLRQDQG
GLDUUKHDDQGWKHSHUFHLYHGILQDQFLDOEXUGHQRILOOQHVVWUHDWP HQW>$DURQVRQ $DURQVRQ
@6XEMHFWVDQVZHUTXHVWLRQVEDVHGRQV\PSWRPVVWDWXVRYHUWKHSUH FHGLQJZHHN
11.6.1.2 FACIT-F ATIGUE  
7KH)$&,7)DWLJXH6FDOHLVDLWHPHDV\WRDGPLQLVWHUWRROW KDWPHDVXUHVDQLQGLYLGXDOÂ¶V
OHYHORIIDWLJXHGXULQJWKHLUXVXDOGDLO\DFWLYLWLHVRYHUWKHS UHFHGLQJZHHN7KHOHYHORIIDWLJXHLV
PHDVXUHGRQDILYHSRLQWRUGLQDOVFDOH QRWDWDOOIDWLJXHG WR YHU\PXFKIDWLJXHG
>:HEVWHU @
11.6.1.3 EQ-5D 
7KH(4'LVDVWDQGDUGL]HGLQVWUXPHQWIRUPHDVXULQJJHQHULFKH DOWKVWDWXV7KH(4'FRQVLVWV
RIWKH(4'GHVFULSWLYHV\VWHPDQGWKH(4YLVXDODQDORJXHVFDO H9$67KH(4'
GHVFULSWLYHV\VWHPFRPSULVHVWKHIROORZLQJGLPHQVLRQVPRELOL W\VHOIFDUHXVXDODFWLYLWLHV
SDLQGLVFRPIRUWDQGDQ[LHW\GHSU HVVLRQHDFKGLPHQVLRQKDVOH YHOVQRSUREOHPVVRPH
SUREOHPVH[WUHPHSUREOHPV> (XUR4RO @6XEMHFWVDQVZHUTXHVWLRQVEDVHGRQV\PSWRPV
DQGKHDOWKVWDWXVRQWKHGD\WKHTXHVWLRQQDLUHLVFRPSOHWHG
11.6.2 T REATMENT SATISFACTION QUESTIONNAIRE  
$WUHDWPHQWVDWLVIDFWLRQTXHVWLRQQDLUHXVLQJDSRLQW/LNHUWU HVSRQVHVFDOHZLOOEHDGPLQLVWHUHG
WRDOOVXEMHFWVWRDVVHVVRYHUDOO VDWLVIDFWLRQZLWK6&DGPLQLVW UDWLRQRIWKHVWXG\PHGLFDWLRQDQGWR
DVVHVVWKHLUSUHIHUHQFHIRUGDLO\6&VHOILQMHFWLRQDWKRPHFRP SDUHGZLWKELZHHNO\LQIXVLRQV
JLYHQE\DKHDOWKFDUHSURIHVVLRQDOLQWKHFOLQLF
5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
7KHTXHVWLRQQDLUHZLOOEHFRPSOH WHGDWWKHHQGRIWKHZHHN7 UHDWPHQW3HULRG
11.6.3 B IOMARKERS  
%ORRGVDPSOHVZLOOEHFROOHFWHGD WGHVLJQDWHGWLPHSRLQWVFRQF RPLWDQWZLWK3.DQG3'
VDPSOLQJVHH 7DEOH$OOELRPDUNHUVZLOOEHDQDO\ ]HGE\ELRORJLFDORUELRFKHPLFDO DVVD\VDW
DQDFFUHGLWHGODERUDWRU\'HWDLOHGLQVWUXFWLRQVUHJDUGLQJVDPSO HFROOHFWLRQSURFHVVLQJDQG
VKLSSLQJZLOOEHSURYLGHGLQDVHSDUDWHODERUDWRU\PDQXDO
7KHVWXG\RIELRPDUNHUVUHODWHGWRFRPSOHPHQWIXQFWLRQWKURPER VLVLQIODPPDWLRQDQGOLYHU
IXQFWLRQZLOOSURYLGHIXUWKHULQVLJ KWLQWRWKHFOLQLFDOHIILFD F\DQGVDIHW\RI5$LQ31+
VXEMHFWV&RPSOHPHQWSURWHLQOHYHOVDQGFRPSOHPHQWDFWLYLW\ZLO OEHWHVWHGWRHYDOXDWHUHVSRQVH
WR5$DQGXQGHUVWDQGVXEMHFWFKDUDFWHULVWLFVUHODWHGWRY DULDWLRQVLQUHVSRQVHWRGUXJ
0DUNHUVRIWKURPERVLVDQGLQIODPPDWLRQZLOOEHWHVWHGWRDVVHVV FRUUHODWLRQZLWKFRPSOHPHQW
IXQFWLRQDQGFOLQLFDOUHVSRQVHWR5$DQGWRLGHQWLI\PDUN HUVWKDWPD\FRUUHODWHZLWK
WKURPERWLFULVNLQ31+VXEMHFWV$GGLWLRQDOO\PDUNHUVIRUOLYH UIXQFWLRQZLOOEHDVVHVVHGWR
HYDOXDWHWROHUDELOLW\RI5$$OLVWRIDQDO\WHVZLOOEHF UHDWHGWKURXJKUHYLHZRIWKH
OLWHUDWXUHRQJRLQJFOLQLFDOVWXGLHVDQGRQJRLQJH[SORUDWRU\Z RUNDQGPD\EHILQDOL]HGDIWHU
FRPSOHWLRQRIWKHVWXG\
7KHFRPSOHWLRQRIWKHVHLQYHVWLJDW LRQVPD\EHFRQGLWLRQDOEDVHG RQWKHUHVXOWVRIWKLVRURWKHU
FOLQLFDOVWXGLHVDQGVDPSOHVPD\EHVHOHFWHGIRUDQDO\VLVRQW KHEDVLVRIFOLQLFDORXWFRPH7KH
UHVXOWVRIWKHELRPDUNHULQYHVWLJ DWLRQVPD\EHUHSRUWHGVHSDUDW HO\IURPWKHPDLQFOLQLFDOVWXG\
UHSRUW
11.6.4 P HARMACOGENOMIC ASSESSMENTS  
3DUWLFLSDWLRQLQWKHSKDUPDFRJHQRP LFDVVHVVPHQWLVRSWLRQDODQG VXEMHFWVPXVWFRQVHQWWRWKH
SKDUPDFRJHQRPLFDQDO\VLVXVLQ JDVHSDUDWHFRQVHQWIRUP
)RUVXEMHFWVZKRRSWWRSDUWLFLSDWHLQSKDUPDFRJHQRPLFVVWXGLHV DEORRGVDPSOHZLOOEH
REWDLQHGRQ'D\$OOJHQRPLFDQDO\ VHVZLOOEHSHUIRUPHGDWDQ DFFUHGLWHGODERUDWRU\'HWDLOHG
LQVWUXFWLRQVUHJDUGLQJVDPSOH FROOHFWLRQSURFHVVLQJDQGVKLSS LQJZLOOEHSURYLGHGLQDVHSDUDWH
ODERUDWRU\PDQXDO
*HQRPLFVWXGLHVZLOOEHSHUIRUPHGHJGHR[\ULERQXFOHLFDFLG> '1$@VHTXHQFLQJ'1$FRS\
QXPEHUDQDO\VLVULERQXFOHLFDFLG>51$@H[SUHVVLRQSURILOLQJW RH[SORUHZKHWKHUVSHFLILF
JHQRPLFIHDWXUHVFRUUHODWHZLWKUHVSRQVHRUUHVLVWDQFHWRVWXG\ GUXJ
7KHFRPSOHWLRQRIWKHVHLQYHVWLJDW LRQVPD\EHFRQGLWLRQDOEDVHG RQWKHUHVXOWVRIWKLVRURWKHU
FOLQLFDOVWXGLHVDQGVDPSOHVPD\EHVHOHFWHGIRUDQDO\VLVRQW KHEDVLVRIFOLQLFDORXWFRPH7KH
UHVXOWVRIWKHJHQRPLFLQYHVWLJD WLRQVPD\EHUHSRUWHGVHSDUDWHO \IURPWKHPDLQFOLQLFDOVWXG\
UHSRUW
5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
12 SAFETY REPORTING 
12.1 D EFINITIONS  
12.1.1 A DVERSE EVENT  
$Q$(LVDQ\XQWRZDUGPHGLFDORFFXUUHQFHLQDVXEMHFWDGPLQLVWH UHGDSKDUPDFHXWLFDOSURGXFW
DQGZKLFKGRHVQRWQHFHVVDULO\KDYHDFDXVDOUHODWLRQVKLSZLWK WKLVWUHDWPHQW$Q$(FDQ
WKHUHIRUHEHDQ\XQIDYRUDEOHD QGXQLQWHQGHGVLJQLQFOXGLQJDF OLQLFDOO\VLJQLILFDQWDEQRUPDO
ODERUDWRU\ILQGLQJIRUH[DPSOHV\PSWRPRUGLVHDVHWHPSRUDOO \DVVRFLDWHGZLWKWKHXVHRID
PHGLFLQDOSURGXFWZKHWKHURUQRWF RQVLGHUHGUHODWHGWRWKHPHG LFLQDOSURGXFW
7KHIROORZLQJDUHQRWFRQVLGHUHGWREH$(VGHVSLWHUHTXLULQJKR VSLWDOL]DWLRQ
x3UHH[LVWLQJFRQGLWLRQVWKDWLQWKHRSLQLRQRIWKHLQYHVWLJDWR UGLGQRWZRUVHQRUSURJUHVV
GXULQJVWXG\SDUWLFLSDWLRQ
x5RXWLQHO\VFKHGXOHGSURFHGXUHVRUWUHDWPHQW
x(OHFWLYHSURFHGXUHVWKDWKDGEHHQV FKHGXOHGSULRUWRVWXG\SDUW LFLSDWLRQLHVLJQLQJRIWKH
,&)
12.1.2 S ERIOUS ADVERSE EVENT  
$Q6$(LVDQ\XQWRZDUGPHGLFDORFFXUUHQFHWKDW
xUHVXOWVLQGHDWK
xLVOLIHWKUHDWHQLQJQRWHWKDWWKLVUHIHUVWRDQHYHQWLQZKLFK WKHVXEMHFWZDVDWULVNRIGHDWKDW
WKHWLPHRIWKHHYHQWLWGRHV QRWUHIHUWRDQHYHQWWKDWK\SRW KHWLFDOO\PLJKWKDYHFDXVHG
GHDWKLILWZHUHPRUHVHYHUH
xUHTXLUHVKRVSLWDOL]DWLRQRUSURO RQJDWLRQRIH[LVWLQJKRVSLWDOL] DWLRQ
xUHVXOWVLQSHUVLVWHQWRUVLJQLILFDQWGLVDELOLW\LQFDSDFLW\
xUHVXOWVLQDFRQJHQLWDODQRPDO\ELUWKGHIHFW
$Q6$(PD\DOVREHDQ\RWKHULPSRUWDQWPHGLFDOHYHQWWKDWPD\Q RWEHLPPHGLDWHO\
OLIHWKUHDWHQLQJRUUHVXOWLQGHDWKRUKRVSLWDOL]DWLRQEXWPD\ MHRSDUGL]HWKHVXEMHFWRUUHTXLUH
LQWHUYHQWLRQWRSUHYHQWRQHRIWKH RWKHURXWFRPHVOLVWHGLQWKH GHILQLWLRQDERYH([DPSOHVRI
VXFKHYHQWVLQFOXGHLQWHQVLYHWUHDWPHQWLQDQHPHUJHQF\URRPRU DWKRPHIRUEURQFKRVSDVP
K\SHUNDOHPLDRUFRQYXOVLRQVWKDWGRQRWUHVXOWLQDIRUPDOKRV SLWDOL]DWLRQ
(OHFWLYHKRVSLWDOL]DWLRQVVFKHGXOHGSULRUWRVWXG\SDUWLFLSDWLR QLHVLJQLQJRIWKH,&)VKRXOG
QRWEHUHSRUWHGDV6$(V
5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
12.1.3 A DVERSE EVENTS OF SPECIAL INTEREST  
12.1.3.1 T HROMBOTIC ADVERSE EVENTS  
$OOVXEMHFWVVKRXOGEHPRQLWRUHGIRUVLJQVDQGV\PSWRPVRIWKUR PERWLFHYHQWVDWDOOVWXG\YLVLWV
ZHHNO\IRUWKHILUVWZHHNVIROORZHGE\HYHU\ZHHNV7KHP HWKRGRIGLDJQRVLVHJ
XOWUDVRXQGFRPSXWHGWRPRJUDSK\>&7@PDJQHWLFUHVRQDQFHLPDJLQ J>05,@YHQRJUDPRURWKHU
>VSHFLI\@IRUDQ\UHSRUWHGHYH QWVKRXOGEHUHFRUGHGLQWKHH&5 )$OO$(VVKRXOGEHUHFRUGHGDV
$(VSHU6HFWLRQ DQG6HFWLRQ 
12.1.3.2 H EPATIC ADVERSE EVENTS  
$OOVXEMHFWVVKRXOGEHPRQLWRUHGIRUVLJQVDQGV\PSWRPVRIKHSD WLFRUELOLDU\G\VIXQFWLRQ/LYHU
IXQFWLRQWHVWV/)7V$/3$/7$67**7'LUHFW%LOLUXELQDQG ,QGLUHFW%LOLUXELQDUH
PRQLWRUHGZHHNO\IRUWKHILUVWZHHNVIROORZHGE\HYHU\ZHHN VGXULQJWKHVWXG\7KH
IROORZLQJJXLGHOLQHLVSURYLGHG
x,QVXEMHFWVZLWKLVRODWHG$/7RU$67HOHYDWLRQ![8/1ZLWKQRR WKHUH[SODQDWLRQIRUWKH
HOHYDWLRQVFRQWDFWWKHPHGL FDOPRQLWRUWRUHYLHZWKHFDVHGH WDLOVDQGGHWHUPLQHLIWKH
VXEMHFWVKRXOGFRQWLQXHVWXG\WUHDWPHQWUHGXFHGRVHRUGLVFRQ WLQXHVWXG\WUHDWPHQW7KH
VXEMHFWVKRXOGEHPRQLWRUHGXQWLOWKHHOHYDWHGHQ]\PHVUHWXUQW ROHVVWKDQRUHTXDOWR
[8/1
x,QVXEMHFWVZLWKLVRODWHGGLUHFWELOLUXELQHOHYDWLRQ![8/1ZLW KQRRWKHUH[SODQDWLRQIRUWKH
HOHYDWLRQVFRQWDFWWKHPHGLFDO PRQLWRUWRUHYLHZWKHFDVHGH WDLOVDQGGHWHUPLQHLIWKH
VXEMHFWVKRXOGFRQWLQXHVWXG\WUHDWPHQWUHGXFHGRVHRUGLVFRQ WLQXHVWXG\WUHDWPHQW7KH
VXEMHFWVKRXOGEHPRQLWRUHGXQWLOWKHGLUHFWELOLUXELQUHWXUQW ROHVVWKDQRUHTXDOWR[8/1
x6XEMHFWVZLWKLVRODWHG$/7RU$67HOHYDWLRQV![8/1FRQFXUUHQWO \ZLWKGLUHFWELOLUXELQ
HOHYDWLRQ![8/1DQGDQRUPDO$/3ZLWKQRRWKHUH[SODQDWLRQIRU WKHHOHYDWLRQVKRXOGEH
SHUPDQHQWO\GLVFRQWLQXHG7KHPHGLFDOPRQLWRUVKRXOGEHFRQWDFW HGDVVRRQDVSRVVLEOHWR
UHYLHZWKHFDVH7KHVXEMHFWVKRXOGEHPRQLWRUHGXQWLOWKHHOHY DWHGHQ]\PHVUHWXUQWR*UDGH
1DWLRQDO&DQFHU,QVWLWXWH&RP PRQ7HUPLQRORJ\&ULWHULDIRU$GY HUVH(YHQWV1&,&7$&(
9HUVLRQRUORZHUDQGWKHGLUHFWELOLUXELQLVOHVVWKDQR UHTXDOWR[8/1
$OO$(VVKRXOGEHUHFRUGHGDV$(VSHU6HFWLRQDQG
12.1.3.3 P ANCREATIC ENZYME ELEVATIONS  
6XEMHFWVVKRXOGEHPRQLWRUHGGXULQJWKHVWXG\IRUV\PSWRPVRIS DQFUHDWLWLVRUFKROHF\VWLWLV
3DQFUHDWLFHQ]\PHVDP\ODVHDQGOLSDVHDUHPRQLWRUHGZHHNO\IR UWKHILUVWZHHNVIROORZHGE\
HYHU\ZHHNVGXULQJWKHVWXG\
x,QVXEMHFWVZLWKHOHYDWLRQVRIDP\ODVHRUOLSDVHWR1&,&7&$( 9HUVLRQ*UDGH
![8/1VWXG\GUXJVKRXOGEHGRVHUHGXFHGLIDWWKHPJNJ GDLO\GRVHRUSHUPDQHQWO\
GLVFRQWLQXHGLIDWWKHPJ NJGDLO\GRVH7KHVXEMHFWVKRX OGEHPRQLWRUHGXQWLODP\ODVH
DQGRUOLSDVHUHWXUQVWR*UDGHRUORZHU7KHPHGLFDOPRQLWRU VKRXOGEHFRQWDFWHGWR
UHYLHZWKHFDVH
5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
x,QVXEMHFWVZLWKHOHYDWLRQVRIDP\ODVHRUOLSDVHWR1&,&7&$( 9HUVLRQ*UDGH
![8/1VWXG\GUXJVKRXOGEHSHUPDQHQWO\GLVFRQWLQXHG7KHVXE MHFWVKRXOGEHPRQLWRUHG
XQWLODP\ODVHDQGRUOLSDVHUHWXUQVWR*UDGHRUORZHU7KHP HGLFDOPRQLWRUVKRXOGEH
FRQWDFWHGWRUHYLHZWKHFDVH
$OO$(VVKRXOGEHUHFRUGHGDV$(VSHU 6HFWLRQ DQG6HFWLRQ 
12.1.3.4 I NJECTION SITE REACTIONS  
7KHLQYHVWLJDWRUVKRXOGDVVHVVWKHLQMHFWLRQVLWHDWHDFKVFKHG XOHGYLVLWIRU
x3DLQWHQGHUQHVVHU\WKHPDDQGLQGXUDWLRQVHYHULW\7DEOH
x(U\WKHPDDQGLQGXUDWLRQUHFRUGWKHPD[LPXPOLQHDUGLDPHWHU
x%OLVWHUVXOFHUDWLRQQHFURVLVUH FRUGWKHPD[LPXPOLQHDUGLDPH WHUDQGVHYHULW\
x/\PSKDGHQRSDWK\
,QDGGLWLRQWKHLQYHVWLJDWRUZLOOZKHQHYHUSRVVLEOHWDNHGH LGHQWLILHGSKRWRVRIWKHLQMHFWLRQ
VLWHUHDFWLRQ,65
,QMHFWLRQVLWHUHDFWLRQVVKRXOGEHUHFRUGHGDV$(VSHU6HFWLRQ DQG6HFWLRQDQG
UHFRUGHGRQWKH,65VSHFLILFH &5)DQG$(H&5)DVDSSURSULDWH
Table 5 Grading the Severity of Local Injection Site Reactions 
Local Reaction 
to Injectable 
ProductGrade 1
(Mild)Grade 2
(Moderate)Grade 3
(Severe)Grade 4
(Potentially Life 
Threatening)
3DLQ 'RHVQRWLQWHUIHUH
ZLWKDFWLYLW\5HSHDWHGXVHRI
QRQQDUFRWLFSDLQ
UHOLHYHU!KRXUVRU
LQWHUIHUHVZLWK
DFWLYLW\$Q\XVHRIQDUFRWLF
SDLQUHOLHYHURU
SUHYHQWVGDLO\
DFWLYLW\(PHUJHQF\URRP
YLVLWRU
KRVSLWDOL]DWLRQ
7HQGHUQHVV 0LOGGLVFRPIRUW
WRWRXFK'LVFRPIRUWZLWK
PRYHPHQW6LJQLILFDQW
GLVFRPIRUWDWUHVW(PHUJHQF\URRP
YLVLWRU
KRVSLWDOL]DWLRQ
(U\WKHPD
UHGQHVVWRFP WRFP !FP 1HFURVLVRU
H[IROLDWLYH
GHUPDWLWLV
,QGXUDWLRQ
VZHOOLQJWRFPDQG
GRHVQRWLQWHUIHUH
ZLWKDFWLYLW\WRFPRU
LQWHUIHUHVZLWK
DFWLYLW\!FPRU
SUHYHQWVGDLO\
DFWLYLW\1HFURVLV

5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
12.1.3.5 I NFECTION  
$OOVXEMHFWVVKRXOGEHPRQLWRUHGIRUVLJQVDQGV\PSWRPVRI1HLV VHULDPHQLQJLWLGLVLQIHFWLRQ
6XEMHFWVDUHPRQLWRUHGHYHU\ ZHHNVIRUDGYHUVHHYHQWV
7RUHGXFHWKHULVNRILQIHFWLRQGXULQJWKHVFUHHQLQJSHULRGD OOVXEMHFWVPXVWKDYHDQHJDWLYH
UHVXOWIRU1HLVVHULDPHQLQJLWLGLVFRORQL]DWLRQYLDWKURDWVZDE SULRUWRVWXG\HQWU\$OOVXEMHFWV
PXVWKDYHGRFXPHQWDWLRQRISULRU1 HLVVHULDPHQLQJLWLGLVYDFFLQD WLRQDQGERRVWHULIDSSURSULDWH
SULRUWRVWXG\HQWU\
'XULQJWKH7UHDWPHQW3HULRGWRP LWLJDWHWKHULVNRILQIHFWLRQ VXEMHFWVZLOOEHFRXQVHOHGDQG
UHPLQGHGRIHDUO\VLJQVDQGV\PSWRPVRI1HLVVHULDPHQLQJLWLGLV LQIHFWLRQ$SDWLHQWVDIHW\FDUG
GHWDLOLQJWKHVLJQVDQGV\PSWRPVRILQIHFWLRQZLWKLQVWUXFWLRQV WRVHHNLPPHGLDWHPHGLFDO
DWWHQWLRQZLOOEHSURYLGHGWRHDFKVXEMHFW7KHFDUGZLOODOVR GHVFULEHWKHVXEMHFWÂ¶VSDUWLFLSDWLRQ
LQWKHVWXG\DQGWKHULVNVRILQI HFWLRQDVVRFLDWHGZLWKLQKLELW LRQRIWKHWHUPLQDOFRPSOHPHQW
V\VWHP7KHSDWLHQWVDIHW\FDUGPXVWEHFDUULHGZLWKWKHSDWLHQ WDWDOOWLPHVZKLOHRQWUHDWPHQW
$OO$(VVKRXOGEHUHFRUGHGDV$(VSHU 6HFWLRQ DQG6HFWLRQ
12.1.3.6 D OSE MODIFICATION FOR OTHER ADVERSE EVENTS   
)RUDOO*UDGHÂ•WUHDWPHQWHPHUJHQW$(VRWKHUWKDQWKHKHSDWLF DQGSDQFUHDWLF$(VGHVFULEHG
LQVHFWLRQV DQGVWXG\GUXJVKRXOGEHGRVHUHGXFHGLIDWWKHPJNJGDLO\ 
GRVHRUSHUPDQHQWO\GLVFRQWLQXHGLIDWWKHPJNJGDLO\GR VH
$OO$(VVKRXOGEHUHFRUGHGDV $(VSHU6HFWLRQDQG6HFWLRQ 
12.2 E VALUATION AND CLASSIFICATIONS  
12.2.1 S EVERITY  
7KHLQYHVWLJDWRUVKRXOGGHWHUPLQHWKHVHYHULW\RIWKHUHSRUWHG $(E\XVLQJWKH1&,&7&$(
9HUVLRQ7KHVHFULWHULDZLOO EHSURYLGHGLQDVHSDUDWHP DQXDO
)RUDQ\UHSRUWHG$(QRWGHVFULEH GLQWKH1&,&7&$(WKHIROORZL QJJXLGHOLQHVPXVWEH
FRQVLGHUHGIRUVHYHULW\HYDOXDWLRQ
Adverse Event Severity
0LOG 6\PSWRPVEDUHO\QRWLFHDEOHWRVXEMHFWRUGRHVQRWPDNHVXEMHF W
XQFRPIRUWD EOHGRHVQRWLQIOXHQFHSHUIRUPDQFHRUIXQFWLRQLQJ
SUHVFULSWLRQGUXJQRWRUGLQDULO\QHHGHGIRUUHOLHIRIV\PSWRPV 
0RGHUDWH 6\PSWRPVRIDVXIILFLHQWVHYHULW\WRPDNHVXEMHFWXQFRPIRUWDE OH
SHUIRUPDQFHRIGDLO\DFWLYLW\LVLQIOXHQFHG VXEMHFWLVDEOH WRFRQWLQXHLQ
VWXG\WUHDWPHQWIRUV\PSWRPVPD\EHQHHGHG
6HYHUH 6\PSWRPVFDXVHVHYHUHGLVFRPIRUWV\PSWRPVFDXVHLQFDSDFLWDWL RQRU
VLJQLILFDQWLPSDFWRQ VXEMHFWÂ¶VGDLO\OLIHVHYHULW\PD\FDXVHFHVVDWLRQRI
WUHDWPHQWZLWKVWXG\WUHDWPHQWWUHDWPHQWIRUV\PSWRPVPD\EH JLYHQ
5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
Adverse Event Severity
0LOG 6\PSWRPVEDUHO\QRWLFHDEOHWRVXEMHFWRUGRHVQRWPDNHVXEMHF W
XQFRPIRUWD EOHGRHVQRWLQIOXHQFHSHUIRUPDQFHRUIXQFWLRQLQJ
SUHVFULSWLRQGUXJQRWRUGLQDULO\QHHGHGIRUUHOLHIRIV\PSWRPV 
DQGRUVXEMHFWKRVSLWDOL]HG
12.2.2 C AUSALITY  
7KHFDXVDOUHODWLRQVKLSRIWKH$(WRVWXG\PHGLFDWLRQZLOOEHD VVHVVHGE\ERWKWKHLQYHVWLJDWRU
DQGWKH6SRQVRU7KHDVVHVVPHQW RIFDXVDOUHODWLRQVKLSWRVWXG\ GUXJVKRXOGEHHYLGHQFHEDVHG
DQGQRWEDVHGRQWKHSUHPLVHWKDWDOO$(VDUHFDXVDOO\UHODWHG WRVWXG\GUXJXQWLOSURYHQ
RWKHUZLVH'HIDXOWFDWHJRUL]DWLRQRIÂµUHODWHGÂ¶ZLWKRXWVXSSRUWL YHHYLGHQFHIRUDFDXVDO
UHODWLRQVKLSWRVWXG\GUXJLVJHQHUDOO\XQLQIRUPDWLYHDQGGRHV QRWFRQWULEXWHWRXQGHUVWDQGLQJRI
WKHVDIHW\SURILOHRIWKHGUXJZLWKUHVSHFWWRWKHLQWHQGHGSRS XODWLRQ
([DPSOHVRIHYLGHQFHWKDWZRXOGVXJJHVWDFDXVDOUHODWLRQVKLSE HWZHHQWKHGUXJDQGWKH$(
LQFOXGHRFFXUUHQFHRIDQ$(WKDWLVNQRZQWREHVWURQJO\DVVRFL DWHGZLWKGUXJH[SRVXUHHJ
LQMHFWLRQVLWHUHDFWLRQRUDQ$(WKDWLVRWKHUZLVHXQFRPPRQL QWKHVWXG\SRSXODWLRQ/DFNRI
HIILFDF\RIVWXG\GUXJLQLVRODWLRQOHDGLQJWRXQPDVNLQJRIX QGHUO\LQJV\PSWRPVDQGVLJQVRI
GLVHDVHVKRXOGQRWEHFRQVLGHUHGHYLGHQFHRIUHODWHGQHVV
7KHFDXVDOUHODWLRQVKLSRIHDFK$(LVDVVHVVHGXVLQJDELQDU\V \VWHPZLWKDOO$(VFODVVLILHGDV
HLWKHUÂµUHODWHGÂ¶RUÂµQRWUHODWHGÂ¶
Related7KHUHLVÂµUHDVRQDEOHSRVVLELOLW\
WKDWWKHGUXJFDXVHGWKH$( 7KH$(IROORZVD
UHDVRQDEOHWHPSRUDODVVRFLDWLRQIURPWKHWLPHRIVWXG\GUXJDGP LQLVWUDWLRQ7KHUHLVVXSSRUWLYH
HYLGHQFHWRVXJJHVWDSRVVLEOHFDXVDOUHODWLRQVKLSLUUHVSHFWLY HRIWKHGHJUHHRIFHUWDLQW\
EHWZHHQWKHREVHUYHG$(DQGWKHVWXG\GUXJ7KHUHLVQRDOWHUQD WLYHPRUHOLNHO\H[SODQDWLRQIRU
WKH$(/DFNRIVWXG\GUXJHIILFDF\LVQRWFRQVLGHUHGE\LWVHO IWREHHYLGHQFHRIUHODWHGQHVV
Not Related: /DFNRIDUHDVRQDEOHWHPSRUDODVVRFLDWLRQIURPWKHDGPLQLVWUDWL RQRIWKHVWXG\
GUXJDQGWKHRFFXUUHQFHRIWKH$(7KHUHLVHYLGHQFHRIDQDOWH UQDWLYHH[SODQDWLRQWKDWLVPRUH
OLNHO\DVDFDXVHRIWKH$(
12.3 R ECORDING , REPORTING , AND MONITORING  
12.3.1 R ECORDING AND REPORTING  
7KHLQYHVWLJDWRUPXVWPDNHHYHU\HIIRUWWRSURSHUO\HYDOXDWHDO OLQIRUPDWLRQUHOHYDQWWRWKH
UHSRUWHG$(LQVXFKDZD\WKDW DGLDJQRVLVFDQEHFRQILGHQWO\P DGHDQGUHSRUWHG)RUH[DPSOH
LWLVSUHIHUDEOHWRUHSRUWÂ³SQHXPRQLDÂ´DVWKH$(UDWKHUWKDQLW VV\PSWRPVHJÂ³UDOHVÂ´RUÂ³IHYHUÂ´
DVVHSDUDWH$(V
:KHQUHFRUGLQJDQGRUUHSRUWLQJ$(VRU6$(VWKHIROORZLQJHOHP HQWVPXVWEHLQFOXGHG
xWKHIXOILOOHGFULWHULDIRUVHULRXVQHVVDVSUHVHQWHGLQ 6HFWLRQ 
5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
xWKHVHYHULW\RIWKHH YHQWDVGHILQHGLQ 6HFWLRQ 
xWKHUHODWLRQVKLSRIWKHHYHQWWRVWXG\WUHDWPHQWDVGHILQHGLQ 6HFWLRQ
$FWLRQVWDNHQLQUHODWLRQWRWKH$(ZLOOEHUHFRUGHGDVGUXJGL VFRQWLQXHGGUXJLQWHUUXSWHGGRVH
UHGXFHGGRVHLQFUHDVHGFRQFRPL WDQWPHGLFDWLRQRWKHUDFWLRQ HJGLDJQRVWLFWHVWLQJRUQR
DFWLRQ$Q\PHGLFDWLRQJLYHQWRWUHDWWKH$(ZLOOEHUHFRUGHGV HSDUDWHO\LQWKHFRQFRPLWDQW
PHGLFDWLRQOLVWRIWKHH&5)
7KHRXWFRPHRIWKH$(ZLOOEHUH FRUGHGDVGDWHHQGHGRQJRLQJ RUUHVXOWLQJLQGHDWKZLWKGDWH
RIGHDWK
12.3.1.1 A DVERSE EVENTS  
3UHH[LVWLQJFRQGLWLRQVWKDWDUHGHWHFWHGSULRUWRDGPLQLVWUDWL RQRIWKHILUVWGRVHRIVWXG\GUXJ
ZLOOEHUHFRUGHGDVSDUWRIPHGLFD OKLVWRU\)RUDOOVXEMHFWV WKH$(UHSRUWLQJSHULRGZLOOVWDUW
ZLWKWKHILUVWDGPLQLVWUDWLRQRIVWXG\GUXJRQ'D\DQGZLOOH QGZLWKWKHILQDOVWXG\YLVLWDIWHU
ZKLFKQRQHZ$(VDUHWREHUHSRUWHG:KHQSRVVLEOHRQJRLQJ$(V DVVHVVHGDVUHODWHGWRWKH
VWXG\GUXJZLOOEHIROORZHGXQWLOUHVROYHGRUVWDELOL]HG
7KHVXEMHFWVZLOOEHPRQLWRUHGWKURXJKRXWWKHVWXG\IRUDQ\$(V LQFOXGLQJDEQRUPDOFOLQLFDOO\
VLJQLILFDQWODERUDWRU\YDOXHVFOLQLFDOO\VLJQLILFDQWILQGLQJV DWYLWDOVLJQVPHDVXUHPHQWV
VSRQWDQHRXVUHSRUWVE\VWXG\VXEMHFWVDQGREVHUYDWLRQVE\WKH VWXG\SHUVRQQHO$GYHUVHHYHQWV
ZLOOEHFRGHGXVLQJ0HG'5$DIWH UWKHH&5)VKDYHEHHQPRQLWRUHG DQGVLJQHGE\WKH
LQYHVWLJDWRU
$OO$(VZLOOEHUHFRUGHGLQWKHH&5)7KHLQYHVWLJDWRUZLOODVV HVVDQGUHFRUGDQ\$(LQGHWDLO
LQFOXGLQJWKHGDWHDQGWLPHRIRQVHWHYHQWGLDJQRVLVLINQRZQ RUVLJQV\PSWRPVHYHULW\WLPH
FRXUVHHQGGDWHRURQJRLQJUHODWLRQVKLSRIWKH$(WRVWXG\G UXJDQGDQ\DFWLRQVWDNHQ$OO
$(VVKRXOGEHUHSRUWHGVHSDUDWHO \LHUHFRUGSHUHYHQW5H SRUWLQJRI$(VLVHYHQWEDVHGLH
DQRQJRLQJHYHQWZLOOQRWEHFORVHGXQWLOUHVROYHGRUDWWKHHQ GRIVWXG\)RUWKH$(GHVFULSWLRQ
DGLDJQRVLVLVSUHIHUUHGRYHUV \PSWRPV,IQRGLDJQRVLVFDQEH PDGHHDFKV\PSWRPZLOOEH
UHSRUWHGDVDVHSDUDWH$($EEUHYLDWLRQVVKRXOGEHDYRLGHG'HV FULSWLYHZRUGVVKRXOGEHXVHG
IRURQJRLQJFRQGLWLRQVDVDSSOLFDEOHHJH[DFHUEDWLRQRIKHUS HVJHQLWDOLVRUZRUVHQLQJRI
HF]HPD
12.3.1.2 S ERIOUS ADVERSE EVENTS  
$Q\6$(H[SHULHQFHGE\WKHVXEMHFWIURPVLJQLQJWKH,&)WKURXJK WRGD\VDIWHUWKHODVWGRVH
RIVWXG\GUXJUHJDUGOHVVRIVHYHULW\RUFDXVDOLW\PXVWEHUHF RUGHGRQWKHH&5)DQG6$()RUP
7KHVWXG\VLWHPXVWIRUPDOO\QRWLI\WKH6SRQVRURIWKH6$(ZLWK LQKRXUVIURPWKHWLPHWKH
VWXG\VLWHEHFRPHVDZDUHRIWKH6$($IRUPDOQRWLILFDWLRQPXVW EHVXEPLWWHGWRWKH6SRQVRU
UHJDUGOHVVRIWKHIROORZLQJ
xVHYHULW\
xFDXVDOLW\
5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
xZKHWKHURUQRWWKHVXEMHFWUHFHLYHGVWXG\WUHDWPHQWRUXQGHUZHQ WVWXG\UHODWHGSURFHGXUHV
7KH,(&,5%ZLOOEHQRWLILHGDVUHTXLUHGE\ORFDOUHJXODWLRQV 7KHLQYHVWLJDWRUZLOOEH
UHVSRQVLEOHIRUVXEPLWWLQJWKHUHTXLUHGVDIHW\LQIRUPDWLRQWRW KHDSSURSULDWH,(&,5%LQFOXGLQJ
DQ\VDIHW\UHSRUWVUHFHLYHGIURPWKH6SRQVRUDVZHOODVDQ\6$( VRFFXUULQJDWKLVRUKHUVLWH
7KH6SRQVRURUGHVLJQHHZLOOSUHSDUHDQ\UHTXLUHGVDIHW\UHSR UWVIRUUHJXODWRU\DXWKRULWLHVDQG
DOODFWLYHLQYHVWLJDWRUV7KHVHUHSRUWVZLOOEHSURYLGHGDVDGG HQGDWRWKH,QYHVWLJDWRUÂ¶V%URFKXUH
DQGWKHLQYHVWLJDWRUZLOOSODFHWKHVHZLWKWKHEURFKXUH
12.3.1.3 D EATH  
$Q\HYHQWZLWKDQRXWFRPHRIGHDWKVKRXOGEHDSSURSULDWHO\UHFR UGHGLQWKHH&5)$OOLGHQWLILHG
FDXVHVRIGHDWKLQFOXGLQJDQDVVHVVPHQWRIWKHSRVVLEOHUHODWL RQVKLSRIHDFKWRVWXG\WUHDWPHQW
PXVWEHUHSRUWHGDV6$(VDVRXWOLQHGLQ 6HFWLRQ $Q\DXWRSV\RURWKHUSRVWPRUWHP
ILQGLQJVLQFOXGLQJDFRURQHUÂ¶VUHSRUWVKRXOGEHSURYLGHGZKHQ DYDLODEOH
12.3.2 M ONITORING  
$OO$(VVKRXOGEHPRQLWRUHGE\WKHLQYHVWLJDWRUXQWLOUHVROXWLR QRUVWDELOL]DWLRQ
12.3.2.1 P OST-STUDY EVENTS  
$Q\6$(WKDWZDVFRQWLQXLQJDWWKHWLPHRIVXEMHFWGLVFRQWLQXDW LRQRUVWXG\FRPSOHWLRQVKRXOG
EHPRQLWRUHGE\WKHLQYHVWLJDWRUXQWLOUHVROXWLRQRUVWDELOL]DW LRQ
6$(VWKDWRFFXUZLWKLQGD\VDIWHUWKHVXEMHFWGLVFRQWLQXHVI URPRUFRPSOHWHVWKHVWXG\VKRXOG
EHUHSRUWHGXVLQJWKHVDPHSURFHGXUHVRXWOLQHGLQ6HFWLRQ 7KHVH6$(VVKRXOGEH
UHFRUGHGLQWKH&5)IRUWKLVVWXG\IRUVXEMHFWVZKRGRQRWHQUR OOLQWKHH[WHQVLRQVWXG\DQG
UHFRUGHGLQWKHH[WHQVLRQVWXG\&5)IRUVXEMHFWVZKRHQUROOLQ WKHH[WHQVLRQVWXG\
12.4 S PECIAL CIRCUMSTANCES  
12.4.1 P REGNANCY  
6XEMHFWVDQGWKHLUSDUWQHUVVKRXOGDYRLGSUHJQDQF\WKURXJKRXWW KHFRXUVHRIWKHVWXG\
3UHJQDQF\LQDVWXG\VXEMHFWRUSDUWQHUPXVWEHUHSRUWHGWRWKH 6SRQVRUZLWKLQZRUNLQJGD\RI
WKHVLWHEHFRPLQJDZDUHRIWKHSUHJQDQF\6XEMHFWVZLWKDSRVLW LYHSUHJQDQF\WHVWEHIRUHVWXG\
GUXJGRVLQJPXVWQRWEHGRVHG
,QIRUPDWLRQUHJDUGLQJDSUHJQDQF\RFFXUUHQFHLQDVWXG\VXEMHFW RUSDUWQHUDQGWKHRXWFRPHRI
WKHSUHJQDQF\ZLOOEHFROOHFWHG
3UHJQDQF\LQDVWXG\VXEMHFWRUSDUWQHULVQRWLQLWVHOIFRQV LGHUHGDQ$(+RZHYHUWKHPHGLFDO
RXWFRPHRIDQHOHFWLYHRUVSRQWDQHRXVDERUWLRQVWLOOELUWKRU FRQJHQLWDODQRPDO\LVFRQVLGHUHGDQ
6$(DQGPXVWEHUHSRUWHGWRW KH6SRQVRUZLWKLQKRXUVRIWKH VLWHEHFRPLQJDZDUHRIWKH
HYHQW7KHSURFHGXUHRIHOHFWL YHDERUWLRQVKRXOGQRWEHUHSRUWH GDVDQ$(
5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
12.4.2 O THER  
&HUWDLQVDIHW\HYHQWVFDOOHGÂµ6SHFLDO6LWXDWLRQVÂ¶WKDWRFFXU LQDVVRFLDWLRQZLWKVWXG\
PHGLFDWLRQVPD\UHTXLUHUHSRUWLQ J7KHVH6SHFLDO6LWXDWLRQVL QFOXGHEXWDUHQRWOLPLWHGWRWKH
IROORZLQJ
x2YHUGRVHRIWKHPHGLFLQDOSURGXFW
x6XVSHFWHGDEXVHPLVXVHRIWKHPHGLFLQDOSURGXFW
x,QDGYHUWHQWRUDFFLGHQWDOH[ SRVXUHWRWKHPHGLFLQDOSURGXFW
x0HGLFDWLRQHUURULQYROYLQJ PHGLFLQDOSURGXFWZLWKRUZLWKRXWV XEMHFWSDWLHQWH[SRVXUH
WRWKHVSRQVRUÂ¶VPHGLFLQDOSU RGXFWHJQDPHFRQIXVLRQ
6SHFLDOVLWXDWLRQVVKRXOGEHUHSRUWHGRQWKH6SHFLDO6LWXDWLRQV &5)ZKHWKHUWKH\UHVXOWLQDQ
$(6$(RUQRW6SHFLDO6LWXDWLRQV DVVRFLDWHGZLWKDQ$(6$(VKR XOGDOVREHUHSRUWHGRQWKH
FRUUHVSRQGLQJ$(6$(IRUPV
5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
13 STATISTICAL AND ANALYTICAL PLANS 
13.1 S AMPLE SIZE DETERMINATION  
$VDPSOHVL]HRIVXEMHFWVZLOO \LHOGDVWDQGDUGHUURURIDSSU R[LPDWHO\8/IRUDQ/'+
PHDQFKDQJHIURPEDVHOLQHHVWLPDWH7KLVDVVXPHVDVWDQGDUGGHY LDWLRQRI8/IRUWKH
EDVHOLQHDQGSRVWEDVH OLQHHQGSRLQWVDQGDZLWKLQVXEMHFWFRUU HODWLRQHVWLPDWHRI7KH/'+
VWDQGDUGGHYLDWLRQHVWLPDWHRI8/LVEDVHGRQWKHUHVXOWV VXPPDUL]HGE\+LOOPHQ
>+LOOPHQ @
13.2 A NALYSIS POPULATIONS  
$QDO\VLVSRSXODWLRQVLQWKLVVWXG\DUHGHILQHGLQWKHVHFWLRQV WKDWIROORZ
13.2.1 S AFETY POPULATION  
7KH6DIHW\3RSXODWLRQZLOOLQFO XGHDOOVXEMHFWVZKRUHFHLYHDW OHDVWRQHLQMHFWLRQRI5$
13.2.2 E FFICACY EVALUABLE POPULATION  
7KH(IILFDF\(YDOXDEOH3RSXODWLRQZLOOLQFOXGHDOOVXEMHFWVLQ WKH6DIHW\3RSXODWLRQZKR
FRPSOHWHWKHZHHN7UHDWPHQW3HULRG
13.2.3 P ER PROTOCOL POPULATION  
7KH3HU3URWRFRO3RSXODWLRQZLOOLQ FOXGHDOOVXEMHFWVLQWKH6D IHW\3RSXODWLRQZKRFRPSOHWHWKH
ZHHN7UHDWPHQW3HULRGDQGKD YHQRPDMRUSURWRFROYLRODWLRQV 
13.2.4 P HARMACOKINETIC POPULATION  
7KH3.3RSXODWLRQZLOOLQFOXGHD OOVXEMHFWVLQWKH6DIHW\3RSXO DWLRQZKRKDYHDWOHDVWSODVPD
VDPSOHREWDLQHGIRU3.DVVHVVPHQW
13.2.5 P HARMACODYNAMIC POPULATION  
7KH3'3RSXODWLRQZLOOLQFOXGHD OOVXEMHFWVLQWKH6DIHW\3RSXO DWLRQZKRKDYHDWOHDVWSODVPD
VDPSOHREWDLQHGIRU3'DVVHVVPHQW
13.3 S TATISTICAL PLAN 
13.3.1 G ENERAL CONSIDERATIONS  
'DWDZLOOEHVXPPDUL]HGGHVFULSWLYHO\'HWDLOVRIWKHVWDWLVWLF DODQDO\VLVPHWKRGRORJ\ZLOOEH
SURYLGHGLQD6WDWLVWLFDO$QDO\VLV3ODQ
13.3.2 S UBJECT DISPOSITION  
$GLVSRVLWLRQRIDOOFRQVHQWHGVXEMHFWVZLOOEHSURYLGHG7KLV ZLOOLQFOXGHDEUHDNGRZQRI
VXEMHFWVZKRFRQVHQWHGZHUHWUHDWHGGLVFRQWLQXHGWUHDWPHQWD QGZHUHORVWWRIROORZXSRU
5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
ZLWKGUHZFRQVHQW$GGLWLRQDOO\DVXPPDU\RIVXEMHFWVLQFOXGHG LQWKHDQDO\VLVSRSXODWLRQV
GHILQHGLQ 6HFWLRQ ZLOOEHSURYLGHG
13.3.3 D EMOGRAPHY AND BASELINE DISEASE CHARACTERISTICS  
4XDQWLWDWLYHYDULDEOHVZLOOEHVXPPDUL]HGZLWKWKHPHDQPHGLDQ DQGUDQJH&DWHJRULFDO
YDULDEOHVZLOOEHVXPPDUL]HGXVLQJFRXQWVDQGSURSRUWLRQV
13.3.4 S AFETY ANALYSIS  
6DIHW\DQDO\VHVZLOOEHSHUI RUPHGRQWKH6DIHW\3RSXODWLRQ
13.3.4.1 A DVERSE EVENTS  
$GYHUVHHYHQWV$(ZLOOEHFRGHGXVLQJ0HG'5$YHUVLRQRU KLJKHU
,QFLGHQFHUDWHVIRUWUHDWPHQWHPHUJHQWDGYHUVHHYHQWV7($(E\ PD[LPXPVHYHULW\DQG6$(V
ZLOOEHVXPPDUL]HG7KH VHVXPPDULHVZLOOEHSURYLGHGUHJDUGOHVV RIFDXVDOLW\DQGIRUHYHQWV
WKDWDUHFRQVLGHUHGSRVVLEO\UHODWHGWRWUHDWPHQWZLWK5$ 7($(VDUHGHILQHGDVIROORZV
x$Q$(WKDWRFFXUVDIWHUWUHDWPHQW VWDUWWKDWZDVQRWSUHVHQWDW WKHWLPHRIWUHDWPHQWVWDUWRU
x$Q$(WKDWLQFUHDVHVLQVHYHULW\DIWHUWUHDWPHQWVWDUWLIWKH HYHQWZDVSUHVHQWDWWKHWLPHRI
WUHDWPHQWVWDUW
$(VRFFXUULQJEHIRUHWKHILUVWGRVHRIVWXG\GUXJZLOOEHVXPPD UL]HGVHSDUDWHO\
13.3.4.2 A DVERSE EVENTS OF SPECIAL INTEREST  
13.3.4.2.1 T HROMBOTIC ADVERSE EVENTS  
7KURPERWLF$(VZLOOEHVXPPDUL]HGVHSDUDWHO\E\V\VWHPRUJDQFO DVVDQGSUHIHUUHGWHUP7KH
HYHQWVLQ7DEOH0$9(FULWHULD> +LOOPHQ @ZLOOEHHYDOXDWHGL QWKHDVVHVVPHQWRI
WKURPERWLF$(V
5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
Table 6 Thrombotic Event Description (MAVE Criteria) 
7KURPERSKOHELWLV'HHSYHLQWKURPERVLV 0HVHQWHULF9LVFHUDOD UWHULDOWKURPERVLV
3XOPRQDU\HPEROXV +HSDWLF3RUWDOYHLQWKURPERVLV
0\RFDUGLDOLQIDUFWLRQ 'HUPDOWKURPERVLV
7UDQVLHQWLVFKHPLFDWWDFN *DQJUHQHQRQWUDXPDWLFQRQGLDEHWLF
5HQDOYHLQWKURPERVLV &HUHEUDODUWHULDORFFOXVLRQFHUHEURYDVFXODUDFFLGHQW
$FXWHSHULSKHUDOYDVFXODURFFOXVLRQ &HUHEUDOYHQRXVRFFOXVLRQ
$PSXWDWLRQQRQWUDXPDWLFQRQGLDEHWLF 5HQDODUWHULDOWKURPERVLV
0HVHQWHULF9LVFHUDOYHLQWKURPERVLV 2WKHU
8QVWDEOHDQJLQD 
$EEUHYLDWLRQ0$9( PDMRUDGYHUVHYDVFXODUHYHQW
13.3.4.2.2 H EPATIC ADVERSE EVENTS  
+HSDWLFDQGELOLDU\$(VDQGZLOOEH VXPPDUL]HGVHSDUDWHO\E\V\ VWHPRUJDQFODVVDQGSUHIHUUHG
WHUP/LYHUIXQFWLRQWHVWVZLOO EHVXPPDUL]HGE\FKDQJHVIURPE DVHOLQHDQGJUDGHGLQVHYHULW\
XVLQJWKH1&,&7&$(FULWHULD
13.3.4.2.3 P ANCREATIC ENZYME ELEVATIONS  
3DQFUHDWLF$(VDQGZLOOEHVXPPDU L]HGVHSDUDWHO\E\V\VWHPRUJD QFODVVDQGSUHIHUUHGWHUP
3DQFUHDWLFHOHYDWLRQVZLOOEHV XPPDUL]HGE\FKDQJHVIURPEDVHOL QHDQGJUDGHGLQVHYHULW\XVLQJ
WKH1&,&7&$(FULWHULD
13.3.4.2.4 I NJECTION SITE REACTIONS  
,65VZLOOEHVXPPDUL]HGVHSDUDWHO \E\V\VWHPRUJDQFODVVDQGSU HIHUUHGWHUP7KHVXPPDU\ZLOO
LQFOXGHDGGLWLRQDOGHWDLOVRQWKH VHHYHQWVDVGHVFULEHGLQ 6HFWLRQ 
13.3.4.2.5 I NFECTION  
$(VUHODWHGWRLQIHFWLRQZLWK Neisseria meningitidis ZLOOEHVXPPDUL]HGVHSDUDWHO\E\V\VWHP
RUJDQFODVVDQGSUHIHUUHGWHUP
13.3.4.3 C LINICAL LABORATORY EVALUATION  
4XDQWLWDWLYH ODERUDWRU\HQGSRLQWVZLOOEHVXPPDUL]HGE\WLPHSRLQWXVLQJGHV FULSWLYHVWDWLVWLFV
13.3.4.4 E LECTROCARDIOGRAMS  
'HVFULSWLYHVWDWLVWLFVIRU(&*SDUDPHWHUVLHKHDUWUDWH+5 35LQWHUYDO55LQWHUYDO456
LQWHUYDO47LQWHUYDO47F%LQ WHUYDODQG47F)LQWHUYDODWHDF KDVVHVVPHQWWLPHSRLQWZLOOEH
SUHVHQWHG
5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
13.3.4.5 V ITAL SIGNS  
'HVFULSWLYHVWDWLVWLFVIRUYLWDOVLJQVLHKHDUWUDWHERG\W HPSHUDWXUHDQGEORRGSUHVVXUHZLOOEH
SUHVHQWHG
13.3.4.6 P HYSICAL EXAMINATION  
7KHFRPSOHWHVHWSK\VLFDOH[DPLQDWLRQILQGLQJVZLOOEHSURYLGHG LQOLVWLQJV&OLQLFDOO\
VLJQLILFDQWSK\VLFDOH[DPLQDWLRQDEQRUPDOLWLHVZLOOEHLQFOXGHG DQGVXPPDUL]HGDV$(VLI
DSSURSULDWH
13.3.5 E FFICACY ANALYSIS  
1RIRUPDOVWDWLVWLFDOFRPSDULVRQVZLOOEHSHUIRUPHG6XPPDU\VW DWLVWLFVIRUWKHSULPDU\DQG
RWKHUHIILFDF\HQGSRLQWVZLOOEHSURYLGHGLQFOXGLQJWKHPHDQP HGLDQVWDQGDUGGHYLDWLRQDQG
VWDQGDUGHUURU
13.3.6 C LINICAL PHARMACOLOGY ANALYSIS  
13.3.6.1 P HARMACOKINETIC ANALYSIS  
'UXJH[SRVXUHZLOOEHHYDOXDWHGXV LQJ3.SDUDPHWHUVGHULYHGIUR PQRQFRPSDUWPHQWDOPHWKRGV
$OOFDOFXODWLRQVIRUWKHILQDODQDO\VLVZLOOEHEDVHGRQDFWXDO VDPSOLQJWLPHV,QGLYLGXDO3.
SDUDPHWHUVZLOOEHSUHVHQWHGLQOLVWLQJVDQGVXPPDUL]HGXVLQJG HVFULSWLYHVWDWLVWLFV
13.3.6.2 P HARMACODYNAMIC ANALYSIS  
1RIRUPDOVWDWLVWLFDOFRPSDULVRQVZLOOEHSHUIRUPHG6XPPDU\VW DWLVWLFVZLOOEHSURYLGHG
LQFOXGLQJWKHPHDQPHGLDQVWDQGDUGGHYLDWLRQDQGVWDQGDUGHU URU
13.3.7 I NTERIM ANALYSIS  
'XULQJWKLVRSHQODEHOVWXG\WKH6SRQVRUZLOOUHYLHZVDIHW\DQ GHIILFDF\GDWDDVLWEHFRPHV
DYDLODEOHGXULQJWKH7UHDWPHQW3HULRG)ROORZLQJFRPSOHWLRQRI WKHZHHN7UHDWPHQW3HULRG
GDWDZLOOEHFOHDQHGDQGORFNHGDW WKHLQGLYLGXDOVXEMHFWOHYHO DQGZLOOEHDYDLODEOHIRUILQDO
DQDO\VLVE\WKH6SRQVRURQDUROOLQJEDVLV
5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
14 ETHICAL CONSIDERATIONS 
7KLVVWXG\VKDOOEHFRQGXFWHGL QDFFRUGDQFHZLWKWKHHWKLFDOSU LQFLSOHVWKDWKDYHWKHLURULJLQLQ
WKH'HFODUDWLRQRI+HOVLQNLDQGWKDWDUHFRQVLVWHQWZLWK*RRG& OLQLFDO3UDFWLFH*&3DQG
DSSOLFDEOHUHJXODWRU\UHTXLUHPHQWV
14.1 I NSTITUTIONAL REVIEW BOARD /INDEPENDENT ETHICS COMMITTEE 
COMMUNICATIONS  
3ULRUWRVWXG\LQLWLDWLRQWKHLQYHVWLJDWRULQVWLWXWLRQVKRXOG KDYHZULWWHQDQGGDWHG
DSSURYDOIDYRUDEOHRSLQLRQIURPWKH,(&,5%IRUWKHVWXG\SURWR FROZULWWHQ,&)FRQVHQWIRUP
XSGDWHVVXEMHFWUHFUXLWPHQWSURF HGXUHVHJDGYHUWLVHPHQWV DQGDQ\RWKHUZULWWHQLQIRUPDWLRQ
WREHSURYLGHGWRVXEMHFWV$FXUUHQWFRS\RIWKH,QYHVWLJDWRUÂ¶ V%URFKXUHPXVWEHSURYLGHGWRWKH
,(&,5%DVSDUWRIWKHZULWWHQDSSOLFDWLRQ'XULQJWKHVWXG\W KHLQYHVWLJDWRULQVWLWXWLRQVKRXOG
SURYLGHWRWKH,(&,5%DOOGRFXPHQWVVXEMHFWIRUUHYLHZ
14.1.1 P ROGRESS REPORTS  
7KHLQYHVWLJDWRUVKRXOGVXEPLWZULWWHQVXPPDULHVRIWKHVWXG\V WDWXVWRWKH,(&,5%DQQXDOO\RU
PRUHIUHTXHQWO\LIUHTXHVWHGE\WKH,(&,5%
14.1.2 F INAL INVESTIGATOR REPORT  
8SRQFRPSOHWLRQRIWKHVWXG\WKHLQYHVWLJDWRULQVWLWXWLRQVKRX OGSURYLGHDVXPPDU\RIWKH
VWXG\Â¶VRXWFRPHWRWKH,(&,5%DQGWKHUHJXODWRU\DXWKRULWLHVZ LWKDQ\UHTXLUHGUHSRUWV
14.2 I NFORMED CONSENT OF STUDY SUBJECTS  
,QREWDLQLQJDQGGRFXPHQWLQJLQIRUPHGFRQVHQWWKHLQYHVWLJDWRU VKRXOGFRPSO\ZLWKWKH
DSSOLFDEOHUHJXODWRU\UHTXLUHPHQWVDQGVKRXOGDGKHUHWR*&3D QGWRWKHHWKLFDOSULQFLSOHVWKDW
KDYHWKHLURULJLQLQWKH' HFODUDWLRQRI+HOVLQNL
7KHZULWWHQ,&)DQGDQ\RWKHUZULWWHQLQIRUPDWLRQWREHSURYLGH GWRVXEMHFWVVKRXOGEHUHYLVHG
ZKHQHYHULPSRUWDQWQHZLQIRUPDWLRQEHFRPHVDYDLODEOHWKDWPD\E HUHOHYDQWWRWKHVXEMHFWÂ¶V
FRQVHQW$Q\UHYLVHGZULWWHQ,&)DQGZULWWHQLQIRUPDWLRQVKRXOG UHFHLYHWKH,(&,5%Â¶V
DSSURYDOIDYRUDEOHRSLQLRQLQDGYDQFHRIXVH7KHVXEMHFWRUWK HVXEMHFWÂ¶VOHJDOO\DFFHSWDEOH
UHSUHVHQWDWLYHVKRXOGEHLQIRUPHGL QDWLPHO\PDQQHULIQHZLQI RUPDWLRQEHFRPHVDYDLODEOHWKDW
PD\EHUHOHYDQWWRWKHVXEMHFWÂ¶VZLOOLQJQHVVWRFRQWLQXHSDUWLF LSDWLRQLQWKHVWXG\7KH
FRPPXQLFDWLRQRIWKLVLQIRUPDWLRQVKRXOGEHGRFXPHQWHG
7KHLQYHVWLJDWRUVKRXOGIXOO\LQIRUPWKHVXEMHFWRUWKHVXEMHFW Â¶VOHJDOO\DFFHSWDEOHUHSUHVHQWDWLYH
RIDOOSHUWLQHQWDVSHFWVRIWKHVWXG\LQFOXGLQJWKHZULWWHQLQ IRUPDWLRQDQGWKHDSSURYDO
IDYRUDEOHRSLQLRQE\WKH,(&,5%%HIRUHLQIRUPHGFRQVHQWPD\E HREWDLQHGWKHLQYHVWLJDWRU
VKRXOGSURYLGHWKHVXEMHFWRUWKHV XEMHFWÂ¶VOHJDOO\DFFHSWDEOH UHSUHVHQWDWLYHDPSOHWLPHDQG
RSSRUWXQLW\WRLQTXLUHDERXWGHWDLOVRIWKHVWXG\DQGWRGHFLGH ZKHWKHURUQRWWRSD UWLFLSDWHLQWKH
VWXG\$OOTXHVWLRQVDERXWWKHVWXG\VKRXOGEHDQVZHUHGWRWKH VDWLVIDFWLRQRIWKHVXEMHFWRUWKH
VXEMHFWÂ¶VOHJDOO\DFFHSWDEOHUHSUHVHQWDWLYH  
5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
3ULRUWRDVXEMHFWÂ¶VSDUWLFLSDWLRQLQWKHVWXG\WKHZULWWHQ,& )VKRXOGEHVLJQHGDQGSHUVRQDOO\
GDWHGE\WKHVXEMHFWRUE\WKHVXEMHFWÂ¶VOHJDOO\  DFFHSWDEOHUHSUHVHQWDWLYHDQGE\WKHSHUVRQZKR
FRQGXFWHGWKHLQIRUPHGFRQVHQWGLVFXVVLRQ,IDVXEMHFWLVXQDE OHWRUHDGRULIDOHJDOO\
DFFHSWDEOHUHSUHVHQWDWLYHLVXQDEOHWRUHDGDQLPSDUWLDOZLWQH VVVKRXOGEHSUHVHQWGXULQJWKH
HQWLUHLQIRUPHGFRQVHQWGLVFXVVLRQ
3ULRUWRSDUWLFLSDWLRQLQWKHVWXG\WKHVXEMHFWRUWKHVXEMHFW Â¶VOHJDOO\DFFHSWDEOHUHSUHVHQWDWLYH
VKRXOGUHFHLYHDFRS\RIWKHVLJQHGDQGGDWHGZULWWHQ,&)DQGD Q\RWKHUZULWWHQLQIRUPDWLRQ
SURYLGHGWRWKHVXEMHFWV'XULQJ DVXEMHFWÂ¶VSDUWLFLSDWLRQLQW KHVWXG\WKHVXEMHFWRUWKHVXEMHFWÂ¶V
OHJDOO\DFFHSWDEOHUHSUHVHQWDWLYHVKRXOGUHFHLYHDFRS\RIWKH VLJQHGDQGGDWHGFRQVHQWIRUP
XSGDWHVDQGDFRS\RIDQ\DPHQGPHQWVWRWKHZULWWHQLQIRUPDWLRQ SURYLGHGWRVXEMHFWV
$VHSDUDWHFRQVHQWIRUPZLOOEHSURYLGHGIRUVDPSOHFROOHFWLRQ IRUSKDUPDFRJHQRPLFWHVWLQJ
14.3 P ROTOCOL COMPLIANCE  
7KHLQYHVWLJDWRULQVWLWXWLRQVKRXOGFRQGXFWWKHVWXG\LQFRPSOL DQFHZLWKWKHSURWRFRODJUHHGWR
E\WKH6SRQVRUDQGUHJXODWRU\DXWKRULWLHVLIUHTXLUHGDQGZKL FKZDVJLYHQDSSURYDOIDYRUDEOH
RSLQLRQE\WKH,5%,(&7KHLQYHVWLJDWRULQVWLWXWLRQDQGWKHVS RQVRUVKRXOGVLJQWKHSURWRFRORU
DQDOWHUQDWLYHFRQWUDFW WRFRQILUPDJUHHPHQW
7KHLQYHVWLJDWRUVKRXOGQRWLPSOHPHQWDQ\GHYLDWLRQIURPRUFK DQJHVWRWKHSURWRFROZLWKRXW
DJUHHPHQWE\WKH6SRQVRUDQGSULRUUHYLHZDQGGRFXPHQWHGDSSURY DOIDYRUDEOHRSLQLRQIURPWKH
,(&,5%RIDQDPHQGPHQWH[FHSWZKHUHQHFHVVDU\WRHOLPLQDWHLP PHGLDWHKD]DUGVWRVWXG\
VXEMHFWVRUZKHQWKHFKDQJHLQYROYHVRQO\ORJLVWLFDORUDGPLQLV WUDWLYHDVSHFWVRIWKHVWXG\HJ
FKDQJHLQPRQLWRUFKDQJHRIWHOHSKRQHQXPEHU:KHQDQLPSRUWD QWGHYLDWLRQIURPWKHSURWRFRO
LVGHHPHGQHFHVVDU\IRUDQLQGLYLGXDOVXEMHFWWKHLQYHVWLJDWRU PXVWFRQWDFWWKH0HGLFDO0RQLWRU
IRUWKHVWXG\
6XFKFRQWDFWPXVWEHPDGHDVVRRQDVSRVVLEOHWRSHUPLWDUHYLH ZE\WKH6SRQVRUWRGHWHUPLQH
WKHLPSDFWRIWKHGHYLDWLRQRQWKHVXEMHFWÂ¶VSDUWLFLSDWLRQDQG RUWKHDVVHVVPHQWRIVDIHW\RU
HIILFDF\LQWKHVWXG\$Q\VLJQLILFDQWSURWRFROGHYLDWLRQVDIIH FWLQJVXEMHFWHOLJLELOLW\DQGRU
VDIHW\PXVWEHUHYLHZHGDQGRUDSSURYHGE\WKH,(&,5%DQGUHJX ODWRU\DXWKRULWLHVDV
DSSOLFDEOHSULRUWRLPSOHPHQWDWLRQ
7KHLQYHVWLJDWRUVKRXOGGRFXPHQWDQGH[SODLQDQ\GHYLDWLRQIURP WKHDSSURYHGSURWRFRO
14.4 P ROTECTION OF CONFIDENTIALITY  
3ULRUWRVWXG\SDUWLFLSDWLRQWKHLQYHVWLJDWRUVKDOOLQIRUPWKH VXEMHFWRUWKHVXEMHFWÂ¶VOHJDOO\
DFFHSWDEOHUHSUHVHQWDWLYHWKDWWKHPRQLWRUVDXGLWRUV,(& ,5%DQGWKHUHJXODWRU\DXWKRULWLHV
ZLOOEHJUDQWHGGLUHFWDFFHVVW RWKHVXEMHFWÂ¶VRULJLQDOPHGLFDO UHFRUGVIRUYHULILFDWLRQRIFOLQLFDO
VWXG\SURFHGXUHVDQGRUGDWDZLWKRXWYLRODWLQJWKHFRQILGHQWLD OLW\RIWKHVXEMHFWWRWKHH[WHQW
SHUPLWWHGE\WKH  DSSOLFDEOHODZVDQGUHJXODWLRQVDQGWKDWE\VLJQLQJDZULWWHQ ,&)WKHVXEMHFWRU
WKHVXEMHFWÂ¶VOHJDOO\DFFHSWDEOHUHSUHVHQWDWLYHLVDXWKRUL]LQJ VXFKDFFHVV
,QDGGLWLRQSULRUWRVWXG\SDUWLFLSDWLRQWKHVXEMHFWPXVWEH LQIRUPHGWKDWWKHUHFRUGVLGHQWLI\LQJ
WKHVXEMHFWZLOOEHNHSWFRQILGH QWLDODQGWRWKHH[WHQWSHUPLW WHGE\WKHDSSOLFDEOHODZVDQGRU
5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
UHJXODWLRQVZLOOQRWEHPDGHSXEOLFO\DYDLODEOHLIWKHUHVXOW VRIWKHVWXG\DUHSXEOLVKHGWKH
VXEMHFWÂ¶VLGHQWLW\ZLOOUHPDLQFRQILGHQWLDO
14.5 D ISCLOSURE OF STUDY RESULTS  
7KH6SRQVRUZLOOSRVWWKHUHVXOWVRIWKHVWXG\LQDSXEOLFO\DF FHVVLEOHGDWDEDVHLQDFFRUGDQFH
ZLWKWKHDSSOLFDEOHODZVDQGUHJXODWLRQV
5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
15 REGULATORY AND ADMINISTRATIVE CONSIDERATIONS 
15.1 Q UALITY ASSURANCE  
4XDOLW\DVVXUDQFHDQGTXDOLW\FRQWUROV\VWHPVVKDOOEHLPSOHPHQ WHGDQGPDLQWDLQHGZLWKZULWWHQ
VWDQGDUGRSHUDWLQJSURFHGXUHV623VWRHQVXUHWKDWWKHVWXG\L VFRQGXFWHGDQGGDWDDUH
JHQHUDWHGGRFXPHQWHGUHFRUGHGDQGUHSRUWHGLQFRPSOLDQFHZL WKWKHSURWRFRO*&3DQGWKH
DSSOLFDEOHUHJXODWRU\UHTXLUHPHQ WV4XDOLW\FRQWUROVKDOOEH DSSOLHGWRHDF KVWDJHRIGDWD
KDQGOLQJWRHQVXUHWKDWDOOG DWDDUHUHOLDEOHDQGKDYHEHHQSUR FHVVHGFRUUHFWO\
$QDJUHHPHQWPXVWEHVHFXUHGIURP DOOLQYROYHGSDUWLHVWRHQVXU HGLUHFWDFFHVVWRDOOVWXG\
UHODWHGVLWHVVRXUFHGRFXPHQWV DQGUHSRUWVIRUWKHSXUSRVHRI PRQLWRULQJDQGDXGLWLQJE\WKH
6SRQVRUDQGRILQVSHFWLRQE\UHJXODWRU\DXWKRULWLHV
15.1.1 M ONITORING  
2QVLWHPRQLWRULQJYLVLWVZ LOOEHFRQGXFWHGEHIRU HDWUHJXODU LQWHUYDOVGXULQJDQGDIWHUWKH
VWXG\DVDSSURSULDWHE\6SRQVRUDSSURYHGPRQLWRUV$WDPLQLP XPWKHDFFXUDF\DQG
FRPSOHWHQHVVRIWKHH&5)HQWULHVVRXUFHGRFXPHQWVDQGRWKHUV WXG\UHODWHGUHFRUGVZLOOEH
FKHFNHGDJDLQVWRQHDQRWKHUGXULQJ WKHVHYLVLWV$IWHUHDFKPRQ LWRULQJYLVLWDUHSRUWRIDQ\
VLJQLILFDQWILQGLQJVIDFWVGHYLDWLRQVDQGGHILFLHQFLHVZLOOE HFRPPXQLFDWHGWRWKHLQYHVWLJDWRU
7KHDFWLRQVWDNHQWRDGGUHVVWKHILQGLQJVDQGVHFXUHFRPSOLDQFH VKRXOGEHGRFXPHQWHG
15.1.2 A UDIT  
$QDXGLWPD\EHSHUIRUPHGLQGHSHQGHQWO\RIDQGVHSDUDWHO\IURP URXWLQHPRQLWRULQJWR
HYDOXDWHFOLQLFDOVWXG\FRQGXFWDQGFRPSOLDQFHZLWKWKHSURWRFR O623V*&3DQGWKHDSSOLFDEOH
UHJXODWRU\UHTXLUHPHQWV
15.2 C LINICAL RESEARCH ORGANIZATIONS  
$&OLQLFDO5HVHDUFK2UJDQL]DWL RQZLOOEHXWLOL]HGWRDVVLVWLQ WKHFRQGXFWRIWKLVVWXG\
$FFUHGLWHGFHQWUDOODERUDWRULHV ZLOOEHXVHGIRUWKHDQDO\VLVR IVDIHW\ODERUDWRU\VDPSOHVDQGIRU
WKHELRDQDO\WLFDOWHVWLQJRI3.DQG3'EORRGVDPSOHV
15.3 D ATA MANAGEMENT  
15.3.1 C ASE REPORT FORMS  
&DVHUHSRUWIRUPVPXVWEHFRPSOH WHGIRUHDFKVXEMHFWVFUHHQHGH QUROOHGLQWKLVVWXG\7KHVH
IRUPVZLOOEHXVHGWRWUDQVPLWLQIRUPDWLRQFROOHFWHGGXULQJWKH VWXG\WRWKH6SRQVRUDQG
UHJXODWRU\DXWKRULWLHVDVDSSOLFDEOH7KHFDVHUHSRUWIRUPGDW DIRUWKLVVWXG\DUHEHLQJFROOHFWHG
ZLWKDQH&5)7KHGRFXPHQWDWLRQUH ODWHGWRWKHYDOLGDWLRQRIWK HH&5)VZLOOEHPDLQWDLQHGLQ
WKH7ULDO0DVWHU)LOH7KH7ULDO0DVWHU)LOHZLOOEHPDLQWDLQHG E\WKH&52DQGWKH6SRQVRU
7KHLQYHVWLJDWRUZLOOGRFXPHQWVXEMHFWGDWDLQKLVKHURZQVXEM HFWILOHV7KHVHVXEMHFWILOHVZLOO
VHUYHDVVRXUFHGDWDIRUWKHVWX G\$OOH&5)GDWDUHTXLUHGE\W KLVSURWRFROZLOOEHUHFRUGHGE\
5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
LQYHVWLJDWLYHVLWHSHUVRQQHO$OOGDWDHQWHUHGLQWRWKHH&5)ZL OOEHVXSSRUWHGE\VRXUFH
GRFXPHQWDWLRQ
7KHLQYHVWLJDWRURUDQDXWKRUL]HGPHPEHURIWKHLQYHVWLJDWRUÂ¶V VWDIIZLOOPDNHDQ\QHFHVVDU\
FRUUHFWLRQVWRWKHH&5)$OOFKDQJHLQIRUPDWLRQLQFOXGLQJWKH GDWHDQGSHUVRQSHUIRUPLQJWKH
FRUUHFWLRQVZLOOEHDYDLODEOHYLDWKHDXGLWWUDLOZKLFKZLOO EHSDUWRIWKHHOHFWURQLFGDWDFDSWXUH
V\VWHP)RUDQ\FRUUHFWLRQDUHDVRQIRUWKHDOWHUDWLRQZLOOEH SURYLGHG7KHH&5)VZLOOEH
UHYLHZHGSHULRGLFDOO\IRUFRPSOHWHQHVVDQGDFFHSWDELOLW\E\6SR QVRUSHUVRQQHORUWKHLU
UHSUHVHQWDWLYHV7KH6SRQVRURUWKHLUUHSUHVHQWDWLYHVZLOOD OVREHDOORZHGDFFHVVWRDOOVRXUFH
GRFXPHQWVSHUWLQHQWWRWKHVWXG\LQRUGHUWRYHULI\H&5)HQWULH V7KHLQYHVWLJDWRUZLOOUHYLHZWKH
H&5)VIRUFRPSOHWHQ HVVDQGDFFXUDF\DQGSURYLGHKLVRUKHUHOHF WURQLFVLJQDWXUHDQGGDWHWR
H&5)VDVHYLGHQFHWKHUHRI
$FFHVVWRWKHHOHFWURQLFGDWDFDSWXUHV\VWHPZLOOEHSDVVZRUGS URWHFWHGDQGZLOOEHUHPRYHG
IURPWKHLQYHVWLJDWRUVLWHDWWKHHQGRIWKHVLWHÂ¶VSDUWLFLSDWL RQLQWKHVWXG\'DWDIURPWKHH&5)
ZLOOEHDUFKLYHGRQDSSURSULDWHGD WDPHGLDDQGSURYLGHGWRWKH LQYHVWLJDWRUDWWKDWWLPHDVD
GXUDEOHUHFRUGRIWKHVLWHÂ¶VH&5)GDWD,WZLOOEHSRVVLEOHIRU WKHLQYHVWLJDWRUWRPDNHSDSHU
SULQWRXWVIURPWKDWPHGLD
15.3.2 S OURCE DOCUMENTS  
6RXUFHGRFXPHQWVDUHGHILQHGDV RULJLQDOGRFXPHQWVGDWDDQGU HFRUGV7KHVHPD\LQFOXGH
KRVSLWDOUHFRUGVFOLQLFDODQGRIILFHFKDUWVODERUDWRU\GDWDL QIRUPDWLRQVXEMHFWV
GLDULHVRU
HYDOXDWLRQFKHFNOLVWVSKDUPDF\GLVSHQVLQJDQGRWKHUUHFRUGVU HFRUGHGGDWDIURPDXWRPDWHG
LQVWUXPHQWVPLFURILFKHVSKRWRJUDSKLFQHJDWLYHVPLFURILOPRU PDJQHWLFPHGLD(&*V;UD\V
XOWUDVRXQGVDQJLRJUDPVYHQRJUDPV&7VFDQVDQGRU05,VFDQV 'DWDFROOHFWHGGXULQJWKLV
VWXG\PXVWEHUHFRUGHGRQWKHDSSURSULDWHVRXUFHGRFXPHQWV
7KHLQYHVWLJDWRUVLQVWLWXWLRQVZLOOSHUPLWVWXG\UHODWHGPR QLWRULQJDXGLWV,(&,5%UHYLHZ
DQGUHJXODWRU\LQVSHFWLRQVSURYLGLQJGLUHFWDFFHVVWRVRXUFH GDWDGRFXPHQWV
15.4 P REMATURE TERMINATION OR SUSPENSION OF THE STUDY  
,IWKH6SRQVRU  WHUPLQDWHVRUVXVSHQGVWKHVWXG\WKHLQYHVWLJDWRULQVWLWXWLRQ VKRXOGSURPSWO\
LQIRUPWKH,(&,5%DQGSURYLGHWKH,(&,5%DGHWDLOHGZULWWHQH [SODQDWLRQRIWKHWHUPLQDWLRQRU
VXVSHQVLRQ,IWKH,(&,5%WHU PLQDWHVRUVXVSHQGVLWVDSSURYDO IDYRUDEOHRSLQLRQRIWKHVWXG\
WKHLQYHVWLJDWRULQVWLWXWLRQVKRXOGSURPSWO\QRWLI\WKH6SRQVRU DQGSURYLGHWKH6SRQVRUZLWKD
GHWDLOHGZULWWHQH[SODQDWLRQRIWKHWHUPLQDWLRQRUVXVSHQVLRQ
15.5 C LINICAL STUDY REPORT  
:KHWKHUWKHVWXG\LVFRPSOHWHGRUSUHPDWXUHO\WHUPLQDWHGWKHF OLQLFDOVWXG\UHSRUWZLOOEH
SUHSDUHGDQGSURYLGHGWRWKHUHJXODWR U\DJHQFLHVDVUHTXLUHGE\ WKHDSSOLFDEOHUHJXODWRU\
UHTXLUHPHQWV
5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
15.6 P UBLICATION POLICY  
7KH6SRQVRUUHFRJQL]HVWKHLPSRUWDQFHRIFRPPXQLFDWLQJWKHUHVX OWVRIVFLHQWLILFVWXGLHV
LQFOXGLQJFOLQLFDOWULDOVDQGWKHUHIRUHVWURQJO\VXSSRUWVWKH LUSXEOLFDWLRQRIWULDOILQGLQJVLQ
SHHUUHYLHZHGVFLHQWLILFMRXUQDOVDQGSUHVHQWDWLRQRIGDWDDWS URIHVVLRQDOVRFLHW\VHPLQDUVRU
FRQIHUHQFHV7KH6SRQVRUDOVRKDVOHJLWLPDWHFRUSRUDWHDQGLQYH VWRUUHVSRQVLELOLWLHVLQFOXGLQJ
EXWQRWOLPLWHGWRSURWHFWLQJFRQILGHQWLDOLQIRUPDWLRQDERXWL WVSURSULHWDU\SURGXFWVDQG
REWDLQLQJSDWHQWSURWHFWLRQIRULWVLQWHOOHFWXDOSURSHUW\
7KHUHIRUHWKHIROORZLQJSURFHGXUHVDSSO\WRDQ\FRPPXQLFDWLRQ LQFOXGLQJZULWWHQRUDORU
HOHFWURQLFPDQXVFULSWDEV WUDFWRWKHUSXEOLFDWLRQRUSUHVHQW DWLRQRIUHVXOWVRULQIRUPDWLRQ
DULVLQJIURPWKLVVWXG\LQFOXGLQJDQ\DQFLOODU\VWXGLHVLQYROY LQJWULDOVXEMHFWVWRDQ\WKLUG
SDUWLHV
x7KHSURSRVHGFRPPXQLFDWLRQZLOOEHSUHSDUHGLQFROODERUDWLRQZL WKWKH6SRQVRU7KHILUVW
SXEOLFDWLRQIURPWKLVVWXG\LVH[SHFWHGWREHDVXPPDU\RISDUW LDORUFRPSOHWHGDWDMRLQWO\
SURGXFHGE\WKH6SRQVRUDQGWKHSDUWLFLSDWLQJLQYHVWLJDWRUV7K HSDUWLFLSDWLQJLQYHVWLJDWRUV
ZLOOEHLQYLWHGWRFRQWULEXWHDVFRDXWKRUVLQWKHMRLQWFRPPXQ LFDWLRQ,IDMRLQW
FRPPXQLFDWLRQZLWKDVXPPDU\RIDOOSURWRFROUHVXOWVKDVQRWEH HQVXEPLWWHGIRUSXEOLFDWLRQ
ZLWKLQHLJKWHHQPRQWKVRIFRPSOHWLRQRUWHUPLQDWLRQRIWKH VWXG\DWDOOSDUWLFLSDWLQJ
VLWHVDQGILQDOORFNLQJRIWKHVWXG\GDWDEDVHWKHSDUWLFLSDWLQ JLQYHVWLJDWRUVZLOOEHIUHHWR
SXEOLVKVHSDUDWHO\VXEMHFWWRWKHSURFHGXUHVVHWIRUWKLQWKLV VHFWLRQ
x7KHILQDOSURSRVHGYHUVLRQPXVW EHVXEPLWWHGWRWKH6SRQVRUIRU UHYLHZDQGFRPPHQWDWOHDVW
GD\VSULRUWRSUHVHQWDWLRQVXEPLVVLRQIRUSXEOLFDWLRQRUR WKHUGLVVHPLQDWLRQ
x,QWKHHYHQWWKH6SRQVRUUHDVRQD EO\GHWHUPLQHVWKDWDSURSRVHG FRPPXQLFDWLRQFRQWDLQV
FRQILGHQWLDORUSDWHQWDEOHPDWHUL DOWKH\PD\UHTXLUHHLWKHURI WKHIROORZLQJ
o7KHPDWHULDOEHUHPRYHGIURPWKHFRPPXQLFDWLRQ
o7KHFRPPXQLFDWLRQPD\EHGHOD\HGWRSHUPLWILOLQJWKHDSSURSULD WHLQWHOOHFWXDOSURSHUW\
SURWHFWLRQ7KHVHSURFHGXUHVDSSO\ UHJDUGOHVVRIZKHWKHUWKHVW XG\LVFRPSOHWHGDV
SODQQHGRULVWHUPLQDWHGSUHPDWXUHO\IRUDQ\UHDVRQ
$OOSXEOLFDWLRQVZLOOJLYH5D3KDUPDFHXWLFDOV,QFDQGRULWV UHVHDUFKSHUVRQQHODSSURSULDWH
FUHGLWLHDXWKRUVKLSRUDFNQRZOHGJ HPHQWIRUDQ\GLUHFWFRQWU LEXWLRQPDGHE\WKHP
$XWKRUVKLSZLOOEHGHFLGHGMRLQWO\E\WKHLQYHVWLJDWRUVDQGWKH 6SRQVRU0DQXVFULSWVZLOO
FRQIRUPWRWKH8QLIRUP5HTXLUHPHQ WVIRU0DQXVFULSWV6XEPLWWHGW R%LRPHGLFDO-RXUQDOV
LQFOXGLQJEXWQRWOLPLWHGWRWKHVWDQGDUGVIRUDXWKRUVKLSFRQ WDLQHGWKHUHLQ
5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
16 REFERENCES 
$DURQVRQ1.HWDO7KH(XURSHD Q2UJDQL]DWLRQIRU5HVHDUFKDQG 7UHDWPHQWRI&DQFHU4/4
&DTXDOLW\RIOLIHLQVWUXPHQWIRUXVHLQLQWHUQDWLRQDOFOLQ LFDOWULDOVLQRQFRORJ\-1DWO&DQFHU
,QVW
$DURQVRQ1.HWDO7KH(XURSHD Q2UJDQL]DWLRQIRU5HVHDUFKDQG 7UHDWPHQWRI&DQFHU
(257&PRGXODUDSSURDFKWRTXDOLW\RIOLIHDVVHVVPHQWLQRQFRO RJ\DQXSGDWH,Q6SLONHU%
HG4XDOLW\RI/LIHDQG3KDUPDFR HFRQRPLFVLQ&OLQLFDO7ULDOV QG(G1HZ<RUN1<
/LSSLQFRWW:LOOLDPV	:LONLQV
%HVDUDE$HWDO0HWDDQDO\VLVRIVXEFXWDQHRXVYHUVXVLQWUDYHQ RXVHSRHWLQLQPDLQWHQDQFH
WUHDWPHQWRIDQHPLDLQKHPRGLDO\VLVSDWLHQWV$P-.LGQH\'LV 
%URGVN\5$3DUR[\VPDOQRFWXUQDOKHPRJORELQXULD%ORRG 
%URGVN\5$+RZ,WUHDWSDUR[\VPDOQRFWXUQDOKHPRJORELQXULD%O RRG
(XUR4RO*URXS(XUR4RODQHZIDFLOLW\IRUWKHPHDVXUHPHQWRIKH DOWKUHODWHGTXDOLW\RIOLIH
+HDOWK3ROLF\
+LOO$HWDO7KHLQFLGHQFHDQGSUHYDOHQFHRISDUR[\VPDOQRFWX UQDOKHPRJORELQXULD31+DQG
VXUYLYDORISDWLHQWVLQ<RUNVKLUH%ORRG$EVWUDFW 
+LOO$HWDO6XVWDLQHGUHVSRQVHDQGORQJWHUPVDIHW\RIHFXOL] XPDELQSDUR[\VPDOQRFWXUQDO
KHPRJORELQXULD%ORRG
+LOOPHQ3HWDO(IIHFWRIWKH FRPSOHPHQWLQKLELWRUHFXOL]XPD ERQWKURPERHPEROLVPLQSDWLHQWV
ZLWKSDUR[\VPDOQRFWXUQDOKHPRJORELQXULD%ORRG 
+LOOPHQ3HWDO7KHFRPSOHPHQ WLQKLELWRUHFXOL]XPDELQSDUR[\ VPDOQRFWXUQDOKHPRJORELQXULD
1(QJO-0HG
-DQJ-+HWDO3UHGLFWLYH)DFWRUVRI0RUWDOLW\LQ3RSXODWLRQR I3DWLHQWVZLWK3DUR[\VPDO
1RFWXUQDO+HPRJORELQXULD31+5H VXOWVIURPD.RUHDQ31+5HJLV WU\-.RUHDQ0HG6FL

.DLUHPR(HWDO$QDWLRQZLGHVXUYH\RISDUR[\VPDOQRFWXUQDOK DHPRJORELQXULDLQ)LQODQG
+DHPDWRORJLFD>VXSSO@$EVWUDFW
/HH-:HWDO&OLQLFDOVLJQVD QGV\PSWRPVDVVRFLDWHGZLWKLQF UHDVHGULVNIRUWKURPERVLVLQ
SDWLHQWVZLWKSDUR[\VPDOQRFWXUQDOKHPRJORELQXULDIURPD.RUHDQ 5HJLVWU\,QW-+HPDWRO

1DND\DPD+HWDO(FXOL]XPDEGRVLQJLQWHUYDOVORQJHUWKDQG D\VPD\EHDVVRFLDWHGZLWK
JUHDWHUULVNRIEUHDNWKURXJKKHPRO\VLVLQSDWLHQWVZLWKSDUR[\V PDOQRFWXUQDOKHPRJORELQXULD
%LRO3KDUP%XOO
5$
3URWRFRO5$ $PHQGPHQW''- DQXDU\
&21),'(17,$/
1LVKLPXUD-HWDO*HQHWLFYDULDQWVLQ&DQGSRRUUHVSRQVHWR HFXOL]XPDE1(QJO-0HG

1LVKLPXUD-,HWDO&OLQLFDOFRXUVHDQGIORZF\WRPHWULFDQDO\ VLVRISDUR[\VPDOQRFWXUQDO
KHPRJORELQXULDLQWKH8QLWHG6WDWHVDQG-DSDQ0HGLFLQH Â±
3DUNHU&HWDO'LDJQRVWLFVDQGPDQDJHPHQWRISDUR[\VPDOQRFWX UQDOKHPRJORELQXULD%ORRG

3DUNHU&-7KHSDWKRSK\VLRORJ\RISDUR[\VPDOQRFWXUQDOKHPRJORE LQXULD([S+HPDWRO

5RVVH:)3DUR[\VPDO1RFWXUQDO+HPRJORELQXULD2USKDQHW(QF\FORS HGLD'HFHPEHU
KWWSZZZRUSKDQHWGDWDSDWKR*%XN31+SGI
6FKUH]HQPHLHU+HWDO%DVHOLQHFKDUDFWHULVWLFVDQGGLVHDVHEX UGHQLQSDWLHQWVLQWKH
,QWHUQDWLRQDO3DUR[\VPDO1RFWXUQDO+HPRJORELQXULD5HJLVWU\+DH PDWRORJLFD
6RFLHÂ*HWDO3DUR[\VPDOQRFWXUQDOKDHPRJORELQXUDORQJWHUP IROORZXSDQGSURJQRVWLF
IDFWRUV/DQFHW
6ROLULVÂŠ6XPPDU\RI3URGXFW&KDUDFWHULVWLFV$OH[LRQ3KDUPD8./WG8[E ULGJH0LGGOHVH[
8.
6ROLULVÂŠ863DFNDJH,QVHUW$OH[ LRQ3KDUPDFHXWLFDOV,QF&KHVK LUH&786$'HFHPEHU

6WRQHU./HWDO,QWUDYHQRXVYHUVXVVXEFXWDQHRXVGUXJDGPLQLVW UDWLRQ:KLFKGRSDWLHQWV
SUHIHU"$V\VWHPDWLFUHYLHZ3DWLHQW
:HEVWHU.HWDO7KHIXQFWL RQDODVVHVVPHQWRIFKURQLFLOOQHVV WKHUDS\)$&,7PHDVXUHPHQW
V\VWHPSURSHUWLHVDSSOLFDWLRQVDQGLQWHUSUHWDWLRQ+HDOWK4X DO/LIH2XWFRPHV
